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ABSTRACT 
 
Pharmacological Antagonism and the Olfactory Code 
 
Mihwa Na 
 
Advisor: Professor Kevin Ryan 
 
Mammals can detect and discriminate uncountable odors through their odorant receptors. 
To accommodate the countless and diverse odors, exceptionally large numbers of odorant 
receptor (OR) genes are expressed in mammals. In addition, the mammals utilize a combinatorial 
code, where an odorant molecule can activate multiple ORs; an OR also responds to a set of 
multiple odorants. In nature, an odor is often a complex mixture of multiple odorant molecules. 
The combination of the ORs activated by each constituent generates the unique olfactory code 
for the particular odor.  
Some odorants can antagonize select ORs, as discussed in Chapter 1. An antagonist 
within an odor mixture can conceivably affect the olfactory code of the odor mixture by 
inhibiting other constituents that alone would function as agonists. While it is clear that some 
odorants can be the antagonists of select odorant receptors, the degree to which odorant 
antagonism contributes to the olfactory code of naturally occurring odor mixtures is unknown. 
As described in the following chapters, my studies aimed to obtain better understanding of the 
odorant antagonism at the molecular level, using populations of dissociated primary mouse 
olfactory sensory neurons and calcium imaging.  
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Firstly, we probed for the prevalence of odorant antagonism in a naturally occurring odor, 
using charred wood odor mixture as an example. This mixture was chosen because its 
constituents have structural similarities between each other, as described in Chapter 2; the 
odorant antagonists that have been identified thus far show structural similarities to their cognate 
agonists. The results of this study suggested that the role of odorant antagonism is insignificant 
in encoding of the charred wood mixture; each constituent contributed additively to make up the 
olfactory code of the mixture.  
The structure and conformation of the odorants are important for OR activation and 
antagonism. Conversely, the vibrational theory of olfaction states that the activation of the OR 
depends on the intramolecular vibration of the odorant.1, 2 Previously, numerous behavioral and 
molecular studies have suggested that the insects could differentiate the deuterated odorants from 
the non-deuterated odorants, in support of the vibrational theory, although the structure of the 
insect ORs are unrelated to that of the mammalian ORs. We posited that if the deuterated 
odorants could bind but fail to activate the ORs that are activated by the non-deuterated odorants, 
the deuterated odorants could serve as antagonists. However, the psychophysical studies on 
humans have shown mixed results. A recent study using a set of modified mouse and human 
ORs expressed in a heterologous system showed that the deuterated and non-deuterated odorants 
activated the cognate recombinant ORs with equal potency, arguing against the vibrational 
theory. Herein, we tested this controversy on the primary mouse olfactory sensory neurons using 
calcium imaging, where the un-modified, endogenous ORs are expressed along with the 
endogenous downstream signaling molecules. As described in Chapter 3, at the concentrations 
above the detection threshold, the individual mouse ORs could not differentiate the 
isotopologues. At the molecular level, there was no evidence of vibrational mechanism of OR 
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activation. Our findings confirmed the implausibility of the vibrational theory of olfaction in the 
primary mouse OSNs. Consequently, the deuterated odorants were not suitable as odorant 
antagonists. In this chapter we also point out that replacing H with D in small molecules 
decreases the hydrophobicity of the molecule. The hydrophobic effect contributes to ligand-
receptor binding, and may explain differences observed in insect studies. 
Some odorants are known for their synergistic ability to enhance the percept of other 
odorants when used in a mixture.3, 4 One such example is methyl dihydrojasmonate (MDHJ), 
which itself has a weak floral odor.4-6 While its odor is weak on its own, MDHJ is known for its 
ability to “boost” the floral character of other odorants.4 Published molecular level studies on this 
widely known observation are lacking. To address this deficiency, and as described in Chapter 4, 
we examined how MDHJ affects the olfactory code of a floral odor mixture, using a rose oil odor 
mixture as an example. Our results revealed that when added to the mixture, MDHJ can activate 
additional OSNs, aside from the OSNs that are activated by the rose oil odor constituents. MDHJ 
also inhibited some ORs that are otherwise activated by the rose oil odor constituents. Our results 
suggested that MDHJ can “fine-tune” the olfactory code of the rose oil odor mixture by not only 
by activating ORs but also through odorant antagonism. However, a control experiment indicated 
that this property is likely not unique to MDHJ. 
Also described in this thesis is some preliminary work aimed at profiling the 3’ 
untranslated regions of the odorant receptor genes. The mRNA 3’ untranslated regions (3’ UTR) 
often contain the gene regulatory elements such as AU-rich elements and binding sites for 
miRNA and RNA binding proteins.7 Thus the 3’ UTR can provide dynamic regulation of gene 
expression. While the importance of 3’ UTR in gene regulation is in general well-established, the 
3’ ends of the odorant receptor genes have been incompletely annotated. In relation to this side 
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project, the methods that can be used to target 3’ UTR of the odorant receptor genes for profiling 
were reviewed, and a technical study of in vitro 3’ processing completed. (Chapters 5 - 7) 
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Part I. Odorant Receptor-Ligand Interactions 
Chapter 1. General Introduction to the Mammalian Odorant Receptors and their Ligands 
 
Synopsis 
Odors provide important information to humans and animals about the chemical make-up 
of the surroundings. The naturally occurring odors are often are complex mixtures of multiple 
volatile small molecule ligands (usually less than 300 Daltons) of odorant receptors (ORs), 
known as odorants. The odorants interact and activate a set of multiple ORs in the nose. The ORs 
belong to the largest multi-gene family of G-protein coupled receptors (GPCRs). The set of 
multiple ORs activated by the odor mixture represents the olfactory code of the odor.  
Odorants have been shown to play dual roles, as they can function as agonists of some 
ORs while serving as antagonists of other ORs. The odorant antagonist could affect, by 
increasing the complexity of, the olfactory code of the odor mixture by inhibiting, either partially 
or fully, OR responses to other components of a mixture. While it is clear that some odorants can 
inhibit select ORs, how the odorant antagonism shapes the encoding of the naturally occurring 
odor mixture has not been investigated at the receptor level. This introductory chapter describes 
what is known about ORs and how they interact with their ligands to convert the chemical 
information of the odorants into neuronal signals. We also discuss how an odorant antagonist in 
the odor mixture might modulate the OR responses to other constituents in the mixture.  
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Section 1.A. Peripheral Olfactory System 
Mammals use odorant receptors to detect and discriminate odorants. 
Mammals use the olfactory system to 
draw information about their chemical 
environment. The olfactory system detects and 
discriminates a large number of small, 
structurally diverse, volatile molecules, known 
as odorants. A psychophysical test estimated 
that humans could distinguish at least 1 trillion 
distinct odors, although this approximation has 
been disputed recently.8-10 Exceptionally large 
number of OR genes and combinatorial coding 
system are employed to achieve such an 
olfactory capability. Throughout this study, 
mice were used as a model system to explore 
how an odor is recognized by the peripheral 
olfactory system.  
 
1.A.1. Anatomy of the Mouse Nose 
  The first step of odor detection and 
discrimination comprises the interaction 
between an odorant and an OR on the ciliary 
membrane of the olfactory sensory neurons 
 
Figure 1-1. Anatomy of the mouse olfactory system 
(a) In a sagittal view of a mouse head, the MOE and 
the OB are shaded in green. The MOE is covering the 
turbinates. The convoluted structure of the turbinates 
serves to increase the surface area of the epithelium. 
(b) The OSNs in the MOE have their cilia in the mucus 
layer of nasal cavity. Each OSN expresses one out of 
~1000 OR genes on the cilia membrane. The OSNs 
that express the same ORs converge their unbranched 
axons in a glomerulus of the olfactory bulb.  
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(OSN). The odorants are inhaled into the posterior nasal cavity, where the main olfactory 
epithelium (MOE) is found wrapping around the convoluted bone structures, known as 
turbinates. (Fig. 1-1a) The MOE harbors the bipolar olfactory sensory neurons (OSNs), 
supporting cells and basal cells. Among these cells, only OSNs serve as a primary sensory 
neuron.11 Each OSN projects a single dendrite towards the surface of the MOE. (Fig. 1-1b) The 
dendrite ends in a knob-like shape, from which 20-30 cilia protrude.11 The ORs are most highly 
expressed in the ciliary membrane, although lower expression is detected in the cell bodies and 
axons.12, 13 An adult mouse has about 10 million mature OSNs.14 The mouse OSNs are spatially 
organized into 4 zones within the MOE, depending on the type of ORs they express.15 The OSNs 
of the identical ORs are randomly distributed within the zone, but their axons converge to one or 
a few glomeruli in the olfactory bulb (OB).15, 16 From the olfactory bulb, the secondary neurons 
known as mitral cells pass on the olfactory signal to the olfactory cortex of the brain.11 (Fig. 1-
1b) my studies concern the peripheral sensory input and how it is generated to define an odor, 
rather than how the olfactory code is processed in the OB and brain.  
 
1.A.2. Odorant Receptors: their Gene Expression and Protein Structures 
The ORs are expressed by exceptionally large number of genes.17 Humans have 300~400 
predicted odorant receptor genes while mice have ~1100.17-19 It is currently understood that each 
mature OSN expresses only one type of OR, although the mechanism by which an OSN chooses 
one OR gene remains unclear. 20-24 Because of this ‘one neuron-one receptor’ rule, the activation 
of an OSN reflects the activity of the OR expressed in that cell, allowing investigation of the 
receptor by looking at individual, cellular responses.    
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All ORs belong to class A G-protein coupled receptor (GPCR) family, similar to those 
known to be involved in neurotransmission, photoreception and many other physiological 
processes.11  All GPCRs are predicted to share the same basic structure of 7 trans-membrane 
domain structure. On the one hand, ORs share most of the sequence motifs that characterize class 
A GPCRs, such as rhodopsin. For instance, class A GPCR motif, GN in the first transmembrane 
domain (TM1) is conserved in 99% of the mouse ORs.25 The common disulfide bridge between 
2 C residues of TM3 and the 2nd extracellular loop (EC2) is also conserved in ORs. On the other 
hand, some features are unique to ORs. ORs have a long second extracellular loop and two 
conserved extracellular disulfide bonds. Other consensus sequences of ORs include 
LHxPMYFFLxxLSxxD in the first intracellular loop and 2nd transmembrane domain (TM2), 
MAYDRYVAICxPLxY over the end of TM3 and the beginning of the 2nd intracellular loop, SY 
at the end of TM5, KAFSTCxSH at the beginning of TM6, and PxLNPxIYSLNR in TM7.25-27 
(The residues in bold letters indicate the residues that are also conserved in non-olfactory, class 
 
Figure 1-2. Schematic representation of an olfactory receptor and some of its conserved sequences The 
conserved residues specific to most ORs are highlighted in green. The residues that are also conserved in non-
olfactory class A GPCRs are highlighted in yellow. The schematic was created based on information from de 
March et al. 201525 TM: transmembrane domain, IC: intracellular loop EC: extracellular loop 
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A GPCRs.) The typical CWxP motif of the class A GPCRs is not present in ORs.25 Each OR 
differs in the hypervariable region spanning over 3rd, 4th, and 5thtransmembrane alpha helices 
domain. The hypervariable residues in these domains are understandably suggested to be 
involved in ligand specificity and binding, though no odorant receptor crystal structures have 
been solved to confirm this.26, 28, 29 Based on structural studies on other GPCRs and molecular 
simulations, GPCR activation is generally related to the movements of TM3 and TM6.27  
 
Section 1.B. Olfactory Signal Transduction Pathway 
An OR activation can be detected via imaging calcium influx.  
An interaction of an odorant agonist with an OR initiates a cascade of intracellular events 
that lead to a neuronal signal. This excitatory signaling pathway essentially converts the 
chemical information of an odorant into a neuronal signal as depicted in Figure 3. At first, the 
receptor-agonist complex has increased affinity for the olfactory G-protein that is specific for 
olfactory signaling, Golf. (Fig. 1-3a and b)
30 This heterotrimeric G-protein consists of the three 
membrane-bound subunits- Gαolf which is bound to GDP, Gγ, and Gβ. (Fig. 1-3b) When bound 
by GDP, Gαolf is in its inactive form. Upon binding the receptor-agonist complex, the Gαolf is 
activated by exchanging GDP for the 10-fold more concentrated GTP. (Fig. 1-3c) The GPCR is 
therefore a type of GEF, a guanine nucleotide exchange factor. The odorant binding is estimated 
to be very brief; a mathematical model based on responses of dissociated amphibian OSNs 
predicted that only one molecule of Golf may be activated per one odorant binding event during 
its fleeting dwell time.31 Similar experiments using dissociated mouse OSNs also supported that 
a single binding of an agonist to the OR had a low probability of activating the downstream 
signal transduction pathway.32 Once activated, the GTP bound Gαolf  is released from the γ and β 
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subunits and binds/induces adenylyl 
cyclase type III (AC-III) to produce 
cAMP from ATP.33 cAMP then binds to 
the cyclic nucleotide gated (CNG) 
channels, causing calcium influx along 
with sodium into the cilia. The increase 
in local Ca2+ opens the calcium gated 
chloride channel and chloride is expelled, 
amplifying the depolarization.34 The 
calcium influx, together with chloride 
efflux elicits depolarization, an action 
potential that propagates to the OSN 
soma and in turn, to the olfactory bulb. I 
used this calcium influx as it occurs in 
dissociated OSNs to monitor the 
activation of an OR by odorants applied 
in solution. 
 
Section 1.C. Molecular Recognition of Olfactory Ligands 
Odorants can activate, partially activate, and/or inhibit ORs. 
 The GPCRs are thought to oscillate between several conformations, including active and 
inactive conformations.35 The receptors interact with various types of ligands and the interactions 
lead to shifts in the equilibrium of the receptor conformations.35 Agonists prompt full (maximal) 
 
Figure 1-3. The olfactory signal transduction pathway 
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activation of the receptors and subsequent cellular response.35 The predicted or known site where 
the natural agonists bind the receptors are known as orthosteric binding sites. Binding of agonists 
alters the equilibrium towards active conformations of the receptors, leading to higher affinity for 
the G-protein.35 (Fig. 1-3b) It has also been suggested that coupling of the agonist abound 
receptors with cognate G-protein further stabilizes the active state of the receptors.36 Inverse 
agonists bind to the constitutively active receptors and stabilize the inactive conformation, 
thereby reducing the basal activity of the receptors.37, 38 Antagonists bind to the receptors 
without activating. Unlike the inverse agonists, the antagonists exhibit no effect on the receptors 
in absence of the agonists.37 Rather, they inhibit the receptor activation by blocking the access of 
the orthosteric binding site by other ligands.35, 38 (Although the term ‘antagonist’ refers to the 
orthosteric antagonist in this study, in some studies, ‘antagonist’ represents any ligand that 
decreases the receptor activity, either via orthosteric sites or allosteric sites.39) Partial agonists 
activate the receptors incompletely, even at saturating concentrations. Binding of the partial 
agonists also inhibits the other agonists from fully activating the receptors.35, 37, 38 Ligands can 
bind GPCRs on the orthosteric sites as well as other sites, called allosteric binding sites. 
Increasing numbers of allosteric ligands of GPCRs have been discovered recently.40-43 Allosteric 
ligands modulate the receptor’s conformation, and may reduce or enhance the agonist-induced 
responses. The allosteric ligands that reduce or enhance the receptor’s response to the agonists 
are known as negative allosteric modulators (NAMs) and positive allosteric modulators (PAMs), 
respectively. Due to lack of crystal structures of ORs, the detailed conformational changes 
elicited by OR-ligand interactions are not yet characterized but are predicted to follow the 
conformational changes observed for other class A GPCRs, such as the β2-adrenergic receptor.25, 
44 In general, odorants have been most extensively studied as agonists. However, functional 
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assays using molecular imaging studies have shown that odorants can interact with ORs as 
agonists, partial agonists, and antagonists on ORs.45-53 
 
Section 1.D. Odorant Receptors and their Ligands: Deorphanization 
Extremely small number of ORs are paired with their cognate odorants. 
Much research has been done to deorphan ORs, that is, to identify their ligands. 
(reviewed by Peterlin et al.54)  Screening the response of native OSNs to multiple odorants, 
followed by identification of the ORs via single cell RT-PCR revealed several odorant/OR 
pairs.20, 55, 56 Such experiments also showed that a single OR can be activated by a series of 
odorants; the set of odorant ligands that can bind an OR defines the receptive field of that 
receptor. Each OR is expected to exhibit a unique receptive field, which may partially overlap 
with the receptive field of other ORs. 
A specific, known OR can be deorphaned in the homologous native OSNs, via gene 
targeting or recombinant OR expression via adenoviral vector. The gene targeting approach 
visualizes the OSNs that bear a particular endogenous OR of interest, by inserting fluorescent 
marker protein sequences adjacent to the endogenous OR gene. The visualization of the OSNs of 
interest is then coupled to various imaging assays to record the responses of the ORs. Since the 
fluorescent marker proteins are translated separately from the OR, the resulting OR proteins are 
unmodified. Mouse ORs M71 and M72 were deorphaned using gene targeting.16, 57 Use of 
recombinant adenovirus allows over-expression of a single OR in OSNs.48, 58 Here, rats are 
infected with the recombinant adenovirus containing a constitutively active promoter, the OR, 
and green fluorescent protein (GFP). The ORs and GFP are expressed from the same mRNA but 
separately, not as a fusion protein, leaving the receptor unmodified. Infecting rats with 
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recombinant adenovirus containing OR-I7 sequences showed a number of OSNs expressing OR-
I7. These OSNs expressed the exogenous OR-I7 in addition to their endogenous ORs.48, 58  These 
homologous systems are advantageous in that all olfactory signal transduction pathway 
components are preserved and the receptors are unmodified but identified. However, difficulty of 
the methodologies decelerates the deorphanization. Thus far, use of OSNs led to deorphanization 
of 7 ORs: rat OR-I7, mouse OR-I7, MOR23, MOR-EG, MOR-EV, M71, and M72.54  
Heterologous systems offer deorphanization of ORs in more high-throughput scale. By 
selecting a large panel of odorants analogous to the known agonist of a known OR, a more 
comprehensive investigation of the receptor’s receptive field is possible. Cell lines such as 
HEK293T cells, HeLa cells, and Xenopus oocytes, baculovirus Sf9 insect cell system have been 
used for heterologous expression of select ORs.51, 59-63 The major impediment in using the 
heterologous system is that OR proteins tend to be retained in endoplasmic reticulum when 
expressed in heterologous cells.59 In order for correct receptor trafficking, additional proteins 
such as receptor-transporting proteins are often co-transfected with the ORs.54, 64 Certain 
modifications on ORs have also been shown to assist in receptor trafficking. For instance, most 
of the heterologously expressed ORs also bear 20 N-terminal amino acid sequences of rhodopsin 
on their N-termini.45, 47, 49-51 (Designated as rho-tag in Table1-1) Besides the trafficking issues, 
the heterologous cell lines lack the canonical downstream signaling components that are used by 
the OSNs, such as Golf and CNGA2 (a subunit of the cyclic nucleotide gated channel). The 
identity of the G-protein has been shown to be especially important, as it affects the receptive 
field of the OR.51 Owing to these obstacles, only a small percentage of ORs have been 
deorphaned so far; out of ~400 human and ~1000 mouse ORs, ~8% and ~10% have been 
matched with activating odorants using both homologous and heterologous systems.54  
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Section 1.E. Combinatorial Olfactory Code 
An odor is represented by a combinatorial olfactory code. 
An odor is encoded at the periphery by a population of ORs that are activated by the 
odorants.20 As described above, an OR can be activated by multiple odorants. Different ORs 
respond to unique but overlapping sets of odorants. Reciprocally, one odorant can stimulate 
multiple ORs; different odorants activate distinct but overlapping combinations of ORs. The set 
of ORs that responds to a given odorant represents the olfactory code of that odorant. Using the 
combination of ORs with various receptive fields, the olfactory system is capable of detecting 
even the smallest differences in odorant structures, as in aliphatic odorants with carbon chain 
lengths differing by even one carbon.  
In nature, an odor is seldom comprised of a single molecule. Rather, a pool of diverse 
compounds at various concentrations makes up the odor. How each constituent contributes in 
making up the olfactory code of the whole mixture is not thoroughly understood. Even the minor 
constituents have been shown to be important for a characteristic percept of the mixture.65 Also, 
it has been repeatedly observed that the response to an odor mixture cannot be calculated from 
linear summation of the responses to its constituents.66-68 69With the diverse constituents in a 
mixture, and the large number of ORs with different receptive fields, the number of possible 
olfactory code is immense; hence called the combinatorial olfactory code. In addition, each 
odorant may activate an OR as an agonist, partially activate it as a partial agonist, or inhibit it as 
an antagonist, introducing more variables in the combinatorial olfactory code.50 Because an odor 
is encoded by the combination of different ORs, my studies focused on response patterns of the 
population of ORs instead of deorphaning a single OR.  
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Section 1.F. Odorant Antagonism 
Some odorants serve as antagonists. 
1.F.1. Odorant Receptors, their Cognate Agonists and Antagonists 
As the agonists of select ORs were revealed through deorphanization, numerous odorant 
antagonists were also identified.45-53, 70-73 The odorant antagonists for select ORs and their 
cognate agonists known as of early 2017 are listed in Table 1-1. The antagonists bind to the ORs 
and prevent the receptor activation.37 The partial agonists also inhibit the agonists from fully 
activating the ORs.37 It is noteworthy that the structures of the known antagonists and partial 
agonists displayed significant structural similarities to the cognate agonists of the ORs. (Table 1) 
Such structural similarities suggest the orthosteric antagonism, where the antagonist occupy and 
block the endogenous orthosteric binding site of the agonists.  
 
 
Table 1-1. Select ORs, cognate agonists, and antagonists published to date: The odorants that were shown to 
inhibit the agonist-induced responses without activating the ORs themselves were considered as antagonists. The 
odorants that reduced the agonist responses but also activated the ORs were listed as partial agonists. More than one 
agonist are known for all the ORs listed here. However, only the ones that were experimentally shown to be 
inhibited by the antagonists were listed here.  
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Table 1-1. Continued 
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Table 1-1. Continued 
 
*Citral is a mixture of the geometric isomers, geranial and neral. Both isomers completely inhibited the octanal 
induced response of OR-I7 in calcium imaging experiments.72 *While calcium imaging studies showed no responses 
to citral72, electro-olfactogram showed small response citral48.  
ᶧA recent publication showed opposing results via calcium imaging that α-ionone can also activate OR51E2, 
heterologously expressed in HEK293 cells. 
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1.F.2. Mode of Antagonism 
 Antagonists can inhibit the agonist-induced receptor responses either orthosterically or 
allosterically.39 Orthosteric antagonists compete with agonists for same binding sites on the 
receptors. Binding of the orthosteric antagonists essentially precludes the agonists from 
accessing the binding sites. Therefore, the capability of antagonists to completely block the 
receptor’s activity is often understood as a characteristic of an orthosteric inhibitor. The 
orthosteric antagonists are further divided into competitive and non-competitive subtypes. 
Competitive antagonists interact with the receptors reversibly and hence constantly compete with 
agonists for the binding site. Non-competitive antagonists bind the receptors but dissociate very 
slowly or doesn’t dissociate at all, abolishing the receptor function.  Allosteric antagonists bind 
to the receptors on sites that are different from the natural agonist binding sites. Binding of an 
allosteric antagonist stabilizes an inactive conformation of a receptor, modulating the receptor’s 
interaction with the agonist, the downstream signaling proteins, or both. Since the binding site is 
modulated rather than occluded, GPCR ligands that bind to the allosteric sites are known as 
allosteric modulators in general. The allosteric antagonists are known as NAMs because they 
reduce the receptor response. However, they do not necessarily inhibit the responses completely. 
 
Figure 1-4. Effects of antagonists on agonist induced dose-response curves  
(a) Addition of a competitive antagonist shows a right shift in agonist induced dose-response curve with no 
decrease in maxima. There is no saturation of antagonism.  
(b) Addition of an allosteric modulator also leads to the right shift in agonist induced dose-response curve. 
There is a saturation limit of antagonism. The figure was adapted from Kenakin et al. with modified legends.38 
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The odorant antagonists identified thus far were suggested to be orthosteric competitive 
inhibitors.46-51, 53 Their orthosteric, competitive mode of action is supported by the pattern by 
which the antagonists affect the receptor’s responses to agonists. Take, for example, 
methylisoeugenol which inhibits eugenol response on MOR-EG in a dose dependent manner.50 It 
is the most extensively characterized odorant antagonist in terms of its pharmacology. The 
response to eugenol at 100µM was completely inhibited by 1 mM methylisoeugenol.50 The 
concentration of methylisoeugenol that reduced eugenol response (at 100 µM) to 50% (IC50) at 
fixed agonist concentration was 66 µM. The dose-response curve of MOR-EG showed a shift 
towards the right in presence of 100 µM methylisoeugenol.50 The complete inhibition of the 
receptor response and the parallel right shift of the dose-response curve suggest a simple 
orthosteric antagonism.39 The close structural relationship between the agonist and the antagonist 
also suggest an orthosteric interaction.  
Nevertheless, the mechanism of antagonism should be determined with caution. The 
effect of a strong allosteric antagonist on the dose response curve of the agonist can be similar to 
the effect of a competitive antagonist at certain conditions.39, 74 A single IC50 value does not 
illustrate the mode of inhibition. Instead, the relationship between IC50 value and the wide range 
of agonist concentration can be a helpful indication.39 For competitive antagonists, IC50 values 
are directly related to the agonist concentration; it increases as agonist concentration increases. 
For allosteric antagonists, the relationship is hyperbolic; there is a limit to which IC50 can 
increase. Allosteric antagonists can also show parallel right shift of the dose-response curves, 
resembling the competitive antagonists.39 For clarification, the dose-response curves need to be 
monitored using the antagonists at wide range of concentrations.39 If there is a limit in the right 
shift, the antagonism is considered allosteric rather than orthosteric competitive. Furthermore, 
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the effects of the antagonist on the dose-response curves can be ambiguous as they depend 
largely on the kinetics of the system. More experimental evidence is crucial to deduce the 
mechanism of odorant antagonism.  
 
Section 1.G. Odor Modulation 
Odorant antagonists can potentially be utilized as specific odor modulators. 
Conceivably, antagonism should alter the olfactory code. By inhibiting one or multiple 
ORs, an antagonist could modulate the olfactory code of another odorant or a mixture of 
odorants.  The modulation on the olfactory code of an odorant could subsequently lead to 
modulation of the percept. In fact, undecanal, which is an antagonist of OR17-4 (human OR), 
has shown to reduce the perceived intensity of bourgeonal, an agonist of the receptor.75 Despite 
the evidence of antagonism, the roles of antagonism in encoding of odor mixtures remains 
unclear. A previous study has monitored a subset of the glomeruli in the dorsal region of the 
mouse OB via intrinsic signal imaging.76 No clear evidence of antagonism was found in 
encoding of the naturally occurring odor mixtures that were tested, such as coffee and clove.76   
However, the intrinsic signals not only reflect the activity of the OSNs but it could also represent 
the activation of the secondary neurons, mitral cells, especially at high concentrations of the 
stimuli.77 Such investigation for antagonism among the constituents of the naturally occurring 
odor mixture has not been done at the level of ORs thus far. Thus we aimed to explore the extent 
to which the odorant antagonism contributes to the encoding of naturally occurring odor 
mixtures, at the level of the ORs. (Chapter 2) Combined with such psychophysical evaluations, 
the knowledge of antagonist-agonist identities would provide insights into directed modulation 
of the percepts generated by odor mixtures.  
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Odor modulation is of a special interest in fragrance industry. Using odorant molecules 
with weak or no odor can serve as a good strategy in odor modulation. An odorant antagonist 
might specifically block a malodor. It may also be possible to manipulate a pleasant odor in a 
directed manner using an odorant inhibitor. Methyl dihydrojasmonate (MDHJ), a weak floral 
odorant, is well known in fragrance industry as a ‘booster’; when present in a fragrance mixture, 
it is known to modulate the odor of other odorants.5 Herein, we tested if MDHJ can modulate the 
olfactory code of floral odors through “boosting” or antagonism. (Chapter 4) It is possible that 
MDHJ may serve as a positive allosteric modulator (PAM). A PAM in general is a ligand that 
enhances a receptor activity by binding to an allosteric site. These modulators might not be able 
to activate a receptor but could enhance the activation by the orthosteric agonists. No published 
research has been done at a molecular level on how MDHJ modulates other components in a 
mixture.  
 
Section 1.H. Examining the Olfactory Code using Calcium Imaging on Dissociated 
Olfactory Sensory Neurons 
Surveying populations of native OSNs via calcium imaging allowed probing for odorant 
antagonism. 
To understand the extent of antagonism in making up the olfactory code, the responses of 
the random populations of ORs were monitored throughout the study rather than a single 
particular OR. To that end, dissociated MOE, which contains a population of OSNs expressing 
unidentified ORs were used. Since each OSN expresses a single OR, the cellular response 
represents the OR response. The OSN population is simultaneously subjected to sequential 
application of odorants, and the responses of each OSN are individually analyzed. Such 
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experiments give useful information on the olfactory codes of the tested stimuli. For instance, the 
degree to which two different odorants co-activate the ORs can be deduced from the population 
analysis. The size of an odor’s olfactory code, which is represented by the percentage of ORs 
that respond to the odor, can also be estimated using these random populations. We investigated 
the prevalence of antagonism in encoding of odorant mixtures. We specifically analyzed the 
population responses to the odorant mixtures, and compared them to the responses elicited by 
individual constituents. Although the identities of the responding ORs were not known in this 
process, we could probe the overall frequencies of antagonism.  
Using the dissociated MOE not only enabled us to concurrently test a group of ORs, but 
it also provided a system with ORs in their native, unmodified states, along with natural, 
canonical, downstream signaling molecules. The identity of G-proteins that interact with ORs is 
of particular importance, as receptive fields of ORs are G-protein dependent.51 For example, in 
HeLa cells expressing a mouse OR, S86, along with Gα15, octanoic acid was an agonist.
51 
However, for HeLa cells expressing the OR and Gαolf, octanoic acid did not elicit any response. 
In fact, the octanoic acid was found to be an antagonist of OR86.51 Using the native OSNs 
assures circumvention from such artifacts caused by non-natural signaling molecules. A possible 
downside in using dissociated MOEs is the potential damage to the cilia, where most ORs and 
other signaling molecules are concentrated. Also, the axons of the OSNs are severed during the 
dissection of the MOE and the morphology of these bipolar neurons are lost during the 
dissociation. However, in-situ hybridization and immunostaining experiments have shown that 
ORs and the canonical signaling molecules are also expressed in cell bodies, though at lower 
levels.12, 78, 79  Also, the dissociation procedure is extremely inefficient, resulting in a few 
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hundred viable cells per 10 million, and the possibility of bias during this selection is at least 
possible, though unlikely. 
The antagonist screening was carried out by monitoring the effects of various odorants on 
agonist-induced responses, as often done in pharmacological ligand screenings for antagonists. 
Activation of ORs by the agonists were detected using calcium imaging, taking advantage of the 
downstream increase in intracellular calcium concentration upon agonist-OR binding. (Fig. 1-3) 
Calcium imaging has been widely employed to visually screen the odorant induced responses of 
ORs.50, 53, 80 The calcium signals in response to various stimuli were detected via calcium 
sensitive dye, Fura-2AM. The OR responses to the agonists were measured in absence and then 
in presence of possible antagonists. Using this method, we were able to probe for antagonism on 
the ORs that detect charred wood odor and rose oil odor.  
 
Section 1.I. Overview of this Thesis 
Part I of this study aimed to obtain a better understanding of odorant antagonism, using 
populations of dissociated primary mouse olfactory sensory neurons and calcium imaging. 
Firstly in Chapter 2, the prevalence of odorant antagonism in a naturally occurring odor mixture, 
made up of structurally similar odorants, was explored, using the odor mixture of charred wood 
odor as an example. Screening the primary mouse OSNs revealed that the odorant antagonism 
between the constituents was unimportant for making up the olfactory code of the charred wood 
odor.  
The vibrational theory of olfaction states that the activation of the ORs depends on the 
intramolecular vibrations of the odorants.1, 2, 81 Using the calcium imaging system, we 
investigated whether or not the deuterated odorants and the non-deuterated odorants activate the 
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same set of ORs. If the OR activation depended on the intramolecular vibration, the deuterated 
odorants would not be able to activate the ORs that are activated by the non-deuterated odorants. 
If true, deuteration would convert any agonist to an antagonist, a prediction that drew our 
attention. Chapter 3 describes our results showing that the population of ORs on the primary 
mouse OSNs could not differentiate the deuterated odorants from the non-deuterated odorants, at 
concentrations above the threshold. There was no evidence of vibrational mechanism in 
activation of the ORs.  
 Methyl dihydrojasmonate (MDHJ) is a weak floral odorant that is widely used in in the 
fragrance industry. While MDHJ itself has a weak floral quality, it is often used as a ‘booster’ in 
floral odor mixtures because it accentuates floral odors of other constituents in the mixture.4, 5, 82 
While the modulation of the floral odors by MDHJ has been observed at the behavioral level, 
how MDHJ accomplishes this has been unknown at the receptor level. Using a rose-oil odor 
mixture as a representative floral odor mixture, we explored the effect of MDHJ on the olfactory 
code of other floral odorants, as described in Chapter 4. The responses of the primary mouse 
OSNs showed that MDHJ modulated the response to the rose oil mixture through inhibition, as 
well as by activating additional OSNs.  
 Part II of this thesis describes an incomplete side project aiming to understand the impact 
of pre-mRNA 3’ end cleavage on gene expression and regulation of the odorant receptor genes. 
The accurate formation of 3’ untranslated region (3’ UTR) is a critical requirement for the proper 
gene expression. The 3’UTR is formed by the 3’ cleavage and polyadenylation of the pre-
mRNA, and it often contains regulatory elements such as RNA binding protein binding sites, 
AU-rich elements, and miRNA target sites. The 3’ cleavage is guided by the cis-acting 
polyadenylation signal (PAS). A significant percentage of human and mouse genes harbor 
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multiple PAS.83 The choice of PAS determines where the pre-mRNA is cleaved and 
polyadenylated. Depending on which PAS is used, the regulatory elements are either included or 
excluded, affecting the gene regulation. The use of alternative PAS is also known to be tissue 
specific.84, 85 However, the use of alternative PAS by OR genes, if any, has been poorly 
annotated thus far. In preparation for profiling the 3’ UTR of the OR genes, we first reviewed the 
next generation methods by which the 3’UTRs are targeted for analysis, in Chapter 5. We also 
briefly describe in Chapter 6, the harvest of total RNA from mouse MOE and OB in preparation 
for cDNA library production by 3’ region extraction and deep sequencing (3’ READS). Analysis 
of this data has not yet been done. Finally, in preparation for this side-project, in Chapter 7 we 
describe a method for optimizing in-vitro 3’ cleavage assays using DEAE-fractionated HeLa 
cleavage factors and small scale HeLa nuclear extracts from adherent cells.  
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Part I. Odorant Receptor-Ligand Interactions 
Chapter 2. Antagonism among Charred Wood Phenolic Odorants Contributes Weakly to 
Charred Wood Odor Character 
 
Synopsis 
In nature, an odor is often presented as a blend of multiple odorants. The odor mixture is 
encoded in the mammalian peripheral olfactory system by a combination of odorant receptors 
(ORs). However, the way by which each constituent contributes to the representation of the 
whole mixture remains unclear. Odorants are known to have dual roles, as they can either 
activate or inhibit the ORs. The presence of an antagonist within a mixture of odorants can 
conceivably affect the mixture representation by inhibiting the responses of other constituents. 
This study examined the extent to which the odorant antagonism contributes to characterizing an 
odor mixture at the receptor level. To that end, we tested for the antagonism between individual 
components of the charred wood odor on dissociated mouse olfactory sensory neurons (OSNs) 
via calcium imaging. The odorants in this mixture are closely related in structure, so that any 
effects observed are likely through the orthosteric binding sites on ORs. The contribution of 
antagonism was found to be unimportant in the burnt wood odor mixture. Our data support the 
conclusion that the percept of this mixture results from the additive responses of the ORs to the 
components of the mixture.  
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Section 2.A. Introduction  
Odors in nature are often complex mixtures consisting of several to hundreds of odorants. 
For instance, at least eleven odorants were identified as principal components of a charred wood 
odor.86 More than a hundred odorants have been identified to make up an odor of rose oil.65, 87 To 
interpret such complex stimuli, mammals use the combinatorial olfactory code, wherein each 
odorant of a mixture binds and activates a specific combination of ORs. Each OR can recognize 
and respond to multiple odorants. Moreover, binding of an odorant to an OR can result in 
activation, partial activation, or inhibition of the OR. (Chapter 1, Section 1.B, 1.C) A population 
of the ORs that are activated by an odorant or a mixture of odorants defines the olfactory code of 
the odorant or the mixture.20 Given the diversity of odorants and the high number of ORs in 
mammalian genome, the number of combinations that can represent different odors is enormous. 
This is thought to allow humans to discriminate more than one trillion odors,8 though this 
number has been disputed.9, 10  
In context of a mixture, it is conceivable that an antagonist could modulate the olfactory 
code by reducing the effects of other constituents. Antagonism may partly account for an 
observation that a percept of an odor mixture is not equal to the linear sum of responses to its 
constituents.66-69 Thus far, a few odorants have been identified as antagonists of ORs (human, 1 
rat, and 4 mouse ORs) along with their cognate agonists. (Chapter 1, Table 1-1) 45-53, 73 One of 
these antagonists, undecanal, inhibits a human OR, OR17-4, from responding to its agonist, 
bourgeonal.46 In agreement with the inhibitory role of undecanal, a psychophysical evaluation 
using human subjects revealed that exposure to undecanal prior to bourgeonal reduced the  
perceived intensity of bourgeonal.75 The identified odorant antagonists share structural 
similarities with their respective agonists. Based on the structural similarities between the 
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antagonists and the agonists, it has been suggested that the odorant antagonists competitively 
inhibit the ORs at the speculated orthosteric sites. 
The role of antagonism, if any, in representation of a naturally occurring odor mixture at 
the level of OR populations has not been investigated. Do some odorants fine-tune the olfactory 
code by inhibiting select ORs? Since an odor is perceived by a combinatorial population of ORs 
rather than a single OR, we probed for antagonism between the constituents of a naturally 
occurring odor on populations of mouse ORs. To that end, a naturally occurring and widely 
recognized odor of charred wood was used as an example to compare how OR populations 
respond to the mixture versus each constituent. The detection of charred wood odor is important, 
as it is a typical odor of building fires.86 The charred wood odor is also similar to some of the 
widely used smoky odors and flavors; for instance, many of its constituents are found in tobacco 
smoke, cooked bacon, and smoked salmon.88 Herein, we first characterized how the charred 
wood odor mixture and its constituents are encoded by the ORs via calcium imaging. Then we 
tested all constituents in binary mixtures to identify the agonist/antagonist pairs.  
Surveying the OR population revealed that the response to the charred wood odor 
mixture was slightly different from the linear summation of the responses elicited by individual 
constituents. This hinted at possible cases of antagonism among the charred wood odor 
constituents. The constituents were then tested in binary mixtures in every possible pair to 
identify agonist/antagonist pairs. The results showed evidence for a single case of antagonism 
within the charred wood odor mixture. Although rare, the relationship between the identified 
antagonist and the agonist resembled the case of OR-I7, where length of a molecule with similar 
functional group at one end of the molecule was shown to be important for activation of the OR.  
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Section 2.B. Data & Results 
2.B.1. Charred Wood Odorants 
Heitmann et al. identified the chemical 
composition of the “burnt smell” by sampling 
materials from building fire sites, followed by 
headspace analysis.86, 89 Based on the identified 
compounds and the ratio of their abundance, a 
model “burnt smell” was reconstituted from 
eleven pure chemical compounds.86, 89 This 
mixture contained 2,4-substituted phenols (Fig. 
2-1, compounds 5 and 6) that most likely 
originated from incompletely combusted lignin, 
a polymer present, along with cellulose, in cell 
walls of the wood.89 For practical testing of the 
relationship between the constituents and the mixture, the six most abundant compounds from 
this mixture were chosen for this study. (Fig. 2-1) The mixture of these six compounds accounts 
for 91% of the reconstituted “burnt smell” and it is hereafter referred to as charred wood odor 
mixture. (Fig. 2-1, M1) The three major compounds are methyl phenols (Fig. 2-1, Group 1) – the 
three compounds have the same chemical formula but differ in the position of the methyl groups. 
The less abundant compounds are the methoxy phenols with various substituents on carbon 
number 4. (highlighted in green, Fig. 2-1, Group 2). While the compounds in Group 2 differ in 
size, length and chemical formula, the positions of the substituents remain the same. Through 
 
Figure 2-1. Constituents of the charred wood 
odor  
The most abundant compound, compound 1, was 
used at 30 µM for screening experiments. The 
concentrations of other compounds were adjusted 
according to their percentage in the burnt wood 
mixture. The charred wood odor mixture (M1) 
contained all 6 compounds at the concentrations 
indicated here.  
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screening dissociated mouse OSNs, the structure-activity relationships of these closely related 
compounds were investigated.  
 
2.B.2. Neuronal Responses to Odorant Stimuli as Detected via Calcium Imaging 
The responses of the dissociated OSNs to the mixture and individual charred wood odor 
constituents were recorded using calcium imaging, taking advantage of the calcium influx upon 
OR activation. (Chapter 1, Section 1.B) The calcium signal of an OSN represents the response of 
a specific OR, as each mature OSN expresses a single OR. For that reason, the terms ‘responses 
of OSNs’ and ‘responses of ORs’ are used interchangeably throughout this report. The response 
magnitude from cell to cell varied. Therefore, in every calcium imaging experiment presented 
here, the cellular response to each stimulus was normalized to the cell’s response to forskolin (10 
μM), which is known to induce calcium influx by directly activating adenylyl cyclase III (AC-
III).53, 90 (Fig. 2-2a) The normalized responses were then color coded, and the response profiles 
of the responding OSNs were summarized into heat maps when applicable. (Fig. 2-2b) In the 
color coded heatmaps, responses higher than 90% of the forskolin responses were treated as 
saturating responses, denoted by black boxes. (Fig. 2-2) Responses that were less than 10% of 
the forskolin responses were not regarded as odorant responses, denoted by white boxes. In the 
heatmap, each row illustrates responses of a single OSN, inferring a receptive field for the OR. 
Each column of the heatmap characterizes the overlapping, but unique olfactory code of each 
odorant. While the identities of the ORs expressed by the tested OSNs were unknown, this 
method allowed us to probe the response patterns of the OR population. 
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2.B.3. The Reconstituted Charred Wood Odor Mixture is Activated ~1.7% of the 
Dissociated Mouse OSNs.  
In multiple experiments, a total of 10,309 viable OSNs were screened for their response 
to the charred wood odor mixture (M1, proportional concentration conditions). A mouse has 
~1100 OR genes17-19 and the number of screened viable OSNs exceeded the number of mouse 
OR-genes by nine-fold, possibly covering all expressed ORs at least once. On average, 1.7% 
(standard deviation = 0.4%, 6 biological replicates, 10,309 OSNs in total) of the viable OSN 
populations were activated. The reconstituted charred wood odor mixture, M1, contained the 6 
constituents at concentrations proportional to their natural abundance in the odor, as indicated in 
Fig. 2-1. By “proportional” we mean that the most abundant constituent, compound 1 was 
arbitrarily set at 30 μM, and the concentrations of the other constituents were adjusted according 
to their percentage in the odor. (The concentration proportional to their natural abundance will be 
referred to as the “proportional” concentration hereafter.) The population of OSNs that 
responded to M1 may be taken to represent the olfactory code of the charred wood odor in the 
mouse, at the concentrations we used. Changing the concentration of the odorants would alter the 
percentage of the responding OSNs. For instance, testing a separate group of 1853 OSNs showed 
that, when all constituents are present at 30 μM regardless of their abundance in the natural odor, 
a higher percentage (2.5%) of the population was activated by the charred wood odor mixture.  
 
2.B.4. Odorant Receptor Responses to the Constituent Odorants are Specific. 
Of the 10,309 viable OSNs that were screened with M1, 5,106 OSNs were subsequently 
exposed to individual constituents at the proportional concentration. (The rest, 5,203 OSNs were 
used for different experiments, as discussed later in Fig. 2-6 and Fig. 2-10) In this set of 5,106 
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OSNs, M1 activated 1.53% of the population. (78 out of 5,106 OSNs) A total number of 91 
OSNs responded to one or more of the tested constituents. In addition, 1 OSN responded weakly 
to M1 but showed no clear response to the individual constituents. (Fig. 2-2b: Cell 78) It is 
possible that this OR responded to the summation of several constituents that did not elicit any 
responses on their own. Of the 91 OSNs that responded to one or more of the constituents, three 
OSNs responded to all six constituents individually but failed to respond to M1. (Fig. 2-2b: Cells 
79~82) These cells might specialize in low concentration stimuli. Ten other OSNs responded to 
one or a few constituents but failed to respond to the mixture. (Fig. 2-2b: Cells 83~92) This set 
was of interest to us since it was possible that one or more of the constituents of the mixture 
acted as antagonists, inhibiting the responses of other constituents acting as full or partial 
agonists. 
The screen with individual charred wood odor constituents revealed that the OR 
responses to the odorants were specific. Of the 92 odorant-responding OSNs, 46 responded 
specifically to one compound despite the structural similarities between the constituents. (50.0%, 
Fig. 2-2b: Cells 39-77 and Cells 86-92) Testing of additional OSNs with all constituents at equal 
concentrations still showed that the ORs preferentially respond to 1 constituent. (Fig. 2-3) The 
fact that most ORs can discriminate between the structurally similar constituents even at a high 
concentration shows that the OR responses to the odorants are specific.  
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Figure 2-2. The OSN responses to the charred wood odor mixture and its constituents  
a) A representative calcium imaging recording of an OSN (Cell 2) is shown. M1 is the mixture of all six 
constituents. M1 and all individual constituents (compounds 1-6) were applied at the proportional 
concentrations. The response to each odorant or a mixture was normalized to that of 10 μM forskolin 
(forsk). The boxes on top of each response illustrate the intensity of the responses compared to the 
response of forsk, as used in the heat map. The red bars mark the time at which the stimuli were 
applied. The structures and the concentrations of the individual constituents are shown in the box.  
b) The normalized responses of all OSNs that responded to one or more of the tested stimuli were 
summarized as a heatmap. From 3 mice, 5,106 viable OSNs were tested in total. Of the 5,106 OSNs, 78 
OSNs responded to M1 (1.53%) and 91 OSNs responded to one or more of the constituents.  
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2.B.5. The Subtle Structural Differences among the Charred Wood Odorants are Detected 
by Unique Combinations of ORs  
  Functional Group Recognition by ORs  
Each constituent exhibited a unique olfactory code despite the subtle structural 
differences between them. The population of OSNs that detected the methyl phenols in Group 1 
was distinct from the population that responded to the methoxy phenols in Group 2. (Fig. 2-2b 
and Table 2-1) Of the 92 odorant-responding OSNs, 30 and 43 OSNs responded exclusively to 
Group1 or Group 2 odorants, respectively. (Table 2-1: proportional concentration, Fig. 2-2) The 
two groups of compounds were also readily distinguished at equal concentrations of the 
constituents. (Table 2-1, 30 μM and 100 μM; heatmaps are not shown for these data.) On 
average, at the concentrations tested, 15.8% of the odorant-responding OSNs responded to 
 
Figure 2-3. OR responses discriminate among the charred wood odor phenols.  
Most OSNs were narrowly tuned in the scope of burnt wood odor mixture, responding only to one of the burnt 
wood odor compounds. Lower percentages of OSNs responded to higher number of constituents. The 
concentrations given in Fig. 2-1 are denoted as Proportional Conc. Separate experiments were done to test each 
compound at 30 µM and 100 µM. The number of viable OSNs for the Proportional Conc, 30 µM, and 100 µM 
was 5,106, 10,323, and 2,470, respectively. The percentages were calculated out of the total number of OSNs 
that responded to one or more constituents in each experiment. The number of odorant-responding OSNs for 
Proportional Conc., 30 µM, and 100 µM was 91, 217, and 82 OSNs, respectively.  
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constituents from both Group 1 and Group 2. The remaining 84.2% (37.8% + 46.4%) exclusively 
responded to either Group 1 or Group 2 odorants.  
 
 
Table 2-1. OR populations can distinguish Group1 and Group2 odorants at various concentrations.  
The number of OSNs that exclusively responded to Group 1 compounds, Group 2 compounds and compounds from 
both groups are listed. The concentrations of the constituents used were as follows. Proportional: concentration 
proportional to their natural abundance in the charred wood odor as listed in Fig. 2-1; 30 µM: all constituents tested 
at 30 µM; 100 µM: all constituents tested at 100 µM. The percentages in the parenthesis were calculated by dividing 
the number of OSNs that responded to Group1, Group2 or both by the total number of OSNs that responded to at 
least one constituent, denoted as ‘total odorant-responding OSNs’ and multiplying by 100%. This is a summary of 
multiple experiments. The number of forskolin responding OSNs were 3,351, 8,470, and 2,470 for proportional 
concentration, 30 µM, and 100 µM, respectively. 
 
Concentration 
 Group 1 odorants  
only 
Group 2 odorants 
only 
Odorants from both 
groups 
Total Odorant-
responding OSNs 
Proportional 30 (33.0%) 43 (47.3%) 18 (19.8%) 91 
30 µM 89 (41.0%) 103 (47.5%) 25 (11.5%) 217 
100 µM 31 (37.8%) 38 (46.3%) 13 (15.9%) 82 
Average % 37.8% 46.4% 15.8%  
 
 
Position of Methyl Groups in Group 1 Odorants 
The positions of the methyl groups on compounds 1-3 were recognized by distinct sets of 
OSNs. The OSNs that responded selectively to one of the ortho-, meta-, and para- positions of 
the methyl group are shown in the non-overlapping areas of the Venn diagram. (Fig. 2-4a, b, c) 
The overlapping areas indicate the common OSNs that did not differentiate the odorants. It is 
noteworthy that the ortho-, meta-, and para- isomers of Group1 are better discriminated when 
presented at equal concentrations. At the proportional concentration, the overlap between the 
individual compounds was higher. For instance, out of the 20 OSNs that responded to compound 
2, 18 OSNs also responded to compound 1 at the proportional concentration. Likewise, out of the 
17 OSNs that responded to compound 3, 12 OSNs responded to both compounds 1 and 2. (Fig. 
2-4a) At equal concentrations, compounds 1, 2 and 3 exhibited less overlap, as more OSNs 
exclusively responded to compound 2 or 3. (Fig. 2-4b, c) While the methyl phenols were readily 
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discriminated by some of the ORs, the percentage of OSNs activated by compounds 1, 2, or 3 
were similar when tested at equal concentrations. (Fig. 2-4h, i)  
Size and Length Discrimination 
The methyl phenol compounds of Group 2 were also encoded by unique combinations of 
OSNs. (Fig. 2-4d-f) Most ORs responded specifically to one of the Group 2 odorants, shown by 
the non-overlapping areas of the Venn diagrams. (Fig. 2-4d-f) All three compounds have in 
common the 2-methoxy and phenol groups, but they differ in size of the substituent at position 4. 
(Fig. 2-1, highlighted in green) This agrees with a previous report indicating that the difference 
of a single carbon can be detected by some ORs.20 When the constituents were tested at equal 
concentrations, compound 5 activated a slightly larger percentage of OSNs than the other 
compounds. (Fig. 2-4h, i). Unexpectedly, there were a few OSNs that were activated by 
compound 6 (4-ethyl) and 4 (4-H) but not 5 (4-methyl). We do not understand how a receptor 
could accommodate an ethyl group or H and not accommodate a methyl group. Nevertheless, 
there were very few such OSNs.   
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Figure 2-4. ORs detect and discriminate among Group 1 odorants and Group 2 odorants.  
(a-c) OSNs responding to Group 1 constituents at the proportional concentration, 30 µM, and 100 µM   
Each area of the Venn diagram represents a specific response profile and the number of OSNs with 
that response is given. For instance, at the proportional concentration, the number of OSNs that 
responded to compounds 1, 2 and 3 (Cpd1, Cpd2, and Cpd3 in the figure) only were 12, 2, and 5, 
respectively. There were 12 OSNs that responded to all three of the isomers, represented by the 
overlap between the three circles. The odorants were applied at 30 µM for (b) and 100 µM for (c).  
(d-e) OSNs responding to Group 2 constituents at the proportional concentration, 30 µM, and 100 µM 
(g-i) The percentages of OSNs responding to each constituent at various concentrations 
The percentages were calculated by dividing the number of responding OSNs by the number of 
forskolin-responding OSNs. A total of 5,106, 10,323, and 2,470 OSNs were screened for the 
proportional concentration, 30 µM, and 100 µM, respectively.  
Cpd = compound, forsk = forskolin 
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2.B.6. Major Contributors of the Charred Wood Odor Mixture Code 
At the proportional concentration, 
when the number of the responding cells 
are compared to the total number of 
forskolin-responding cells, the percentage 
of cells responding to each compound 
individually did not vary much. To 
examine the response elicited by the 
charred wood odor mixture, we focused 
on the OSNs that responded to M1. We 
divided the number of cells responding to 
each constituent by the number of the 
total cells activated by the mixture, M1, (instead of forskolin as we usually do) (Fig. 2-5). This 
comparison exaggerated the differences between the numbers of OSNs activated by the 
constituents. Of the 5,106 viable OSNs, 78 OSNs (1.5%) responded to the M1 mixture. (Fig. 2-
2b: column M1, Cells 1-78) The individually applied constituents that activated the most of the 
M1-responding OSNs were compounds 1, 4 and 5, but note that compound 1 was used at 3-4 
times the concentration of the others. Compound 1 activated 45% of the M1-responding OSNs. 
(Fig. 2-2b, Fig. 2-5) Of note, 90% of the M1-responding OSNs responded to compounds 1, 4 or 
5, while compounds 2, 3, and 6 activated fewer cells responding to the M1 mixture. One possible 
implication of this re-examined data is that the M1 mixture response might be dominated to such 
an extent that the same response might be obtainable with just compounds 1, 4 and 5. 
 
Figure 2-5. The compounds 1, 4, and 5 activated the highest 
percentages of the M1-responding OSNs at the proportional 
concentrations. 
Each constituent activated different percentages of the M1 
responding OSNs. The percentages were calculated based on 
the total number of M1 responding OSNs, 78. The cells 
incorporated in this chart are a subset of the cells shown in Fig. 
2-2b.  
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A separate screen of 2,733 viable OSNs gave some support to larger importance of 
compounds 1, 4, and 5. (Fig. 2-6) A mixture made up of these alone (M2) at the proportional 
concentration recapitulated 82% (41 out of 50 OSNs) of the responses of the whole mixture 
(M1). (Fig. 2-6) The minor contributors account for the remaining 18% of the response to M1. It 
is noteworthy that the major contributors of the mixture were not necessarily the most abundant 
constituents. This is in line with previous reports that constituents of low abundance are also 
important for odor perception.65 So, the minor contributors serve to activate additional ORs that 
are required for encoding of the mixture. The 18% of the OSNs that are not activated by M2 are 
undoubtedly crucial for encoding of the charred wood odor mixture. One OSN (Fig. 2-6: Cell 
143) responded to the sub-mixture, M2 but not to the whole mixture, M1. The response, likely 
elicited by one or more of the minor contributors, was inhibited in the whole mixture, M1.  
 
Figure 2-6. The major contributors of the charred 
wood odor mixture are compounds 1, 4, and 5. 
(a) The structures of compounds 1, 4, and 5 are 
shown in the box. These three compounds seem 
to be the major contributors of the population 
response to the burnt wood odor mixture. The 
mixture of the major contributors, M2 was made 
up using the concentrations according to their 
abundance in the mixture.  
(b) Out of 2,733 viable OSNs tested, 50 OSNs 
(1.83%) responded to the whole burnt wood odor 
mixture, M1. The numbers in the Venn diagram 
denote the number of responding OSNs showing 
the corresponding response profile. M2 led to 
activation of 42 OSNs and recapitulated 82% (41 
OSNs) of the population response to the whole 
mixture, M1.  
(c) The heatmap summarizes the responses of all 
OSNs that responded to M1 and M2. Each row 
represents responses of a single OSN.  
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2.B.7. Binary Mixture Experiments Designed to Reveal Antagonism  
Our results showed that some OSNs responded to one or a few constituents of the charred 
wood odor mixture but failed to respond to the whole mixture (M1). (Fig. 2-2, Fig. 2-6) In order 
to identify the agonist/antagonist pairs among the charred wood odor mixture, the constituents 
were tested in binary mixtures in all possible combinations. In the experiments, individual 
constituents and the binary mixtures were applied to the dissociated OSNs in a sequential 
manner.  
The OSNs have been shown to exhibit desensitization upon repeated exposure to their 
agonists.91-93 The complex mechanism of odorant-induced desensitization is not completely 
understood yet. However, it is known to be dependent on intracellular Ca 2+, which binds 
calmodulin and subsequently decreases the affinity of CNG channel towards cAMP.94 It is also 
known that the increase in cAMP leads to phosphorylation of the receptors via cAMP dependent 
protein kinase (PKA) and G-protein-coupled receptor kinase 3 (GRK3).93 The phosphorylation, 
in turn, promotes β-arrestin-mediated internalization of the ORs.93  
It is unknown whether there are cell-to-cell differences in the onset of the desensitization 
and the time required to recover from the desensitization. In our experiments to survey for 
antagonism, the OSNs were exposed to a designated agonist, followed by the binary mixtures 
containing the agonist and the candidate antagonist. When an OSN fails to respond to the binary 
mixture containing the agonist after responding to the agonist alone, the candidate antagonist 
might have inhibited the agonist-induced response. It is also possible however, that the OSN was 
desensitized over repeated applications of the agonist.  
In order to understand whether desensitization was common with the dissociated OSNs in 
our experimental system, the neuronal responses elicited by the repeated pulses of a single 
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odorant were observed. To that end, a group of 898 viable OSNs was exposed to 20 repeated 
pulses of compound 5 at a single concentration, 100 μM. Of the screened 898 viable OSNs, 13 
OSNs (1.40%) responded consistently to each and every pulse of compound 5 despite slight 
desensitization; the magnitude of the responses decreased after the first odorant application. (e.g. 
Fig. 2-7a) Four OSNs (0.45%) showed significant desensitization over repeated applications of 
the agonist. These OSNs responded to the first few odorant applications but completely failed to 
respond to the later applications. (e.g. Fig. 2-7 b) No OSN showed recovery from the 
desensitization within the duration of the experiment. The viability of these neurons were 
checked by their response to forskolin (10 µM). 
It has been previously shown that the OSNs exhibit various levels of odorant-independent 
spontaneous activity.95, 96 The spontaneous activity was shown to be dependent on the identity of 
the OR, as the OSNs expressing different ORs exhibited different levels of the spontaneous 
activity.95, 96 To filter out false positive responses from the basal activities, only the calcium 
response peaks that concur with the time of odorant application, designated by red tick marks, 
were considered as possible odorant-induced responses. Even with this criterion, 4 OSNs 
(0.45%) inconsistently responded to only one or two pulses out of the twenty repeated odorant 
applications. (e.g. Fig. 2-7c) The inconsistent responses may have arisen from the odorant-
independent activity of the ORs that coincidently occurred at the time of odorant application.96 
Another possible explanation for the inconsistent responses is that the tested concentration (100 
µM) may be at the borderline of the threshold concentration for these 4 ORs, where the calcium 
responses might not be reliable.16  
Besides the 898 OSNs that responded to forskolin, 6 OSNs responded consistently to 
multiple applications of odorants at the start of the experiment but ceased to respond to the later 
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odorant applications and forskolin. (e.g. Fig. 2-7d) The cell death of the dissociated neurons over 
time might explain such cases. It is also possible that the OSNs failed to restore the calcium 
concentration to the basal level, due to loss of some calcium metabolism function. This genre of 
cell failure is quite obvious and poses a low risk of misinterpretation as a false positive 
antagonist call. 
A few measures were imposed on the experiments designed to screen for antagonism, to 
control for the desensitization, the basal responses and the loss of cellular functions over time. 
Firstly, the tested agonist of interest was applied at least twice per experiment: once at the start of 
the experiments and once towards the end of the experiments to ensure that the cell is 
maintaining its response over the duration of the experiment. In order to avoid interpreting the 
inconsistent odorant-independent responses (Fig. 2-7c) as antagonism, each agonist was applied 
alone at least twice, in the beginning and towards the end, in all experiments. Only the cells that 
reliably responded to the agonist at the beginning and end of the experiment, at the precise time 
points of odorant application were analyzed. In addition, as with other experiments in this study, 
the OSNs that did not respond to forskolin (activator of AC-III) were excluded from the analysis. 
With these controls, the lack of response from a mixture containing the agonist was interpreted 
as inhibition by the antagonist. 
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Figure 2-7. Response patterns of the OSNs to repeated applications of compound 5 at 100 μM. 
(a) Of the 898 forskolin responding OSNs, 13 OSNs (1.40%) responded consistently to each of the 20 
pulses of 100 μM odorant. This cell is one example. The red marks indicate the time at which the 
stimulus was applied. 
(b) Four OSNs desensitized over the repeated pulses but responded to forskolin. For experiments screening 
for evidence of antagonism, OSNs that fail to respond to the agonist towards the end of the experiment 
were excluded from analysis to control for desensitization.  
(c) Four other OSNs showed one or two responses out of the 20 pulses of the stimulus. The responses of 2 
example OSNs are shown. These OSNs were viable, since they responded to forskolin. In our 
experiments, only the cells that responded reliably at least twice to the agonist exactly at the time of 
applications were included in the analysis.  
(d) Six OSNs ceased to respond to the odorant and forskolin after multiple responses to the odorant. OSNs 
that did not respond to forskolin were not included in the analysis presented in this study.  
(e) The number of OSNs that exhibited the illustrated response patterns are shown.  
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The extent of odorant antagonism within the charred wood odor was extensively 
surveyed by testing the 6 components of the charred wood odor in binary mixtures. In each 
experiment, 1 odorant was tested as an agonist and all other odorants as inhibitors, thereby 
covering all possible combinations. A representative calcium imaging response to binary 
mixtures is shown in Fig. 2-8. This particular OSN responded to compound 1 and 4. Compounds 
2-6 were each applied in binary mixture with compound 1, as possible inhibitors. None of the 
compounds showed inhibition in this case.   
 
2.B.8. A Single Case of Apparent Antagonism within the Charred Wood Odorant Mixture 
The inhibition was rare between binary mixtures of the charred wood odor. Screening a 
total of 8,470 viable OSNs showed 41 OSNs that responded to the constituents. Out of the 41 
responses, only one case of antagonism was observed, unlike what we expected from Fig. 2-2. 
The responses of OSNs to compounds 1-5 were not inhibited by any other compounds tested. 
(Table 2-2) Nonetheless, of the 7 OSNs that responded to compound 6, one OSN showed 
inhibition by compound 4 (1/7 = 14.3%). The response profile of this OSN showed that it 
responded to compound 5 and compound 6 but didn’t show responses to compounds 1-4. (Fig. 2-
 
Figure 2-8. A representative calcium response of an OSN to compound 1 and its binary mixtures 
Compound 1 was tested as an agonist and compounds 2-6 as candidate antagonists. Out of 2,560 viable OSNs 
tested, 16 OSNs responded to compound 1. (0.6%, Table 2) The responses of an example OSN is shown. The red 
tick marks denote the time at which the odorants were applied. The agonist was used at 30 µM. Each binary 
mixture were made up with the agonist and the antagonist, both at 30 µM. The cells were pre-exposed to the 
antagonist alone for 8 seconds prior to each application of the binary mixture. Compounds 2, 3, and 6 did not 
lead to calcium influx in this cell. This OSN responded to all the binary mixtures tested, indicating that 
compounds 2-6 did not inhibit the neuronal response to compound 1. Only the cells that responded to both 
applications of compound 1 were considered for analysis.  
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9a) The binary mixtures of compound 6 with each of compounds 1-3 activated the receptor, so 
compounds 1-3 did not inhibit it. Therefore these responses are elicited by compound 6, showing 
that the OSN reliably responded to compound 6. In contrast, the binary mixture with compound 
4 inhibited the OR response to compound 6. (Fig. 2-9a) Thus it can be inferred that compounds 
4-6 bound to the receptor while compounds 1-3 did not interact with the receptor. The 2-
methoxy-1-phenol edge on compounds 4-6 appears necessary for binding and activation of this 
unidentified receptor, but activation also requires substituent larger than H in the 4-position on 
the ring. In separate experiments, we tested compound 6 at 100 μM as an agonist and compound 
4 at 200 μM as the possible antagonist on a total of 1764 OSNs. Of the 1764 OSNs, 23 OSNs 
(1.3%) responded to compound 6 at 100 μM. None of these responses were inhibited by 
compound 4 at 200 μM. (data not shown) This result may mean that the OR antagonized by 4 
was not expressed in the OSNs of this follow-up experiments. 
 
 
Table 2-2 Summary of binary screening for inhibitors among the charred wood odor mixture  
All constituents were tested at 30 µM. 
Agonist 
 
Possible Inhibitors 
 
OSNs Responding to 
Agonist, % 
Responses 
Inhibited, % 
Inhibitor 
Compound 1 
Compounds 2,3,4,5,6 0.63 
(16/2560) 
0.00 None 
Compound 2 
Compounds 1,3,4,5,6 0.53 
(8/1520) 
0.00 None 
Compound 3 
Compounds 1,2,4,5,6 0.16 
(2/1248) 
0.00 None 
Compound 4 
Compounds 1,2,3,5,6 0.50 
(6/1207) 
0.00 None 
Compound 5 
Compounds 1,2,3,4,6 0.58 
(4/690) 
0.00 None 
Compound 6 
Compounds 1,2,3,4,5 0.56 
(7/1245) 
0.08 Compound 4,  
0.08% 
 
 
Although uncommon, the inhibition of compound 6 by the shorter compound 4 
demonstrated that the size and/or the absence of a comparatively large hydrophobic group in the 
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4-position might be an important factor in odorant antagonism. The similar shape and the 
identical 2-methoxy-1-phenol group of the two molecules may have allowed them to fit into the 
same binding pocket of an OR. To bind and stabilize a fully active state of the receptor however, 
the length of the ethyl group on compound 6 might be essential. (Fig. 2-9) This resembles the 
case of rat OR-I7 whose primary natural product agonist is octanal (Fig. 2-9b, compound 9).53 
That receptor was also activated by compound 8, a conformationally restricted octanal mimic. 
The receptor’s response to octanal has been shown to be antagonized by the shorter molecules 
with same functional group but otherwise highly similar chemical composition, compound 7.53 
(Fig. 2-9b)   
We wondered if this might be a general way to design an antagonist: preserve at one end 
of the molecule its polar functional group, but shorten at the other end its hydrophobic carbon 
 
Figure 2-9. A single case of antagonism 
a) Out of the 1,245 tested viable OSNs, 7 OSNs responded to compound 6. (0.56%) The response of 1 
OSN was inhibited by compound 4 as shown. The red tick marks denote the time at which the odorants 
were applied. Each odorant was given at 30 µM. The binary mixtures consisted of 30 µM of each 
odorant. The response was not inhibited by compounds 1-3, or compound 5. 
b) The structures of the antagonist (compound 4) and the agonists (compounds 5-6) among the charred 
wood odor are shown, highlighting the differences in the length of the odorants. Also shown are the 
antagonist (compound 7) and the agonists (compounds 8-9) of OR-I7. Compound 8-9 has been shown 
to activate rat OR-I7. Compound 8 mimics the extended structure of compound 9, a better known 
agonist for the receptor.53 Compound 7 was identified as an antagonist of OR-I7.53  
Compound 7: 2-cyclohexylacetaldehyde, compound 8: 2-(4-ethylcyclohexyl)acetaldehyde, compound 
9: octanal 
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chain. Specifically, we asked if the removing the hydrophobic group in the 4-position while 
preserving the 2-methoxy-1-phenol edge would result in a compound that can inhibit some 
eugenol-responding ORs. To that end, we asked if compound 4 (guaiacol) could inhibit cells that 
are activated by eugenol (Fig. 2-10a, compound 10), which has an allyl group on the 4-position. 
We screened 1,342 viable OSNs, of which 34 OSNs responded to eugenol (compound 10) at 300 
μM. But only one of the 34 OSNs (2.9%) showed inhibition of the response elicited by eugenol 
(compound 10) by compound 4 (300 μM). (Fig. 2-10b)  
Eugenol (compound 10) is known to be inhibited by methyl isoeugenol (Fig. 2-10a, 
compound 11), on at least one of the known ORs, MOR-EG.50 The structure of methyl 
isoeugenol (compound 11) is similar to that of eugenol, in that it has the 2-methoxy functional 
group on the benzene ring and the hydrophobic alkyl group on 4-position. It however, differs 
from eugenol (compound 10) and some of the charred wood odorants (compounds 4-6) in that it 
has a 1-methoxy functional group instead of 1-phenol. Thus the importance of the hydrophobic 
 
Figure 2-10. Inhibition of eugenol (compound 10) by guaiacol (compound 4) and methyl isoeugenol 
(compound 11)  
a) The structures of compound 4, eugenol (compound 10), and methyl isoeugenol (compound 11) are 
shown. All odorants were tested at 300 μM.  
b) Of the 1,342 viable OSNs, 34 OSNs responded to eugenol (compound 11). Of the 34 OSNs that 
responded to eugenol, the response in 1 OSN was inhibited by compound 4 but not by compound 11.   
c) Of the 34 OSNs that responded to eugenol, 5 OSNs were showed inhibition by methyl isoeugenol 
(compound 11) but not by compound 4.  
Compound 10: 2-methoxy-4-(2-propenyl)phenol, also known as eugenol, compound 11: 1,2-
dimethoxy-4-(prop-1-en-1-yl)benzene, also known as methyl isoeugenol (A mixture of cis- and trans- 
isomers were used.) 
 
44 
 
alkyl group on 4- position was examined by comparing the inhibition of eugenol (compound 10) 
by compound 4 with the inhibition by methyl isoeugenol (compound 11), on the population of 
OSNs. Methyl isoeugenol (compound 11, 300 μM) inhibited a higher number of eugenol-
responding OSNs compared with compound 4. Of the 34 OSNs, 5 OSNs (14.7%) showed 
inhibition by methyl isoeugenol (compound 11). The response of one representative OSN is 
shown in Fig. 2-10c. These results suggested that the absence of the substituent on 4-position of 
compound 4 might be important in inhibiting only a limited number of ORs, and of no value as a 
general approach for designing an antagonist. No OSN that responded to eugenol (compound 10) 
was inhibited by both compound 4 and methyl isoeugenol (compound 11), showing that odorant 
antagonism is OR specific, even when expected to be orthosteric in all cases.  
 
2.B.9. Constituents of the Charred Wood Odor Contributed Additively to Represent the 
Odor Mixture. 
The results presented here suggest that while the charred wood odor constituents may be 
potential antagonists to the ORs, the occurrence of such antagonism in representing this naturally 
occurring odor is uncommon. In other words, each constituent contributed additively to the 
olfactory code of the charred wood odor for the most part. A separate screening of 2,470 viable 
OSNs confirmed this conclusion as they were exposed first with one constituent, compound 1, 
followed by addition of other constituents one by one. (Fig. 2-11) As each constituent was added 
to the mixture, additional OSNs responded until 50 OSNs (2.02%) were activated by the whole 
charred wood mixture (M1). During this procedure no evidence for antagonism was found upon 
addition of the last constituent. An imperfection in this kind of experiment is that for practical 
reasons we had to choose only one order of adding the six odorants – 1, 2, 3, 4, 5, 6 – but there 
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may be up to 46,656 different orders of addition. The number will in effect be less than 46,656 
because of partial redundancy – 2, 3, 4- may occur in many different orders of adding, for 
example. Nevertheless, in view of our binary mixture testing results, in the order of build-up we 
chose, no sign of fine tuning of the olfactory code by antagonism was observed as odors were 
added. And no evidence for mixture suppression was observed under these conditions. This 
experiment supports the conclusion that mouse OSNs respond to the reconstituted charred wood 
mixture in an additive manner, and antagonism does not contribute to the final combination of 
activated OSNs. 
 
 
Figure 2-11. The constituents additively constructed the olfactory code of the charred wood odor 
mixture. 
To a population of 2,470 viable OSNs, compound 1 was applied, followed by sequential addition of other 
constituents one by one. There was no sign of antagonism in this experiment. The olfactory code of M1 was the 
sum of all OSNs activated by each constituents. The constituents of stimuli A-E and M1 are shown. All 
constituents were used at the proportional concentration as shown on the right.  
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Section 2.C. Conclusion 
 The charred wood odor, as tested by a reconstituted artificial charred wood odorant 
mixture, was encoded (i.e. activated) by ~1.7% of the mouse OR population under the specific 
set of conditions we chose. At the receptor level, each constituent was differently recognized by 
the OR population. The unique set of ORs that were activated by each constituent combined to 
make up the olfactory code of the whole mixture without any subtractive effects due to 
antagonism.  
Given the structural similarities between the known agonists and antagonists of some 
ORs (Chapter 1, Table 1-1), we tested for odorant antagonism among the closely related phenol 
compounds that make up the charred wood odor. However, we found almost no role for odorant 
antagonism in encoding the charred wood odor mixture among this OR population. (Chapter 2, 
Table 2-2) In fact, the constituents contributed additively to encode the charred wood odor 
mixture, at least in the order we chose to apply them. (Fig. 2-11) 
In the one case of putative receptor antagonism, compound 4 specifically inhibited the 
OR from responding to compound 6. (Fig. 2-9a) This OR was activated by compounds 5 and 6, 
but inhibited by compound 4. (Fig. 2-9a) It was neither activated nor inhibited by compounds 1-
3, suggesting that the 2-methoxy group in combination with the phenol hydroxyl is required for 
binding this unidentified OR. Once the odorant was bound to the receptor, the length of the alkyl 
substituent at the 4-position was necessary for activating the receptor. The lack of the alkyl 
substituent led to antagonism. The importance of the alkyl substituent could not be generalized to 
other ORs. Only 1 out of the 7 OSNs that responded to compound 6 was inhibited by compound 
4. (Chapter 2, Table 2-2) Also, methyl isoeugenol (compound 11), which has an allyl substituent 
on 4-position inhibited more eugenol-responding OSNs than compound 4. (Fig. 2-10) These 
findings suggested that the odorant antagonism is OR specific.  
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The structural similarities between the antagonist, compound 4, and the agonists, 
compounds 5, 6 suggested orthosteric, competitive antagonism. The low frequency receptor 
antagonism among these closely related odorants might also suggest low occurrence of the 
orthosteric antagonism within natural fragrance mixtures consisting of closely related structures. 
It leaves unanswered the question whether odorant antagonism is more common for naturally 
fragrance mixtures that are composed of structurally diverse odorants, such as rose oil odor 
mixture. (The structures of some constituents are shown in Chapter 4, Fig. 4-1) Higher 
occurrences of odorant antagonism among the more structurally diverse odorants could suggest 
possibility of OR inhibition via allosteric binding sites rather than orthosteric binding sites.   
In the future, coupling calcium imaging experiments with single cell RT-PCR could 
identify the ORs involved in detecting the odor mixture. Identifying the receptor would allow 
follow up investigations on the ORs that exhibited antagonism. For instance, genetically labelled 
OSNs might be used to deorphan the identified ORs.16, 53 
 
Section 2.D. Materials & Methods 
2.D.1. Isolation and Dissociation of Olfactory Epithelium  
All use and care of the laboratory animals were in compliance with guidelines of The 
City College of New York Institutional Animal Care and Use Committee, (Protocol number 
937). Six to eight week old male C57BL/6 mice (Charles River) were overdosed with ketamine 
(Ketaset) at 100 mg/kg and xylazine (AnaSed) at 10 mg/kg via intraperitoneal injection, followed 
by decapitation. The depth of anesthesia was assessed before decapitation by observing inability 
to remain upright, loss of purposeful voluntary movement, and loss of response to reflex 
stimulation (toe pinch with firm pressure). The main olfactory epithelium was dissected out from 
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the head onto an ice tray and placed in the chilled divalent-cation-free-Ringer solution (145 mM 
NaCl, 5.6 mM KCl, 10 mM HEPES, 10 mM glucose, 4 mM EGTA, pH 7.4). The tissue was 
dissociated in 4.6 ml of divalent-cation-free-Ringer solution containing 2.62 U/ml dispase II 
(Roche), 0.54 mg/ml collagenase (Life Technologies), 3.26 mg/ml bovine serum albumin 
(Roche), and 0.1 mg/ml deoxyribonuclease II (Sigma), for 1 hour at 37°C with continuous 
shaking on an incubator shaker. The tissue was then placed in culture media (warmed to 37°C) 
and the cells were further dissociated by brief vortexing (vortex setting between 7~8). The 
culture media consisted of DMEM/F12 supplemented with glutamine (Corning), 10% FBS 
(VWR), 1X insulin transferrin Selenium Ethanolamine (Life Technologies), 1% 100 U/ml 
penicillin, 100 µg/ml streptomycin (Cellgro), and 100 µM ascorbic acid. The dissociated cells 
were allowed to settle on concanavalin A (Sigma, 10 mg/ml) coated coverslips placed in 35 mm 
Petri dishes for 15 minutes. After the cells adhered to the coverslip, 2 ml of culture media was 
added to each Petri dish and the dishes were placed in a CO2 incubator at 37°C for at least 1 
hour.  
 
2.D.2. Calcium Imaging 
After incubation, cells were washed with Ringer’s solution and loaded with Ringer’s 
solution containing 6.25 µM Fura-2 AM (Life Technologies) and 0.02% pluronic acid F-127 
(Life Technologies), for 45 minutes in the dark at room temperature. The coverslips were then 
placed on the bottom of the imaging chamber (RC24-E, Warner Instruments), mounted on an 
inverted fluorescent microscope (Axiovert 200, Zeiss) using the platform and the stage adapter 
(Warner Instruments). The chamber was constantly washed with the Ringer solution at 1 ml/min 
using a peristaltic pump (Rainin) and a vacuum pump to sip away any excess that might 
49 
 
overflow the imaging chamber. Stimuli were injected into the chamber from 5ml syringes via a 
perfusion manifold (Warner Instruments). Each injection lasted 8 seconds. The system for 
perfusion and injection of Ringer solution and odorant stimuli was customized in our lab 
according to the system I was trained on during a few month’s work with Dr. Zita Peterlin in the 
lab of Prof. Stuart Firestein, in the Department of Biological Sciences at Columbia University. 
For ratiometric calcium imaging, the inverted fluorescent microscope was equipped with 
a 10x/0.50 Fluar objective lens, a filter wheel, filter set for 340 nm and 380 nm, CCD camera 
(Model number 01-EXI-BLU-K-F-M-14-C, QI Imaging), and MAC 6000 controller system 
(Ludl Electronic Products Ltd.). This imaging system was assembled by Advanced Imaging 
Company. The time-lapse images were acquired every 4 seconds at 340 nm and 380 nm 
excitation and 510 nm emission and the fluorescent intensities (F) were measured for each cell 
using Metamorph software (Version 7.8.6.0, Molecular Devices). The data shown is the F340/F380 
vs. time, graphed using Excel software after the experiment. For future reference, using 
MetaFluor software should allow real-time acquisition and calculation of the ratio, F340/F380. In 
the system we used, the real-time detection of odorant-induced response was not possible. 
Rather, the captured images were available for analysis after the recording. Due to the short life-
time of the dissociated primary mouse OSNs and our goal to obtain data from the large 
populations of the OSNs, the analysis of the odorant-induced responses were done on the next 
day.   
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2.D.3. Stimuli 
All odorants were mixed on the day of the experiment with DMSO (Alfa Aesar) at a 
concentration 1000 times higher than the working concentration. The working concentrations are 
the final concentrations of the odorants that were applied to the OSNs. Then, the odorants were 
further diluted with Ringer solution into working concentrations just prior to imaging. 
Compounds 1-6 and 8-10 were purchased at the highest purity available. Compounds 1 and 2 (o-
Cresol and m-cresol) were purchased from Oakwood Products, Inc. Compounds 3, 4, and 6 (p-
Cresol, guaiacol, and ethyl guaiacol) were purchased from TCI. Methyl guaiacol (compound 5) 
was purchased from Alfa Aesar. The purity of these odorants were >99% when assessed by gas 
chromatography – mass spectrometry (GCMS QP-2010). Compounds 10 (eugenol) was 
purchased from Alfa Aesar. Compound 11 (methyl isoeugenol) was purchased from Sigma 
Aldrich and purified using flash chromatography (Teledyne Isco CombiFlash Rf-200 flash 
chromatography system) before use by my colleague, Dr. Min Ting Liu. The purity of 
compounds 10 and 11 was > 99%, assessed by gas chromatography (GC-2010 with FID 
detector). All gas chromatography analyses were performed by Dr. Min Ting Liu. And an equal 
detector response to all chemicals present was assumed. At the end of each imaging experiment, 
10 µM forskolin (MP Biomedicals, LLC) was applied in Ringer solution in order to assess the 
viability of the OSNs and the health of the cAMP signal transduction system.   
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Part1. Odorant Receptor-Ligand Interaction 
Chapter 3. A Calcium Imaging Comparison of Deuterated and Non-Deuterated Odorants in the 
Activation of Dissociated Mouse Olfactory Sensory Neurons 
 
Synopsis 
A vibration theory of olfaction states that an intramolecular vibrational energy of the 
odorant is a determinant of odorant receptor activation. One way that has been widely used to 
test the role of the intramolecular vibration in odorant recognition by odorant receptors (ORs) is 
by using deuterated odorants. Replacing the hydrogen atoms of an odorant with the deuterium 
atoms changes the intramolecular vibration while the size and shape of the molecule change 
little. According to the vibration assisted theory, the deuterated odorants (D-odorants) would not 
activate the ORs that are normally activated by the non-deuterated odorants (H-odorants) due to 
the different intramolecular vibration. A recent study has shown that select modified human and 
mouse odorant receptors expressed in a heterologous system were not able to discriminate D-
odorants from the H-odorants.97 However, the theory has not been tested in primary olfactory 
sensory neurons (OSNs) yet at the molecular level. To that end, we tested the all-D-odorants and 
the all-H-odorants on the populations of dissociated primary mouse OSNs, using calcium 
imaging. The activation of ORs by the D-odorants and the H-odorants was compared for the first 
time in the primary mouse OSNs. The results showed that the mouse ORs, including mouse OR-
I7 could not discriminate the deuterated odorants from the non-deuterated ones. This suggested 
that the activation of the ORs are not dependent on the intramolecular vibration of the odorants.  
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Section 3.A. Introduction: Deuterium and the Vibrational Theory of Odorant Receptor 
Activation 
Chemical structures and conformations of odorants are known to be important for OR 
activation and antagonism.53 In contrast, the vibrational theory of olfaction states that the 
activation of the OR depends on the intramolecular vibration of a molecule rather than the 
chemical structure of the molecule.1, 2, 81, 98-100 The proposed mechanism assumes that there is an 
electron donor site and an acceptor site on the OR, with energy difference between the two 
locations.1, 101 It further proposes that electron transfer from the putative donor site to the 
putative acceptor site is required to initiate the downstream neuronal signaling pathway. In the 
absence of an agonist, the electron transfer is prevented due to the energy gap between the two 
sites. The theory predicts that the binding of an odorant that has the vibrational energy that 
matches the energy gap between the donor site and the acceptor site would mediate the transfer, 
via electron tunneling.1 It has been suggested that the theory can be tested by substituting the 
hydrogen atoms of an odorant with deuterium atoms.2, 81, 98-100 The deuterated molecules are 
almost identical to the non-deuterated molecules in size and shape; the average bond length of C-
D is ~0.005 Å  shorter than C-H.102 However, deuterium substitution leads to drastic shift in the 
intramolecular vibration, as evidenced by the different infrared spectra (Fig. 3-1).  
Previous behavioral studies suggested that the insects, such as fruit flies and honeybees 
could smell the differences between the deuterated odorants and the non-deuterated odorants.81, 
100, 103 This finding was confirmed by the calcium imaging of the glomeruli in the antennal lobe 
of the honeybees.99 The insect ORs, unlike the mammalian ORs, share no sequence homology to 
the known GPCRs.104 The insect ORs also have signal transduction pathway that is distinct from 
the mammalian ORs.33, 104 
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For humans, psychophysical experiments have showed mixed results on whether the 
percepts of the isotopologues could be discriminated from each other.98, 105 Isotopologues are the 
molecules that differ only in the isotopic composition.106 At the molecular level, recent 
experiments by Block et al. showed that the deuterated odorants and the non-deuterated odorants 
activated select human and mouse ORs and that they exhibited similar EC50 values in a 
heterologous system.
97 EC50 is the concentration of an agonist that produces 50% of the maximal 
response to the agonist.107 The study employed Hana3A cell line, derived from HEK293T cell 
line.97 The activation of the ORs was detected by cAMP response element driven luciferase 
reporter gene. Hana3A cell line stably expresses RTP1L, RTP2, REEP1, and Gαolf proteins to 
assist expression and function of the ORs.108 The ORs are also transfected into the cells along 
with other accessory proteins and luciferase constructs. The ORs in Hana3A system are often 
tagged with a part of N-terminal sequences of rhodopsin to promote cell-surface expression.108 
This method requires up to ~4 hours of incubation of the odorants with the cells.108 The possible 
artifacts of prolonged exposure of ORs to the odorants has not been investigated. Using this 
system, Block et al. concluded that the ORs in the heterologous system did not discriminate the 
deuterated odorants from the non-deuterated odorants, arguing against the vibrational theory.97 
Such finding has not been tested on the un-modified, primary mouse OSNs at the molecular level 
yet.  
An antagonist, by definition, interacts with the receptor and prevents the initiation of the 
excitatory signal, thereby inhibiting effect of the agonist.37 Because of the similar size and the 
shape, the deuterated odorants and the non-deuterated odorants should bind to the common 
receptors. For instance, Solov’yov et al. proposed that the deuterated 1-octanol and the non-
deuterated 1-octanol would bind to the same receptor.1 They also predicted through ab initio 
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quantum chemistry calculations that the deuterated 1-octanol would not activate the ORs that are 
activated by the non-deuterated 1-octanol, due to differences in the vibrational energy.1 In such 
scenario, the deuterated odorants could potentially antagonize the responses of the non-
deuterated odorants, providing a strategy for targeted inhibition. In fact, if the vibrational theory 
of olfaction were true, deuterating an odorant agonist would reliably produce a receptor 
antagonist, unless electron transfer were required for mere binding. 
In order for the deuterated odorants to function as antagonists, they must not be agonists 
of the ORs that are activated by the non-deuterated odorants. We compared the mouse primary 
OSN population responses elicited by the deuterated odorants with that of the non-deuterated 
odorants. The dissociated OSNs allowed testing of the ORs in their primary environment with 
canonical signaling molecules and with no modifications on the receptor protein. The calcium 
imaging experiments presented below showed that, at concentrations above the detection 
threshold, all ORs that responded to the non-deuterated forms of 1-undecanol, 1-octanol and 
octanal also responded to the deuterated forms of the odorants. This suggested that the activation 
of the ORs were not dependent on the intramolecular vibration of the odorants. Consequently, 
the deuterated odorants were not suitable as antagonists.   
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Figure 3-1. Structures of the deuterated odorants and the non-deuterated odorants, and their vibration 
spectra (IR)  
a) 1-Octanol and 1-Octanol-d17 
b) 1-Undecanol and 1-Undecanol-d23 
c) Octanal and octanal-d16 
The IR spectra were provided by Dr. Min Ting Liu.  
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Section 3.B. Results and Discussion 
3.B.1. Spectral Analysis of Deuterated and Non-Deuterated Odorants Used 
Replacing hydrogen atoms of the odorants with deuterium atoms alters the vibrational 
frequencies of the bonds. The IR spectra of the non-deuterated 1-octanol (H-1-octanol), 1-
undecanol (H-1-undecanol), and octanal (H-octanal), along with their deuterated isotopologues 
(D-1-octanol, D-1-undecanol, and D-octanal) demonstrate the changes caused by the 
replacement. (Fig. 3-1) The C-H stretches of H-1-octanol showed absorption peaks at 3000-2850 
cm-1. (Fig. 3-1a, blue) These absorption peaks were shifted to 2300~2050 cm-1 for D-1-
undecanol, as bonds with heavier atoms absorb at lower frequencies. (Fig. 3-1a, red) H-1-
undecanol, H-octanal and their deuterated isotopologues showed similar shifts. (Fig. 3-1b,c)  
 
3.B.2. Comparing Odorant Receptor Activation by Deuterated Odorants and Non-
Deuterated Odorants on C57BL/6 Mouse Olfactory Sensory Neurons 
 If the activation of the ORs depends on the intramolecular vibrational energy of the 
odorants, the deuterated odorants and the non-deuterated odorants would activate different sets 
of ORs. To that end, we examined the OSN population of the wild type C57BL/6 mice to 
compare their responses to the non-deuterated odorants with that of the deuterated odorants. The 
isotopologues at various concentrations were sequentially applied to the populations of 
dissociated mouse OSNs. In total, 7,520 OSNs were screened with H- and D- isotopologues of 
various odorants in different experiments. This afforded a nominal 7X coverage, because mice 
have ~1,100 OR genes, attempting to cover all expressed ORs. The equal concentrations of the 
deuterated odorants and the non-deuterated odorants were ensured by comparing peak areas of 
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the gas-chromatography analysis. The activation of the ORs by the odorants was detected using 
calcium imaging.  
A positive, odor-induced calcium response was determined by the reliability of the 
response, timing of the response, and the strength of the response. To ensure the reliability of the 
responses, all odorants were tested at least twice at the same concentration; only the OSNs that 
showed reliable responses both times throughout the duration of the experiments were used for 
the analysis. To further control for the possible effects of desensitization, the deuterated odorants 
and the non-deuterated odorants were applied in random orders. Also, the OSNs that responded 
to DMSO, the solvent for the odorants, were excluded from analysis to control for possible 
odorant-independent activity. Any OSN that showed calcium responses that do not coincide with 
the time of odorant application was excluded. In addition, the viability of the cells and their 
signal transduction apparatus were checked with forskolin (10 μM) at the end of each imaging 
experiment. Forskolin directly activates adenylyl cyclase type III (AC-III) and increases the 
intracellular concentration of cyclic AMP (cAMP), consequently leading to calcium influx.109 It 
has been used at 10 μM on dissociated OSNs to induce calcium responses.53, 110, 111 Each calcium 
response was normalized to the response elicited by forskolin. The calcium response was 
considered positive if it was ≥ 10% of the forskolin-induced calcium response.  
 
3.B.2.1. Testing of 1-octanol vs. 1-octanol-d17 by Calcium Imaging 
In order to test if H- and D- isotopologues of 1-octanol could be differentially detected by 
the mouse ORs, the response of the OSN population to H-1-octanol was compared to the 
response to D-1-octanol. The dissociated mouse OSNs were sequentially exposed to DMSO (the 
solvent in which the odorants were dissolved), D-1-octanol, 1-octanol at 3 µM, 10 µM, 30 µM, 
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and 100 µM, followed by forskolin. D-1-Octanol was applied first at each concentration. After 
the pulse of forskolin, the cells were allowed to rest for ~5 minutes. The same odorants were 
then applied again to the same set of OSNs, but this time, H-1-octanol was applied first. (Fig. 3-
2) Essentially, each isotopologue was tested twice at each concentration, for all OSNs. DMSO 
and forskolin were also tested twice. Only the cells that responded consistently to the two 
applications of the odorants and forskolin were considered for analysis. For example, if the OSN 
responded to the first application of forskolin but not the second, the cell was excluded from the 
analysis. Similarly, if the OSN responded only once out of two applications of H-1-octanol at 10 
μM, the cell was excluded from further analysis. It is noteworthy that for reasons unclear at the 
moment, the number of OSNs responding to the tested stimuli decreased significantly after the 
application of the forskolin; while 3,011 OSNs responded to the first application of forskolin, 
only 1,881 OSNs responded to the second application of forskolin. In addition, 47 OSNs were 
excluded from analysis because they showed inconsistent responses to odorant stimuli after the 
first application of forskolin. Consequently, 1,834 OSNs were analyzed for their responses to the 
D- and H- isotopologues. For other experiments in this chapter, all odorant stimuli were tested 
before the application of forskolin.  
The OR population responses to H-1-octanol were similar but not identical to the 
responses elicited by D-1-octanol. Out of the 1834 viable OSNs that were analyzed, 27 OSNs 
responded to both isotopologues at the tested concentrations. (3 µM, 10 µM, 30 µM, and 100 
µM) (Fig. 3-2) A representative response is shown in Fig. 3-2a, Cell 6. One OSN responded to 
H-1-octanol at 3 µM, but it did not respond to D-1-octanol at this concentration. (Fig. 3-2, Cell 
8) This is the result we would expect if a cell could differentiate the H-odorants from the D- 
odorants. However, the cell responded consistently to both isotopologues at higher 
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concentrations tested. (Fig. 3-2, Cell 8) One other OSN responded only to H-1-octanol at 100 
µM; concentrations higher than that were not tested. (Fig. 3-2, Cell 29) In both Cell 8 and Cell 
29, the OSNs responded only to H-odorant at the lowest concentration at which they responded 
to the odorant, i.e. close to the threshold of detection.  
 
 
 
 
 
Figure 3-2. At the concentrations above the detection threshold, all OSNs that responded to H-1-octanol 
also responded to D-1-octanol. 
The dissociated OSN populations were tested with 1-octanol (H) and 1-octanol-d17 (D) at (3 μM, 10 μM, 30 
μM, and 100 μM. The viable OSNs that showed reliable responses to the stimuli were included in the analysis. 
In total, 1,834 viable OSNs were analyzed.  
(a) The OSNs were applied with DMSO (the solvent for odorants), D and H isotopologues at different 
concentrations, followed by a pulse of forskolin (forsk, 10 μM). After application of forsk, the experiment was 
repeated on the same set of OSNs, but with reversed order of application for the isotopologues. Therefore, each 
isotopologue was applied twice at each concentration. The two sets of responses are from a single cell. The red 
marks indicate the time at which the stimuli were applied to the OSNs. Cell 6 responded to both D and H at all 
concentrations tested. Cell 8 responded only to H at 3 μM but responded to both H and D at higher 
concentrations. Cell 29 responded only to H at 100 μM. Concentrations higher than 100 μM were not tested.  
(b) Each calcium response of each individual OSN elicited by the stimulus was normalized based on the 
calcium response elicited by forskolin. The normalized responses were then summarized into a heatmap. Each 
line represents the normalized response pattern of one OSN. The response pattern of Cell 6 is shown as an 
example.  
60 
 
 
3.B.2.2. The Difference in Hydrophobicity of the Deuterated and Non-Deuterated Odorant 
One possible explanation for the observed differential detection threshold for H-1-octanol 
and D-1-octanol at the lowest responding concentrations could be the reduced hydrophobicity of 
the deuterated compounds.112, 113 In a study by Turowski et al., ten compounds and their 
deuterated isotopologues were tested on reverse phase liquid chromatography, using various non-
polar stationary phases.112 The study concluded that the deuterated isotopologues exhibited 
weaker non-polar interactions with the stationary phases, compared to the hydrogen 
isotopologues.112 In support of the differences in the hydrophobicity between the isotopologues, 
 
Figure 3-3. The deuterated odorants and the non-deuterated odorants exhibit different retention times on 
HPLC 
The retention time for deuterated odorants were shorter than that of the non-deuterated odorants on the octadecyl 
(C18) stationary phase of liquid chromatography. The shorter retention time on the hydrophobic phase indicates 
that the deuterated odorants form weaker hydrophobic interactions, compared to the non-deuterated odorants.   
X-axis: time (min), Y-axis: Intensity X106 The LC-MS data was obtained by Dr.Rinat R. Abzalimov.   
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a liquid chromatography-mass spec analysis showed that the retention times of deuterated 1-
undecanol, 1-octanol, and octanal were shorter than that of the non-deuterated odorants. (Fig. 3-
3) Reverse phase high-performance liquid chromatography (HPLC) separates compounds in part 
on the basis of their hydrophobicity, as those that interact more favorably with the hydrophobic 
stationary phase (C18) and less favorably with water elute later. The C-D bonds are ~0.005 Å  
shorter than the C-H bonds.102 And the volume and the polarizability of the molecules slightly 
decrease upon deuteration.112 Turowski et al. suggested that the decreased volume and 
polarizability correlates to the decreased hydrophobicity in the deuterated molecules.112 Various 
studies have shown via molecular modeling, in silico screening, and experimental validations 
that hydrophobic interaction is an important part of odorant binding by the ORs.52, 114, 115  The 
only two OSNs that responded differently to the isotopologues responded to the H-1-octanol, but 
not to D-1-octanol at the threshold concentration. It is conceivable that D-1-octanol failed to bind 
the two ORs at low concentrations due to weaker hydrophobic interactions. Increasing 
concentration may overcome this small effect, rendering the effect of the weaker odorant-OR 
interaction less or un-detectable.  
 
3.B.2.3. A Technical Detour: The Odorant-Induced Responses to Odorants Near the 
Threshold Concentration Can have an Empirical Probability Approaching 0.5.   
 An alternative explanation for the differential odorant-elicited responses to the H-1-
octanol and D-1-octanol is that OSNs could respond in a stochastic manner at the near-threshold 
concentrations. Previous studies have shown that a single odorant molecule binding to an OR has 
a low probability of activating the downstream neuronal signal.31, 32 By measuring the current 
change in response to the odorant stimuli, Ben-Chaim et al. estimated that ~19 odorant-binding 
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events are necessary for signal transduction in a mouse OSN.32 Given the low chances of 
activating the neuronal signal, the odorant induced responses at the near-threshold concentrations 
could be inconsistent. The “sporadic” responses of the ORs to some of their weak agonists have 
also been observed in a previous study by Bozza et al.; M71 showed inconsistent responses to 
benzaldehyde and mouse OR-I7 to hexanal, nonanal, and hydroxycitronellal, when the odorants 
were applied at 25 µM.16 The authors speculated that 25μM was the near-threshold concentration 
for these agonists on these receptors.16   
To gauge if the inconsistent responses at the near-threshold concentrations are prevalent 
in our experimental system, 765 viable OSNs were subjected to application of only the H-1-
octanol at 3 μM, 10 μM, and 100 μM. The odorant application was repeated 4 times per each 
concentration. Of the 765 OSNs tested 17 OSNs responded to the H-1-octanol. While 16 out of 
the 17 odorant-responding OSNs responded consistently, 1 OSN showed inconsistent response at 
the lowest tested concentration, but not the higher concentrations. (Fig. 3-4) Upon repeated 
application of H-1-octanol at 3 µM, the cell responded only twice out of four applications. (Fig. 
 
Figure 3-4. The OR responses might be inconsistent at the threshold concentrations 
a) A representative response to repeated applications of H-1-octanol at 3 μM, 10 μM, and 100 μM is 
shown. Out of 765 viable OSNs, 17 OSNs responded consistently to 1-octanol.  
b) 1 OSN showed inconsistent response to H-1-octanol at 3μM, although it responded consistently at 
higher concentrations.   
The red tick marks indicate the time at which the stimuli were applied. The odorant application lasted 
for 8 seconds.  
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3-4b) Such inconsistency might seem unlikely in Cell 8 and Cell 29, as the cells responded both 
times to the non-deuterated odorant instead of randomly responding to both isotopologues. 
However, because of the unreliable odorant-induced responses at the near-threshold 
concentrations, the differences observed at the lowest responding concentration could not be 
interpreted as true discrimination between the deuterated and the non-deuterated odorants.  
  
3.B.2.4. Testing of 1-Undecanol vs. 1-Undecanol-d23 by Calcium Imaging 
It has been suggested that the effect of the spectral differences between the H- and D- 
odorants is higher for the large odorants with higher number of carbons (therefore the C-H/C-D 
bonds), such as musk odorants.98 However, the musk odorants have been shown to activate a 
very small percentage of mouse ORs, compared to odorants that have aldehyde or alcohol 
functional groups.80 Therefore, using musk odorants was not suitable for a population study. 
Aiming to screen higher number of ORs, with an odorant that has high number of carbons, we 
chose 1-undecanol. It has 3 additional carbons and 6 additional C-H bonds, compared to 1-
octanol. The populations of mouse OSNs were sequentially applied with H-1-undecanol and D-
1-undecanol, followed by forskolin. Each odorant was tested twice at 3 μM and 10 μM. (Fig. 3-
5a, b) In total, 3,664 viable OSNs were screened. As with other experiments, the OSNs that 
showed unreliable responses to the repeated application of a single odorant were excluded from 
further analysis. (3.B.2) In this experiment, 3,650 OSNs were analyzed for their ability to 
discriminate the odorant isotopologues. Fourteen OSNs were excluded due to unreliable 
responses to the odorant, or desensitization, or for odorant-independent responses. (Fig. 3-5c, d)  
Moreover, because the odorants were tested only once at 100 μM, the OSNs that responded only 
at 100 μM were not included in the analysis. (Fig. 3-5e) 
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Mouse primary OSNs did not discriminate H-1-undecanol from D-1-undecanol. (Fig. 3-
5a, b) At 3 μM and 10 μM, the 1-undecanol isotopologues activated 22 and 24 OSNs, 
respectively. (Table 3-1) All OSNs that responded to H-1-undecanol also responded to the 
deuterated D-1-undecanol. The order in which the isotopologues were applied did not affect the 
response pattern of the OSNs. (Fig. 3-5 a, b)  The inconsistent response to the odorants at the low 
concentrations were not observed on this population of OSNs. It is possible that the tested 
concentrations (3 μM and 10 μM) are above the detection threshold of these OSNs for the 1-
undecanol isotopologues. Indeed, for the 24 OSNs that responded to 1-undecanol, the magnitude 
of the responses at 3 μM and 10 μM were always higher or equal to the responses at 100 μM. 
(Fig. 3-5a, b) This suggested that for these OSNs, 3 μM and 10 μM were saturating 
concentrations, well above the detection threshold.  
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Figure 3-5. Mouse OSNs did not discriminate H-1-undecanol from D-1-undecanol at 3 μM and 10 μM. 
In total, 3,664 forskolin-responding OSNs were tested with H-1-undecanol and D-1-undecanol-d23. The red 
marks indicate the time at which the stimuli were applied to the OSNs. In order to account for possible effects 
of desensitization, the order in which each isotopologue was applied was randomized. In order to control for 
possible odorant-independent basal OR activities, each isotopologue was applied twice at 3 μM and 10 μM. A 
higher concentration, 100 μM was included in order to gauge if the lower tested concentrations are saturating 
concentrations for the receptor.  
(a) A representative calcium response shows that this OSN responded to both isotopologues at 3 μM and 10 
μM, when H-1-undecanol was applied first.  
(b) A calcium response of another OSN shows that this cell also responded to both isotopologues at 3 μM and 
10 μM when D-1-undecanol was applied first. Regardless of the order of application none of the OSNs 
responded exclusively to one isotopologue.  
(c) Some OSNs desensitized over repeated pulses of odorant application. These cells were excluded from the 
analysis.  
(d) The cells that showed inconsistent responses to the two pulses of the stimulus at a single concentration were 
excluded from the analysis. It is likely that these responses are odorant-independent. Only the OSNs that 
responded consistently to the same odorant at least twice were considered for the analysis.  
(e) Since 100 μM concentration was tested only once per isotopologue, the OSNs that responded to the odorants 
only at 100 μM were not considered.   
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Table 3-1. Identical sets of OSNs responded to the H-1-undecanol and D-1-undecanol. Of the 3,650 viable 
OSNs that were analyzed, 22 OSNs and 24 OSNs responded to both isotopologues of 1-undecanol.  
Concentration 3μM 10 μM 
Isotopologue of 1-undecanol H D H D 
Number of Responding OSNs 22 22 24 24 
Percentage OSNs 0.60% 0.60% 0.66% 0.66% 
 
 
3.B.3. Comparing Odorant Receptor Activation Elicited by the Deuterated Odorants and 
the Non-Deuterated Odorants on Recombinant OR-I7 Receptor 
The populations of OSNs expressing diverse ORs could not discriminate the H- and D- 
isotopologues, as described above. Recall that each mature OSN has chosen one of the ~1100 
OR genes to express. While we can probe and profile OSNs for their pharmacological responses, 
we are not able to identify the receptor they have chosen, and so cannot associate the behavior 
with a particular OR. Expressing recombinant ORs in rodent OSNs requires an adenovirus 
vector, which we do not have, but we obtained a knock-in mouse expressing a recombinant OR, 
the OR-I7, and we used this mouse to ask if a specific OR could differentiate its known odorant 
agonist from the deuterated isotopologue. Mouse OR-I7 receptors have shown clear responses to 
a natural product agonist, octanal at 25μM.16 Using the odorant at a concentration that is well 
above the observed detection-threshold, we asked if OR-I7 receptors could differentiate H-
octanal from D-octanal.   
 
3.B.3.1. The UB-I7 Mouse and OR-I7 Expression 
In the UB-I7 mouse, the OR-I7 gene was inserted at a locus downstream of the olfactory 
marker protein (OMP) gene, and its mRNA translation is initiated at an internal ribosomal entry 
site (IRES).116, 117 The OMP is known to be expressed in all mature OSNs.118 As a result, the UB-
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I7 mouse broadly expresses the un-modified mouse OR-I7 receptors in all mature OSNs, 
although at lower levels than the endogenous ORs.116, 117 This mouse line is maintained by our 
collaborator at the National Institutes of Health, Dr. Leo Belluscio. In situ hybridization by Dr. 
L. Belluscio confirmed the expression of OR-I7 mRNAs in the main olfactory epithelium (MOE) 
of the UB-I7 mouse. (Fig. 3-6) To check if the functional OR-I7 receptor proteins are expressed, 
the responses of the dissociated UB-I7 OSNs to octanal at various concentrations were recorded 
by calcium imaging.  
 
3.B.3.2. The Olfactory Sensory Neurons from UB-I7 Mice Responded to Octanal via OR-I7 
Compared to the wild type, higher percentages of the dissociated UB-I7 OSNs responded 
to octanal. At 3 µM and 300 µM, octanal activated 3.7% and 6.8% of the tested wild type OSN 
populations, respectively. At the same concentrations, octanal activated 35.7% and 43.4% of the 
UB-I7 OSNs, reflecting ~10 fold and ~6 fold higher population responses compared to the wild 
 
Figure 3-6. Expression of OR-I7 mRNA in UB-
I7 MOE 
In situ hybridization using probes for mouse OR-
I7 shows limited expression of OR-I7 in the wild 
type mouse. (WT I7, dark spots) The broad 
expression of OR-I7 in the UB-I7 mouse is also 
shown. (UB-I7 I7) The red arrowheads point to 
extra dark OSNs that are presumed to express the 
endogenous OR-I7 in addition to the recombinant 
protein. The image was provided by Dr.L. 
Belluscio. 
 
 
68 
 
type. (Fig. 3-7a) It could be estimated that at 30 µM, ~90% (35.7%-3.7%/35.7%) of the octanal-
responding OSNs responded through the recombinant OR-I7. At 300 µM, ~84% ((43.4%-
6.8%)/43.4%) of the octanal-responding OSNs responded through the recombinant OR-I7.  
When compared to the wild type OSNs, UB-I7 OSNs showed higher population response 
to octanal, but not to 1-octanol. The percentage of the wild type OSNs and the UB-I7 OSNs that 
were activated by 1-octanol showed a smaller, ~2 fold difference at 100 µM; 1-octanol activated 
2.68% of the wild type OSNs and 5.2% of the UB-I7 OSNs. (Fig. 3-7b) It has been previously 
shown that the rat OR-I7 receptor does not respond to 1-octanol even at a high concentration (1 
mM).72 This result has been confirmed for the mouse OR-I7 ortholog as well.110, 119 Since 1-
octanol is not an agonist of OR-I7, the responses to 1-octanol are through the endogenous 
receptors in both the wild type OSNs and the UB-I7 OSNs. The percentage of the OSNs 
responding to 1-octanol are similar because the expressed endogenous ORs are expected to be 
similar in the wild type and the UB-I7 mice. This supported that the higher percentage of 
octanal-responding OSNs in the UB-I7 mice is due to the expression of the exogenous, 
recombinant OR-I7. 
We note that while virtually all mature UB-I7 OSNs express OR-I7 mRNA, they are 
expressed along with the chosen endogenous ORs but at levels that are less than 1% of the 
endogenous OR.117 Also, the OSNs are at various stages of maturity, possibly producing cell-to-
cell differences in the amount of OR-I7 transcripts and proteins. This perhaps accounts for the 
fact that not every viable OSN responded to octanal at the tested concentrations. (Fig. 3-7a) In 
line with our observation, a previous study also has shown that OSNs expressing a common OR 
could differ in their sensitivity to the agonist odorant.120 Nevertheless, the expression of OR-I7 
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receptors allowed us to examine whether a specific receptor can differentiate its known ligand 
from the deuterated isotopologue at an above-threshold concentration.  
 
3.B.3.3. The OR-I7 Receptor Does Not Discriminate Octanal from Octanal-d16 
The dissociated UB-I7 OSNs did not differentiate H-octanal from D-octanal. The H- and 
D- isotopologues were sequentially applied onto the dissociated UB-I7 OSNs at 300 µM. The 
responses from individual OSNs were measured using calcium imaging. Out of 2,036 viable 
OSNs, 713 OSNs (35.0%) responded to H-octanal. Every single OSN that responded to H-
octanal also responded to D-octanal, given at the equal concentration. (Fig. 3-8a~c, Table 3-2) 
Based on our comparison with the wild type OSNs in Fig. 3-7, it can be estimated that ~84% of 
these octanal-responding UB-I7 OSNs responded through the recombinant OR-I7. The UB- I7 
OSNs were unable to discriminate H-octanal from D-octanal in mouse primary OSNs. No OSN 
responded exclusively to one specific isotopologue. (Table 3-2) 
 
Figure 3-7. Compared to the wild type OSNs, higher percentages of the UB-I7 OSNs responded to a 
known OR-I7 agonist, octanal. 
a) Compared to the wild type (WT), the UB-I7 mice showed ~10X and ~6X increase in the percentage of 
OSNs that responded to octanal at 30 µM and 300 µM, respectively. For the WT, 1,473 viable OSNs 
were screened. For UB-I7, 930 OSNs were screened.  
b) Unlike the response to octanal, the OSN population response to 1-octanol at 100 µM was similar for the 
WT and the UB-I7 mice. For the WT and the UB-I7 mice, 5,824 and 1,852 viable OSNs were screened. 
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The response profile of the UB-I7 OSNs are summarized in Table 3-2. Compared to the 
octanal isotopologues, 1-octanol activated a smaller percentage of the UB-I7 OSNs. The 
responses elicited by 1-octanol represent the activation of the endogenous ORs, since 1-octanol 
is not an agonist of the OR-I7. In total, 148 (7.27%) of the 2,036 OSNs responded to 1-octanol at 
300 µM. This suggested that the responses to the octanal isotopologues (35.0%) were not due to 
non-specific responses of the endogenous ORs caused by the high concentration of the odorants. 
Of the 148 OSNs that responded to 1-octanol, 146 OSNs responded to the octanal isotopologues 
and 1-octanol. (Fig. 3-8c, Table 3-2) This showed that most of the OSNs that normally express 
the endogenous ORs that respond to 1-octanol also responded to octanal in the UB-I7 mice due 
to the expression of the recombinant OR-I7. The other 2 OSNs responded only to 1-octanol but 
not to the octanal isotopologues. (Fig. 3-8d, Table 3-2) We speculate that the 2 OSNs did not 
express sufficient level of the recombinant OR-I7 receptor protein because the cells were at early 
stages of the neuronal development. Only mature OSNs express OMP and consequently, the 
recombinant OR-I7.  
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Table 3-2. Every UB-I7 OSN that responded to H-octanal also responded to D-octanal.  
Out of 2,036 viable OSNs tested in total, 713 OSNs (35.02%) responded to both isotopologues of octanal at 300 
µM. The response profile of the UB-I7 OSNs are summarized in this table.  
Activating Odorants Number of OSNs Percentage of OSNs 
H-octanal only 0 0% 
D-octanal only 0 0% 
both H-octanal and D-octanal but not 1-octanol 567 27.8% 
H-octanal, D-octanal and 1-octanol 146 7.17% 
1-octanol only 2 0.1% 
 
  
 
 
Figure 3-8. Response of dissociated UB-I7 OSNs to octanal and octanal-d16 
Out of 2,036 viable UB-I7 OSNs tested in total, 713 OSNs (35.0%) responded to both isotopologues of octanal 
at 300 µM. Of the 2,036 viable OSNs, 148 OSNs (7.27%) responded to 1-octanol.   
(a) Each of the octanal isotopologues were tested twice per OSN. The order in which the isotopologues 
were applied were randomized. For a subset of the viable OSNs (620 OSNs), octanal-d16 was applied 
first. 
(b) For the rest of the viable OSNs (1,416 OSNs), octanal was applied first. Regardless of the order of 
application, all OSNs that responded to octanal also responded to octanal-d16.  
(c) Of the 713 OSNs that responded to the octanal isotopologues, 146 OSNs also responded to 1-octanol. 
(d) Some OSNs (2 OSNs) responded to 1-octanol but did not respond to the octanal isotopologues.  
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Section 3.C. Conclusion  
If the differences in the vibrational energy were the determining force in OR activation, 
the deuterated odorants and the non-deuterated odorants should activate completely different set 
of ORs in primary OSNs. The data presented herein indicated that this is not the case, because all 
ORs that responded to the deuterated odorants also responded to the non-deuterated 
isotopologues, at above-threshold concentrations. Based on our results, the deuterated odorants 
are not suitable as inhibitors of the cognate non-deuterated odorants. Rather, both isotopologues 
were agonists to the identical sets of ORs at above-threshold concentrations. 
Opposite responses to the deuterated and non-deuterated odorants were observed in 2 
OSNs, but only at the lowest tested concentration at which the ORs responded to the odorants. 
(Fig. 3-2) The differences might stem from the small differences in hydrophobicity between the 
isotopologues. Another, more feasible possibility is that the responses at the near-threshold 
concentrations are random, like flipping a coin. The single odorant binding to an OR has a low 
probability of activating the canonical downstream signal transduction pathway.31, 32 For this 
reason, near the threshold concentration, the probability of neuronal firing might be low, leading 
to inconsistent responses to the odorants. At higher concentrations, increased number of odorants 
bind to the ORs, leading to such high probability of neuronal firing that it always fires. Unlike in 
patch-clamping, using calcium imaging we never observed continuous spontaneous activation, 
although there were some odorant-independent calcium signals. With more potent ligands, 
radioligand binding assays would afford a more direct way of comparing the affinity of the non-
deuterated odorants and the deuterated odorants for the receptors. But this is a central problem of 
studying the ORs: the ligand-receptor is 2-3 orders of magnitude less potent than most GPCR 
ligands, and radiolabeled ligand displacement assays are not possible. 
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Section 3.D. Materials and Methods 
3.D.1. Isolation and Dissociation of Olfactory Epithelium 
All use and care of the laboratory animals were in compliance with guidelines of The 
City College of New York Institutional Animal Care and Use Committee (Protocol number 937). 
For testing 1-undecanol, 1-undecanol-d23, 1-octanol, 1-octanol-d17, 6-13 week old male C57BL/6 
mice (Charles River) were used. For octanal and octanal-d16 experiments, two of 8-9 week old 
UB-I7 mice, bred and provided by Dr. Leo Belluscio at the National Institute of Health, were 
used.116, 117, 121 In all experiments, the mice were overdosed with ketamine (Ketaset) at 100mg/kg 
and xylazine (AnaSed) at 10 mg/kg via intraperitoneal injection, followed by decapitation. The 
depth of anesthesia was assessed before decapitation by observing inability to remain upright, 
loss of purposeful voluntary movement, and loss of response to reflex stimulation (toe pinch with 
firm pressure). The MOE was dissected out from the heads on ice tray and placed in the chilled 
divalent-cation-free-Ringer solution (145 mM NaCl, 5.6 mM KCl, 10 mM HEPES, 10 mM 
glucose, 4 mM EGTA, pH 7.4). The tissue was dissociated in 4.6 ml of divalent-cation-free-
Ringer solution containing 2.62 U/ml dispase II (Roche), 0.54 mg/ml collagenase (Life 
Technologies), 3.26 mg/ml bovine serum albumin (Roche), and 0.1 mg/ml deoxyribonuclease II 
(Sigma Aldrich), for 1 hour at 37°C with continuous shaking on an incubator shaker. The tissue 
was then placed in culture media (warmed to 37°C) and the cells were further dissociated by 
brief vortexing (vortex setting between 7~8 out of 10). The culture media consisted of 
DMEM/F12 supplemented with glutamine (Corning), 10% FBS (VWR), 1X insulin transferrin 
Selenium Ethanolamine (Life Technologies), 1% 100 U/ml penicillin, 100µg/ml streptomycin 
(Cellgro), and 100 µM ascorbic acid. The dissociated cells were allowed to settle on 
concanavalin A (Sigma, 10 mg/ml) coated coverslips placed in 35 mm Petri dishes for 15 
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minutes. After the cells adhered to the coverslip, 2 ml of culture media was added to each Petri 
dish and the dishes were placed in CO2 incubator at 37°C for at least 1 hour.  
 
3.D.2. Calcium Imaging 
Calcium Imaging was performed as described in Chapter 2, Section2. (2.D.2)  
 
3.D.3. Stimuli 
 The infrared (IR) spectra (Thermo Nicolet 6700 FT-IR spectrometer) of the odorants 
were recorded by my colleague, Dr. Min Ting Liu. For calcium imaging experiments, all 
odorants were diluted in DMSO (Alfa Aesar) fresh on each day of the experiment into 
concentrations 1000 times higher than the working concentrations (e.g. 1 mM DMSO solution 
when a 1 µM Ringer solution is desired). The working concentrations are the final concentrations 
of the odorants that were applied to the OSNs. Then the odorants were further diluted into 
working concentrations in the Ringer solution just prior to imaging. The deuterated odorants 
were purchased from CDN Isotopes. 1-Octanol (Spectrum Chemical), octanal (Sigma Aldrich), 
and octanal-d16 (CDN Isotopes) were purified by flash chromatography (Teledyne Isco 
CombiFlash Rf-200 flash chromatography system) and rid of solvents prior to use.122 Gas 
chromatography-mass spectrometry (GCMS QP-2010) analysis showed purities of >98% for the 
octanal and 1-octanol isotopologues. The gas chromatography analysis (GC-2010 with FID 
detector) on the 1-undecanol (TCI) and 1-undecanol-d23 showed purities of >99%.  
In order to ensure that the isotopologues are compared at equal concentrations, gas 
chromatography was performed on the 1000X stock solutions (3 mM and 10 mM in DMSO) of 
the deuterated and non-deuterated 1-undecanol and 1-octanol prior to each experiment. The peak 
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areas of the deuterated odorants were compared with the peak areas of the non-deuterated 
odorants. On average, the ratio between peak areas of the deuterated and non-deuterated odorants 
was 1.08 (±0.09). All gas chromatography analyses were performed by Dr. Min Ting Liu.  
The liquid chromatography-mass spec (LC-MS) data was obtained using C-18 stationary 
phase. LC-MS was performed by Dr.Rinat R. Abzalimov in Advanced Science Research Center 
(City University of New York). The percent deuteration of the deuterated odorants were 
calculated by Dr. Min Ting Liu, using the peak intensities from the LC-MS. (Table 3-3)  
 
Table 3-3. A summary of the percent deuteration of the deuterated isotopologues used.  
The calculations were done by Dr. Min Ting Liu.  
D-1-octanol 
D17 75-77% 
D16 20-22% 
D15 3-4% 
D-1-undecanol 
D23 74-76% 
D22 20-21% 
D21 4-5% 
D-octanal 
D17 (fully deuterated) 77% 
D16 20% 
D15 3% 
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Part1. Odorant Receptor-Ligand Interaction 
Chapter 4. Does Methyl Dihydrojasmonate Modulate the Olfactory Code of Rose Oil Odorants 
Positively, Negatively, or Not at All? 
Synopsis 
Methyl dihydrojasmonate (MDHJ), also known as Hedione™, is a weak floral odorant 
that is widely used in fragrance industry. It is often used in fragrance mixtures as a ‘booster,’ to 
accentuate the effects of other floral odorants. While its ability to modulate other odorants is 
well-known on the perceptual level, how it works at the molecular level is not known. In 
peripheral mammalian olfactory system, an odor is encoded by a set of specific odorant receptors 
(ORs) activated by the given odorants; a floral odor mixture activates a unique combination of 
ORs, also known as the olfactory code. Using mouse ORs as a model system and rose oil odor as 
a representative floral odor, we investigated how MDHJ alters the olfactory code of the floral 
odor mixture and its constituents. One possible scenario is that MDHJ merely expands the 
olfactory code of the floral odor by activating additional OSNs, and any special effect occurs 
beyond the ORs, at the olfactory bulb or central nervous system. Another possibility is that while 
MDHJ does not activate the ORs on its own, it could increase the responses of the ORs to other 
odorants in the mixture. Such ligands are known as positive allosteric modulators (PAM). We 
found no evidence of positive allosteric modulation. Lastly, MDHJ might also fine-tune the 
olfactory code of the floral odor mixtures by acting as an antagonist, that is, by inhibiting select 
ORs that are otherwise activated by other odorants. The work in this chapter was undertaken at 
the very end of my experimental studies when a computational inquiry into odorant GPCR 
structure by others in the lab suggested that MDHJ might be a weak but general GPCR allosteric 
antagonist for a significant population of mammalian ORs. Our results show that MDHJ can in 
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fact modulate the encoding of the rose oil constituents by inhibiting select population of ORs, as 
well as activating a few additional OSNs. However, preliminary control experiments show 
MDHJ does not seem to be unique in its ability modify the rose oil percept by antagonism, as 
unrelated structures showed the same property. 
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Section 4.A. Introduction 
MDHJ is a pleasant, weak, floral odorant that has been widely used in fragrance industry. 
It was originally synthesized to mimic a fragrant constituent of jasmine flower extract, 
methyljasmonate. MDHJ has also been identified in various natural products such as grapes and 
black tea.6 Since its first synthesis, MDHJ has been a key ingredient in fragrances because of its 
pleasantness and more importantly, its ability to modulate other floral notes by enhancing the 
odors of other low potency floral extracts. Thus MDHJ is an odorant of commercial interest. 
While its role of modulating other floral odorants in a mixture is widely known, how it does so at 
the OR level has not been investigated thus far.   
Due to its role in fragrance industry as the ‘booster’ of other constituents, MDHJ has 
been suggested as a positive allosteric modulator, PAM.5 In general, a PAM binds to an allosteric 
site of the receptor and increases the effect of the agonist. While a PAM doesn’t activate the 
receptor on its own, the conformation shift caused by its binding promotes the receptor’s 
interaction with either the orthosteric agonist or with the cognate G-protein.41 Conceivably, 
MDHJ could also modulate the responses to other odorants via inhibiting a set of ORs, fine-
tuning the olfactory code of the agonists. However, no molecular evidence has been published to 
support MDHJ as a PAM or an antagonist.  
Using naturally occurring, well-characterized rose oil odor as a representative floral odor, 
we explored the impact of MDHJ on the olfactory code of floral odorants. Mammals including 
mice use unique combinations of ORs to encode odorants or mixture odorants.20 It is thought that 
each mature olfactory sensory neuron (OSN) chooses and expresses one type of OR.20-24 
Therefore, the response of an OSN reflects the activity of the OR expressed in that cell. Using 
calcium imaging, we verified that mouse ORs were able to detect and differentiate the 
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constituents of the rose oil mixture as well as MDHJ. The responses of OSN populations to the 
rose oil odorants in absence and presence of MDHJ were compared. According to our results, in 
some cells MDHJ inhibited responses of the ORs that were elicited by the components of the 
rose oil mixture. No evidence of positive modulation was found, suggesting that MDHJ mainly 
modulates the response to the rose oil mixture through inhibition or by merely activating OSNs 
directly itself. However, by comparing MDHJ with other compounds having similar size and 
functional groups, we found that MDHJ’s inhibitory properties are no better than that of the other 
compounds, indicating that MDHJ’s organoleptic effect likely does not come from a widespread 
or obvious inhibition of OSN response to floral agonists. Rather, MDHJ “fine-tuned” the 
olfactory code of the rose oil mixture by inhibiting some ORs while activating other ORs. Based 
the literature and our observations in other projects, this behavior is not unique to MDHJ.  
 
Section 4.B. Results and Discussion 
4.B.1. Rose Oil Odorants and Methyl Dihydrojasmonate (MDHJ) 
 Rose oil is a complex mixture of at least 275 constituents.65 The major components of the 
rose oil odor mixture are the floral terpene alcohols such as (S)-(-)-citronellol, geraniol, and 
nerol.65, 82  The combination of these 3 constituents is often considered a ‘base’ for reconstituting 
the rose fragrance.82 Extensive investigations have revealed that the rose oil also contains other 
structurally diverse alcohols, aldehydes, acids, and esters.82 Many of these minor constituents 
have been found to play central roles in the rose oil fragrance.65, 82 For practicality, the major 
constituents and a select few of the less abundant constituents were used in this study. (Fig. 4-1)  
 MDHJ is a disubstituted pentanone with 4 possible stereoisomers. (Fig. 4-1) Organoleptic 
evaluations have shown that only (+)-cis-MDHJ has intense floral odor; the other three 
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stereoisomers are only weakly fragrant.6  The cis- isomers of disubstituted cyclopentanone 
molecules, however, are known to be thermodynamically unstable.6 It is unknown which of the 4 
isomers exhibit the enhancing effect on other floral odors. The commercially available MDHJ is 
usually a mixture of both cis- and trans- isomers at approximately 10%: 90% ratio, respectively.6 
The mixture has a very subtle floral odor, likely due to low abundance of (+)-cis-MDHJ. This 
mixture of 4 stereoisomers was used in this study.    
 
 
  
 
Figure 4-1. Structures of the rose oil constituents and MDHJ 
M 4-1 is a mixture of all chosen rose oil constituents, each constituent at 30 μM. 
Compounds 4-1, 4-2, 4-3: The terpene alcohols are the major constituents of the rose oil mixture. Compounds 4-
4, 4-5, 4-6, 4-7: Select minor constituents are shown. MDHJ is a mixture of the 4 stereoisomers. Trans-isomers 
are thermodynamically more stable and are more abundant. Of all the isomers, (+)-cis- MDHJ (circled in grey) 
is known to possess the most intense floral character. 
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4.B.2. Mouse Odorant Receptors Detected and Discriminated the Rose Oil Mixture, its 
Constituents, and MDHJ.  
 In order to first verify that mouse ORs can detect the floral odorants, sample populations 
of dissociated mouse OSNs were tested using a mixture of the rose oil constituents (M 4-1) and 
MDHJ as stimuli. The rose oil odor mixture (M 4-1) was produced by mixing the 7 rose oil 
constituents listed in Fig. 4-1, each at 30 μM. On average, 4.3% (standard deviation = 1.8%, 2 
biological replicates) of the OSNs in multiple experiments responded to the mixture. In total, 
5,775 viable OSNs were tested. Of the 5,775 OSNs, 3,786 OSNs were subsequently tested with 
individual components of the rose oil mixture. (data not shown) The other 1,989 OSNs were 
used in another experiment to investigate the inhibition by MDHJ (Fig. 4-2) Each constituent of 
the rose oil mixture activated a different set of ORs, or “olfactory code.”  Each constituent at 30 
μM activated ~1.9% (standard deviation = 0.55%), of the OR population. This showed that, as 
expected, the mouse ORs could detect and discriminate the mixture and constituents of the rose 
oil.  
MDHJ was also detected by the mouse ORs. It is a weak odorant to humans as mentioned 
above (4.B.1), and it activated a relatively small percentage of mouse ORs compared to the rose 
oil constituents; on average, it activated 0.2% of the tested population at 30 μM. (standard 
deviation = 0.03%, 2 biological replicates, 4,255 viable OSNs in total). That is about 10-fold less 
than the average for the rose oil constituents individually at this concentration.  At a higher 
concentration, 300 μM, MDHJ activated 0.87% of the population on average. (standard deviation 
= 0.57%, 4 biological replicates, 6,128 viable OSNs in total) It would be interesting to know 
which isomer of MDHJ is responsible for activation of the ORs, but we did not have the pure 
stereoisomers.   
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4.B.3. MDHJ Modulated the Olfactory Code of the Rose Oil Odor Mixture  
 The response of OSN population to the rose oil odor mixture (M 4-1) was altered in 
presence of MDHJ. (Fig. 4-2) The mixture (M 4-1) elicited responses from 49 viable OSNs 
among the 1,989 viable OSNs tested. (Fig. 4-2, Column A) The ORs of these OSNs essentially 
represent the olfactory code of the rose oil mixture on the subset of cells that dissociated from 
the olfactory epithelium in this experiment. A majority of the OSNs that responded to the rose oil 
odor mixture (M 4-1) did not respond to MDHJ. (Fig. 4-2, Cells 3-49) And some of these 
mixture-elicited responses were inhibited in presence of the higher concentration of MDHJ used. 
(Fig. 4-2, Cells 41-49) Of the 49 mixture-responding OSNs, responses of 1 OSN (1/49=2%) and 
9 OSNs (9/49=18%) were completely inhibited by 30 μM and 300 μM of MDHJ, respectively. 
Besides inhibition, adding 30 μM MDHJ to the rose oil odor mixture (M 4-1) activated 2 other 
OSNs. (Fig. 4-2, Cells 50-51) When a higher concentration, 300 μM of MDHJ was added to the 
rose oil mixture (M 4-1), 9 additional OSNs were activated. (Fig. 4-2, Cells 51-58) 
Consequently, MDHJ modulated the olfactory code of the rose oil mixture at the receptor level 
through activating additional ORs as well as inhibiting some ORs.  
 
4.B.4. No Evidence of Positive Allosteric Modulation was Found. 
 Besides probing for the antagonism, comparing the cellular responses to the rose oil 
mixture in absence and presence of MDHJ allowed us to survey the prevalence of positive 
modulation by MDHJ.  Typically, a high through-put screening for PAMs is done by first setting 
the agonist at a concentration that induces 20% of the maximal response of a single given 
receptor. A PAM would increase the response of the agonist without activating the receptors on 
their own. Because populations of diverse ORs are used in our system rather than a single OR, 
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the response magnitude elicited by the agonist varied and we could not set a 20% maximal 
response. In lieu of this, the OSNs that showed agonist-induced responses that are less than 50% 
of the near-maximal response were considered for analysis to screen for candidate PAMs.  
The OR populations that responded to the rose oil odor mixture (M 4-1), showed no signs 
of positive allosteric modulation by MDHJ. (Fig. 4-2) Of the 1,989 viable OSNs tested, 49 OSNs 
responded to the mixture, M 4-1. (Fig. 4-2) There were 47 OSNs that responded to the mixture 
(M 4-1) but not MDHJ. Among the 47 OSNs, 12 OSNs showed <50% response to M 4-1. (Fig. 
4-2, Cells 35-40, 43-48) The near-maximal response was measured by forskolin, a downstream 
activator of adenylyl cyclase III.53 This population of OSNs showed no clear evidence of the 
positive modulation. None of these OSNs showed increased magnitude of response in presence 
of MDHJ.  
 
Figure 4-2. MDHJ inhibited some OSNs that were 
activated by the rose oil mixture. 
In total, 1,989 viable OSNs were screened. Of these, 49 
OSNs responded M 4-1. Each row summarizes the 
response profile of a single OSN, measured by calcium 
imaging. Each column shows the set of OSNs that 
responded to each stimulus. M 4-1 was made up by 
mixing the rose oil constituents listed in Fig.1, each at 
30 μM. The responses elicited by M 4-1 were inhibited 
by MDHJ in 9 OSNs.  
Only the OSNs that responded consistently to repeated 
application of M 4-1 were considered for analysis of 
antagonism. Inhibition was called when the OSN 
responded to M 4-1 alone but not at all to the mixture of 
M 4-1 and MDHJ. 
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4.B.5. MDHJ Inhibited Odorant Receptor Activation by Structurally Diverse Components 
of the Rose Oil.  
 MDHJ inhibited multiple components of the rose oil, rather than the response to a 
specific constituent. (Fig. 4-3) Select components of the rose oil odor mixture (M 4-1) were 
tested separately as agonists, to examine whether the inhibition by MDHJ targeted the ORs 
activated by a specific component. (Fig. 4-3) A mixture of the terpene alcohols (M 4-2) was 
made by combining compounds 4-1, 4-2, and 4-3, each at 30 μM. (Fig. 4-3a) The terpene 
mixture (M 4-2) and two other structurally dissimilar constituents, compound 4-5, and 4-6 were 
applied separately to the OSN populations at 30 μM. Each agonist was tested alone and with 
MDHJ. (Fig. 4-3) MDHJ was used at 300 μM. Screening 1,189 viable OSNs revealed that 
MDHJ inhibited the responses elicited by the terpene mixture (M 4-2), compound 4-5, and 4-6 in 
a variety of OSNs. (Fig. 4-3b-d, Table 4-1) The percentage of the OSN population inhibited by 
MDHJ was smaller for the terpene mixture (M 4-2) compared to the two other individual 
constituents. The effective concentration of the terpene mixture (M 4-2) was higher due to 
combining the terpene alcohols. The higher effective agonist concentration might lead to 
saturation of the receptors, rendering inhibition difficult to detect. Possibly for that reason, some 
OSNs showed responses to both the terpene mixture (M 4-2) and compound 4-5, but only 
compound 4-5 was inhibited by MDHJ. (Fig. 4-3e) 
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Table 4-1. The number of OSNs whose responses to the rose oil constituents were inhibited by MDHJ. ORs 
responding to the terpene mixture (M 4-2), compound 4-5, and Compound 4-6 were inhibited by MDHJ.  The total 
number of the viable OSNs screened was 1,189. All agonists were tested at 30 μM. The terpene mixture (M 4-2) 
was composed of compounds 4-1, 4-2, and 4-3, each at 30 μM.  
Agonist OSNs Responding to Agonist OSNs Showing Inhibition 
M 4-2 30 2 (6.7%) 
Compound 4-5 28 5 (18%) 
Compound 4-6 13 2 (15%) 
 
 
 
 
  
 
Figure 4-3. MDHJ antagonized multiple components of the rose oil mixture.  
(a) Some constituents of the rose oil mixture, M 4-1 were tested separately with MDHJ. The major rose oil 
components, the terpene alcohols were tested as a sub-mixture, M 4-2. Compounds 4-5 and 4-6 were 
tested individually. 
(b) MDHJ completely inhibited the responses to the sub-mixture, M 4-2, in some OSNs. (Table 4-1) 
(c) Compound 4-5 and (d) compound 4-6 were also antagonized by MDHJ in some cells. (Table 4-1) 
(e)   Of the OSNs that responded to M 4-2 and compound 4-5, in some cases, only the responses to 
compound 4-5 were inhibited.  
       Compound 4-6 were inhibited by MDHJ.   
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4.B.6. MDHJ-Mediated Antagonism was Dose-Dependent. 
 MDHJ inhibited the rose oil constituent in a dose dependent manner. We used compound 
4-5 as an example agonist to characterize the inhibition exerted by MDHJ. With compound 4-5 
at a fixed concentration (30 μM), MDHJ was tested at wide range of concentrations. (10, 30, 100, 
300, and 1000 μM) A group of 2,266 viable OSNs were screened and 15 OSNs responded to 
compound 4-5. Dose dependent inhibition was evident in 11 out of the 15 OSNs. The magnitude 
of the responses induced by compound 4-5 in these OSNs diminished as the concentration of 
MDHJ was raised (Fig. 4-4a); and the magnitude of the responses increased when the MDHJ 
concentration decreased. (Fig. 4-4b) The dose dependent inhibition was also observed at the 
level of OSN population; the number of responding OSNs decreased as the concentration of 
MDHJ was increased. (Fig. 4-4c)  
In another experiment using a separate group of 1,411 OSNs, the concentration of MDHJ 
was held constant at 300 μM, while the concentration of compound 4-5 was increased. At 30, 
100, and 300 μM, compound 4-5 activated 23 OSNs. Among these, the responses of 8 OSNs 
were inhibited by MDHJ. The responses in 6 of these 8 OSNs were rescued to various extents as 
the concentration of compound 4-5 was increased up to 300 µM. (Fig. 4-4d) The dose-dependent 
rescue of the responses elicited by compound 4-5 from the inhibition by MDHJ (300 μM) was 
also observed at the population level. Without MDHJ, 23 OSNs responded to compound 4-5 at 
30 μM. (Fig. 4-4e) With MDHJ (300 μM), only 15 of these OSNs responded to the mixture of 
MDHJ and compound 4-5 (30 μM). (Fig. 4-4e) When concentration of compound 4-5 was 
increased to 100 and 300 μM, 19 and 21 OSNs responded to the mixtures of compound 4-5 and 
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MDHJ (300 μM). (Fig. 4-4e) These data demonstrate that MDHJ antagonizes the ORs that 
respond to compound 4-5.  
  
 
Figure 4-4. MDHJ competitively inhibited compound 4-5 in a dose dependent manner. The representative 
responses are shown in (a), (b), and (d). The red tick-marks indicate the time at which the stimuli were applied. 
Whenever MDHJ was tested in mixture with compound 4-5, MDHJ was applied 8 seconds prior to the mixture 
application. 
a) With compound 4-5 concentration set at 30 μM, the concentration of MDHJ was tested at 0, 10, 30, 
100, 300, and 1000 μM in this order. This representative OSN showed complete inhibition by MDHJ at 
300 and 1000 μM.  
b) With compound 4-5 concentration set at 30 μM, the concentration of MDHJ was tested in a decreasing 
order: 1000, 300, 100, 30, 10, and 0 μM. The response to compound 4-5 on this representative OSN 
showed complete inhibition by MDHJ at 300 and 1000 μM. The response was rescued as the 
concentration of MDHJ decreased.  
c) The number of OSNs responding to 30 μM compound 4-5 decreased as increasing concentrations of 
MDHJ was added. Of the 2,266 OSNs tested, 15 OSNs responded to compound 4-5 in absence of 
MDHJ. However, only 4 OSNs responded to the mixture of compound 4-5 and 1 mM of MDHJ. The 
numbers on top of each bar indicate the number of OSNs that responded to the mixture of compound 4-
5 and MDHJ.  
d) The increasing concentrations of compound 4-5 were tested (0, 3, 30, 100, and 300 μM) with and 
without set concentration of MDHJ (Compound 4-8, 300 μM). In presence of MDHJ, this 
representative OSN responded to compound 4-5 at 300 μM. Without MDHJ, it responded to compound 
4-5 at starting at a lower concentration, 30 μM.  
e) With MDHJ set at 300 μM, the number of OSNs responding to compound 4-5 increased as its 
concentration was raised. 1,411 viable OSNs were screened. In absence of MDHJ, 23 OSNs responded 
to compound 4-5 at 30, 100, and 300 μM. In presence of 300 μM MDHJ, fewer OSNs responded to 
compound 4-5. Increasing the concentration of compound 4-5 reduced the number of OSNs that were 
inhibited by MDHJ.  The numbers on top of the bars indicate the number of OSNs responding to the 
mixtures of compound 4-5 and MDHJ.  
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4.B.7. The ORs that Detect the Rose Oil Constituent Could be Inhibited by Structurally 
Different Compounds as well as by MDHJ  
Many of the odorant antagonists identified to date have shown significant structural 
similarities with their cognate agonists. (Chapter 1, Table 1-1) The odorant binding sites of the 
ORs are predicted to be hypervariable, granting specificity to each receptor.26 The unique shapes 
of the OR binding pockets accommodate multiple ligands that are usually structurally analogous, 
although some broadly tuned ORs are activated by diverse sets of odorant stimuli.114, 123 Based 
on the similarity of their structures, the odorant antagonists have been suggested to be orthosteric 
antagonists, competing with the agonists for the common binding site, but failing to activate the 
cell. In contrast to other odorant antagonists (Chapter 1, Table 1-1), the structure of MDHJ does 
not resemble the agonists that we have tested. It is possible that the ORs which recognize the 
rose oil constituents are relatively broadly tuned; their binding pockets could accommodate a 
wide range of structurally diverse odorants, including MDHJ. In that case, the OR should also be 
antagonized by multiple compounds.  
Therefore, we then asked if the ability to inhibit the ORs that respond to the rose oil odor 
constituents was unique to MDHJ, using compound 4-5 as the example agonist. On average, 
MDHJ at 300 μM inhibited ~31% of the OSNs responding to compound 4-5 at 30 μM. (standard 
deviation = 19%, 4 biological replicates, 10,192 viable OSNs in total) A subset of these OSNs 
was used to compare the inhibition by MDHJ and the inhibition by 2 other compounds whose 
size, chemical composition, and functional groups are similar to MDHJ, but whose structures are 
very different. (Fig. 4-5, compounds 4-8 and 4-9). Like MDHJ, compound 4-8 has the ester 
group and an alkyl chain. Unlike MDHJ, the conformation of compound 4-8 is more flexible 
since it does not have the cyclopentyl ring. The structure/shape of compound 4-9 is completely 
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different from MDHJ, but it contains all the functional groups of MDHJ. (Fig. 4-5) (Note: we 
purchased the compound with two methyls on the carbon between the carbonyl groups, which 
would make this a constitutional isomer of MDHJ, but Sigma misidentified compound, which we 
deduced by NMR as compound 4-9.) These compounds allowed us to test if the structure of 
MDHJ was necessary for inhibiting the rose oil constituents. The antagonists were tested at 300 
μM, and the agonist was set to 30 μM. In this experiment, 1,539 viable OSNs were examined and 
10 OSNs responded to compound 4-5. The responses were inhibited by one or two of the 
candidate antagonists in 5 OSNs. (Table 4-2) It is interesting to note that while these 5 OSNs all 
responded to compound 4-5, they were inhibited by different antagonists, suggesting some 
diversity of the OSNs responding to the rose oil constituent. (Table 4-2)  
 
Figure 4-5. MDHJ and other compounds inhibited the responses to compound 4-5 in some OSNs.   
(a) Structure of MDHJ, methylnonanoate (compound 4-8) and ethyl 3-cyclohyxyl-3-oxopropanoate 
(compound 4-9) are shown. As described in Section 4.D. Materials and Methods, we originally aimed to 
test ethyl 3-cyclohexyl-2,2-dimethyl-3-oxopropanoate, which has two methyl groups between the two 
carbonyl groups. However, we deduced from our NMR analysis that the compound was misidentified 
by the vendor (Sigma Aldrich). The correct identity of the product in fact was ethyl 3-cyclohyxyl-3-
oxopropanoate (compound 4-9), which not have the two methyl groups. NMR analysis was done by Dr. 
Ming Ting Liu and Prof. Kevin Ryan. 
(b) Ten out of 1539 viable OSNs responded to compound 4-5. The response of 1 OSN is shown as an 
example. This OSN was inhibited by MDHJ and compound 4-9 but not compound 4-8.  
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MDHJ inhibited the response elicited by compound 4-5 in 1 out of 10 OSNs in this 
particular experiment (10%). (cell shown in Fig. 4-5b) The response to compound 4-5 in this 
OSN was also inhibited by compound 4-9 but not by compound 4-8. (Fig. 4-5b and Table 4-2) 
No OSN was inhibited by all 3 compounds, ruling out the possibility that the inhibition might be 
an artifact stemming from high concentration of the stimulus. (Table 4-2) Although the number 
of cells tested here is small, and this result is therefore preliminary, it appears that MDHJ might 
not be unique or even special in its ability to inhibit the ORs that respond to the rose oil 
constituent.  
 
Table 4-2. Compound 4-5 was inhibited by the structurally diverse compounds  
The populations of dissociated OSNs were screened using calcium imaging. Of the 1539 viable OSNs, 10 OSNs 
responded to compound 4-5 at 30 μM. MDHJ, compound 4-8, and 4-9 were tested as antagonists at 300 μM. Of the 
10 OSNs, the responses of 5 OSNs were inhibited by one or more of the tested antagonists.  
 
Antagonists 
 
Number of OSNs Showing Inhibition 
 
MDHJ & Compound 4-9 1 
Compounds 4-8 & 4-9 2 
Compound 4-8 only 1 
Compound 4-9 only 1 
 
 
 
Section 4.C. Conclusion 
MDHJ is widely used in fragrance industry to enhance the pleasing floral features of odor 
mixtures.5 Despite its popular use, how MDHJ works at the receptor level is not clear. Our 
mouse model data showed that MDHJ can modulate the olfactory code generated by other floral 
odorants via inhibiting select ORs, but in this preliminary data, to evidently no greater extent 
than compounds of different structure but similar molecular weight and functional groups. 
MDHJ was a weak activator of the mouse OR population. We found no evidence of a role as a 
PAM. MDHJ inhibited multiple floral odorants in a dose-dependent manner, although it is 
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structurally different from the agonists; the ORs that responded to the rose oil constituents could 
resemble the broadly tuned ORs, but of course this is not known and we are unable to identify 
the receptors expressed in these cells. It is also possible that MDHJ is an allosteric inhibitor 
rather than an orthosteric inhibitor, and preliminary computational work by others in the lab 
suggest that this might be the case. Although no allosteric ligands of ORs are known to date, the 
number of small molecule allosteric modulators discovered for other GPCRs have been 
increasing in recent years.41 
Although MDHJ inhibited ORs that were activated by multiple constituents of the rose 
oil odor mixture, the inhibition might not be the basis for modulating other floral odors. We 
found that the inhibition of the rose oil constituents was not a unique property of MDHJ. When 
compared with other compounds (compounds 4-8, 4-9) that are similar to MDHJ in size, 
functional groups and chemical composition, MDHJ inhibited the least number of ORs that 
responded to a rose oil constituent, but a much larger study would be needed to estimate the 
uniqueness of MDHJ in this regard. Taken together, these results suggested that positive 
allosteric modulation is not responsible for the unique organoleptic effects of MDHJ on other 
floral odorants. MDHJ might work as an allosteric antagonist, but preliminary data show it is not 
unique in this regard.   
  
Section 4.D. Materials & Methods 
4.D.1. Isolation and Dissociation of Olfactory Epithelium  
All use and care of the laboratory animals were in compliance with guidelines of The 
City College of New York Institutional Animal Care and Use Committee. (Protocol number 937) 
Six to eight week old male C57BL/6 mice (Charles River) were overdosed with ketamine 
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(Ketaset) at 100 mg/kg and xylazine (AnaSed) at 10 mg/kg via intraperitoneal injection, followed 
by decapitation. The depth of anesthesia was assessed before decapitation by observing inability 
to remain upright, loss of purposeful voluntary movement, and loss of response to reflex 
stimulation (toe pinch with firm pressure). The MOE was dissected out from the head onto an ice 
tray and placed in the chilled divalent-cation-free-Ringer solution (145 mM NaCl, 5.6 mM KCl, 
10 mM HEPES, 10 mM glucose, 4 mM EGTA, pH 7.4). The tissue was dissociated in 4.6ml of 
divalent-cation-free-Ringer solution containing 2.62 U/ml dispase II (Roche), 0.54 mg/ml 
collagenase (Life Technologies), 3.26mg/ml bovine serum albumin (Roche), and 0.1 mg/ml 
deoxyribonuclease II (Sigma), for 1 hour at 37°C with continuous shaking on an incubator 
shaker. The tissue was then placed in warm culture media and the cells were further dissociated 
by brief vortexing. The culture media consisted of DMEM/F12 supplemented with glutamine 
(Corning), 10% FBS (VWR), 1X insulin transferrin Selenium Ethanolamine (Life Technologies), 
1% 100 U/ml penicillin, 100 µg/ml streptomycin (Cellgro), and 100 µM ascorbic acid. The 
dissociated cells were allowed to settle on concanavalin A (Sigma, 10 mg/ml) coated coverslips 
placed in 35mm Petri dishes for 15 minutes. After the cells adhered to the coverslip, 2ml of 
culture media was added to each Petri dish and the dishes were placed in a CO2 incubator at 
37°C for at least 1 hour.  
 
4.D.2. Calcium Imaging 
Calcium imaging was done as described in Chapter 2, Section D. (2.D.2) 
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4.D.3. Stimuli 
All odorants were diluted on each day of the experiment in DMSO (Alfa Aesar) into 
concentrations 1000 times higher than the working concentrations (e.g. 1 mM DMSO solution 
when a 1 µM Ringer solution is desired). The working concentrations are the final concentrations 
of the odorants that were applied to the OSNs. Then the odorants were further diluted into 
working concentrations in the Ringer solution just prior to imaging. Compound 4-1 - 4-8 were 
purchased at highest available purity. Compounds 4-1- 4-5 ((S)-(-)-citronellol, geraniol, nerol, 2-
phenyl ethanol, and methyl eugenol), compound 4-7 (linalool), MDHJ and compound 4-8 
(methylnonanoate) were purchased from TCI. Compound 4-6 (β-ionone) was purchased from 
Alfa Aesar. MDHJ was a mixture of cis- and trans- isomers in ~10%:~90% ratio. The purity of 
all tested odorants except Compound 4-9 were >93% when assessed by gas chromatography 
(GC-2010 with FID detector). In analysis, was assumed that all compounds were equally 
detected by the gas chromatography detector. Compound 4-9 (ethyl 3-cyclohexyl-3-
oxopropanoate) was purchased from Sigma Aldrich. Our original intention was to purchase ethyl 
3-cyclohexyl-2,2-dimethyl-3-oxopropanoate. This compound is a constitutional isomer of 
MDHJ. However, the mass-spectrometry and NMR analysis revealed that the true identity of the 
purchased compound was compound 4-9. This difference is not trivial especially since 
compound 4-9 has more of the enol form than in most ketones due to intramolecular H-bonding 
and stabilization of the enol. The gas chromatography, mass-spectrometry, and NMR were 
performed and analyzed by Min Ting Liu. At the end of each imaging experiment, 10µM 
forskolin (MP Biomedicals, LLC) was given in order to assess viability and near maximal 
responses of the OSNs.   
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Part II. Mammalian Pre-mRNA 3’ Processing and Odorant Receptor Genes 
Chapter 5. An Introduction to pre-mRNA 3’ Cleavage and Genome-wide 3’ End Sequencing 
Methods 
 
Synopsis 
The accurate formation of 3’ untranslated region (3’UTR), is a critical requirement for 
the proper gene expression. Cleavage of the pre-mRNA on 3’ end followed by polyadenylation 
ultimately defines the 3’UTR, which harbors various gene regulatory elements such as AU-rich 
elements, and binding sites for micro-RNA and RNA binding protein. Through the alternative 
polyadenylation (APA), these regulatory elements can be either included or excluded for 
differential regulation.7 The selection of the polyadenylation site has been shown to be tissue 
specific.84, 124 The APA also has been shown to play important roles in cellular development and 
cancer progression.125, 126  
The 3’ UTRs of the odorant receptor (OR) genes in the main olfactory epithelium (MOE) 
have until very recently been poorly annotated. A study by Shum et al. showed through RNA-seq 
analysis that the mouse ORs typically have short 3’ UTRs, and hence fewer negative regulatory 
elements such as miRNA binding site.127 This conceivably contributes to robust expression of the 
odorant receptor genes in olfactory sensory neurons (OSNs); about 1% of the mRNAs in the 
olfactory sensory neuron is devoted to expressing the odorant receptors.11 ORs are also expressed 
in some other tissues, such as testis, heart, etc.128, 129 However, little is known about the 3’ UTR 
of the ectopically expressed OR genes. Thus we aimed in this chapter to provide the necessary 
knowledge in profiling and comparing the 3’ ends of the odorant receptor transcripts in various 
tissues. In order to become familiar with the topic, we first reviewed published next generation 
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sequencing methods that have been used for specifically examining the 3’ UTR and 
polyadenylation site. We discuss the methods of library preparation, in which 3’ untranslated 
regions are specifically targeted for profiling. Several other reviews of this fast-moving field 
came out before we finished the manuscript and it was not published.    
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Section 5.A. Introduction to pre-mRNA 3’ Cleavage 
In eukaryotes, nearly all pre-mRNAs with exceptions of histone mRNAs, undergo 
modifications including 5’-cap addition, splicing and 3’UTR formation for formation of mature 
mRNAs and proper gene expression.130, 131 A critical, obligatory step in this fundamental process 
of transcription is 3’ UTR formation, consisted of co-transcriptional endolytic cleavage of 3’ pre-
mRNA followed by poly adenylation. The proper formation of 3’ end is directly related to the 
fidelity of transcription termination, mRNA localization, stability, differential expression, and 
dynamic regulation.132 The formation of pre-mRNA 3’end is driven by the cis-acting PAS that 
recruits many trans-acting proteins to cleave the 3’ end. An untemplated poly-(A) tail is then 
added to the 3’ end of  the nascent mRNA.133 The complexity arises from the fact that a majority 
of the human transcripts harbor more than one PAS.83 Depending on where the transcript is 
cleaved and polyadenylated, different mRNA isoforms are generated.  
APA has physiological consequences, both qualitatively and quantitatively. For instance, 
APA can produce different protein isoforms of immunoglobulin(Ig) M in B cells; the distal (from 
the 5’ end) PAS is used for the longer, membrane bound isoform of IgM while proximal PAS is 
used for the shorter, secreted isoform.134  If all the PAS are located at the terminal exon, APA 
may lead to mRNA isoforms bearing different 3’ untranslated region (3’UTR) lengths. The 
3’UTR of a gene often contains regulatory elements such as RNA binding protein binding sites, 
AU-rich elements, and miRNA target sites.135 Normally, the distal PAS is utilized to generate 
long 3’UTR, in which case the gene is subject to the dynamic control.126 When the proximal PAS 
is used, the shorter isoform bypasses the negative regulation, increasing the mRNA stability and 
the expression level of the gene. (Fig. 5-1) APA in fact has been suggested as a possible 
mechanism by which some proto-oncogenes are activated.126 PAS usage has also been shown to 
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be highly correlated with the physiological state of the cell. Different tissues use different APA 
patterns.85, 136 It has also been shown that APA plays a crucial role in cellular development and 
differentiation.137, 138 Moreover, APA also has been involved in diseases such as IPEX, cancer, 
type I diabetes, and type II diabetes.139, 140 
 
Section 5.B. Genome-wide 3’ End Sequencing Methods: Review of Library Preparation 
Methods used in 3’-End Sequencing  
Reliable, efficient and high-through put methods are critical for the current and further 
studies of APA. Indeed, numerous techniques have been devised in order to annotate the 3’ ends. 
Herein, the different methods in surveying APA sites to exhaustively profile the PAS usage are 
reviewed, focusing on the library preparation steps of high-throughput methods.  
 
5.B.1. Expressed Sequence Tags (EST) 
 Analysis of ESTs was first used to survey the APA usage.141 ESTs are the short 
sequences produced from randomly selected cDNA clones. Briefly, total mRNA from either 
 
Figure 5-1. Alternative polyadenylation (APA) can generate mRNA isoforms with different lengths of 
3’UTR. Contained in the 3’UTR are the regulatory regions such as miRNA targets, RNA binding protein (RBP) 
binding sites, and A-rich elements (AREs). When the proximal PAS is used, the mRNA avoids the regulation 
imposed by miRNA target sites, AREs, and RBP Binding sites.  
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whole organ, tissue, or a given cell line is isolated. The cDNA library is then synthesized using a 
suitable method. Often, an oligo-dT fragment and reverse transcriptase are used to generate the 
first strand of cDNA. Alternatively, random hexamer primers may be used as primers for the 
reverse transcriptase as well. The mRNA of the RNA-DNA duplex is then nicked using RNAse 
H. The remaining RNA fragments serve as a primer for DNA polymerase I for extension, 
resulting in second strand generation. The cDNA is then cloned into a vector. By using the 
primers that are complimentary to the vector sequence, the ends of cDNA insert can be 
sequenced by automatic DNA sequencers. The resulting length of ESTs ranges from 200 to 400 
nucleotides. The NCBI EST database presently contains about 74 million entries from various 
organisms including human and mouse.  
The ESTs can be used as a tool for gene mapping, polymorphism analysis and expression 
profiles. For PAS usage analysis, 3’ESTs are clustered and aligned to the genomic sequences. 
Using this method, the significant prevalence and tissue specificity of APA was confirmed. 136 
While EST analysis can provide a quick start for APA studies with existing data, the survey of 
APA usage is limited by the defined data size. It was also shown that reverse transcription and 
cDNA selection for amplification can introduce biases.142 Moreover, up to 12% of the ESTs can 
be generated from internal priming of the oligo dT during the library synthesis. 143  
  
5.B.2. Microarray 
A microarray with multiple probes targeting mRNA can also be used as a method to 
analyze APA sites of various transcripts. The extracted transcripts are first reverse transcribed 
and fluorescently labeled. The labeled cDNAs are then hybridized onto the microarray grids. 
Each grid represents a probe, the reverse complimentary sequence derived from the various parts 
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of known mRNA sequence of the gene in study. A set of different probes are often used to detect 
one gene. The fluorescent intensity on the grid is analyzed in order to gage the expression level 
of the genes represented by the probe sets. APA usage can be detected by comparing the reads 
from the probe of the shorter isoform to the probe of the longer isoforms.  
The caveat in APA profiling using microarray is that the method can only confirm the 
known APA sites. In other words, transcripts that go through unannotated RNA editing, splicing 
or APA may not be detected at all. Microarray reads also present weak resolution as they don’t 
reveal the accurate polyadenylation site at a nucleotide level. The difficulty in quantification of 
each 3’UTR isoforms when there are more than two isoforms, is another notable disadvantage.144  
Furthermore, sensitivity of microarray is not high enough to detect the mRNA isoforms that are 
generated at low frequency. Zhang et al. has used the microarray to detect the expression of the 
ORs in mouse MOE although the 3’ ends of the transcripts were not defined145  
 
5.B.3. RNA-Seq 
The whole transcriptome sequencing has become convenient with RNA-Seq, next-
generation sequencing.146 For this high-throughput technique, the polyadenylated mRNAs are 
isolated and fragmented. The fragments are then reverse transcribed using random hexamers and 
sequenced by the next-generation sequencing. This method has advantages over using 
microarray in that it does unbiased screening, detecting expression of unknown genes. The 
ability to detect small amount of gene is another significant benefit. 147  
 
APAs may be revealed by focusing on fragments containing poly-(A), using the data 
obtained from RNA-Seq experiments. However, only a small fraction (~6%) of the  reads come 
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from the 3’ end.148 Therefore, using RNA-Seq as a 3’ end analysis is rather cost-inefficient. As is 
the case with micro array, since the reads are not specific to the 3’end, the accurate determination 
of the cleavage site at a nucleotide level is unlikely. Moreover, the use of random hexamers has 
shown some biases when sequenced.149 Thus, while RNA-Seq is a powerful tool for a 
transcriptome profiling, a modification is necessary for a focused observation on APA usage.  
  
5.B.4. 3’ End Sequencing Methods- Oligo dT Priming 
In order to profile the PAS usage, the obvious need is the high-throughput sequencing 
method that concentrates the reads to the 3’ end of the transcripts.  To that end, many groups 
took modifications of RNA-Seq. Over all, these methods resemble the RNA-Seq procedure 
except that the output reads are 3’biased. This is done by using oligo dT containing adaptors as 
primers to generate cDNA library, followed by PCR amplification and next generation 
sequencing. Because the cDNAs are synthesized with primers binding at the poly A tail, the 
reads can be used to map the cleavage and polyadenylation sites of the mRNA at nucleotide 
level. Also, since next generation sequencing allows multiplexing, the amount of reads that can 
be generated in parallel is immense. Thus, this method is considered suitable for large-scale, 
genome-wide profiling of the PAS usage. However, the use of oligo dT raises one significant and 
common problem, internal priming; a stretch of poly (A) in the middle of a gene may be 
mistakenly considered as the 3’ end.143 Therefore the reads possibly coming from the internal 
priming must be removed computationally for an accurate analysis of APA usage. The following 
methods that utilize oligo dT priming and reverse transcriptase for cDNA synthesis are described 
below: 5.B.4.1. 3’RNA-Seq, 5.B.4.2. PolyA-Capture, 5.B.4.3. 3’Seq, 5.B.4.4. Multiplex Analysis 
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of Poly A-linked Sequences (MAPS), 5.B.4.5. Strategy of sequencing APA sites (SAPAS), 
5.B.4.6. Poly A site sequencing (PAS-Seq), 5.B.4.7. Poly A-Seq. 
  
5.B.4.1. 3’RNA-Seq150 
Yoon and Brem’s group used a slightly modified RNA-Seq method, 3’RNA-Seq to study the 
PAS usage of yeast in normal condition and in stressed condition.150 In this method, the 
polyadenylated mRNAs were isolated from the total RNA using oligo dT and magnetic beads. 
The mRNAs were then subject to first strand cDNA synthesis, using anchored oligo dT (NVT20) 
primer and reverse transcriptase. The anchored oligo dT has a chain of 20 T’s followed by two 
random nucleotides. The letter V is one of the three nucleotides A, C or G. The letter N 
represents any one of the four nucleotides, A, C, G, or T. Such use of anchored oligo dT raises 
the possibility of the primer binding at a proximal end of the poly A chain, the cleavage site. 
Nevertheless, many of the reads do not precisely locate the cleavage site.151 RNase H is then 
used to nick the duplex of cDNA/RNA. The second strand was then generated by DNA 
polymerase I in presence of RNaseH. The Illumina paired-end sequencing adapters were ligated 
onto the double stranded cDNAs, followed by agarose gel purification and PCR amplification. It 
has been shown that the heating the agarose gel to 50ºC in chaotropic buffer during purification 
step might introduce bias against A/T rich sequences.152 This bias could be avoided by melting 
the agarose gel containing DNA at room termperature.152 The sequencing was done by using the 
paired end module on Illumina 2G Genome Analyzer. While Illumina Genome Analyzer 
platform provides high throughput reads, it offers rather short read lengths (25~35 bps).153 
Recently, a library preparation method similar to this was used by another group to annotate the 
3’UTR isoforms in Drosophila.154  
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5.B.4.2. PolyA-Capture 155 
Mangone et al. used PolyA-Capture method to describe the PAS usage in roundworms at 
different developmental stages.155 The total RNA was extracted from C. elegans. The 72 most 
abundant, unwanted ribosome subunit mRNAs were removed by introducing their antisense 
DNA oligos followed by digestion with RNaseH.155 The poly (A) tail containing mRNAs were 
isolated from the total RNA using oligo dT and magnetic beads. The resulting transcripts and 
reverse transcriptase were then used to synthesize the first cDNA strand using biotin labeled, 
anchored oligo dT (NVT20) primer, also containing the sequencing adaptor. Using a modified 
primer as in this case allows bypassing of the ligation of the sequencing adaptors at one end of 
the cDNA. The second cDNA strand was synthesized using DNA polymerase I and RNase H. 
The double stranded cDNA strands were digested with a restriction enzyme DpnII, making a 
sticky overhang for convenient adaptor ligation. It is worth noting that the use of restriction 
enzyme may result in incomplete digestion, which interferes with fair description of the total 
transcript.156 The cDNAs were then PCR amplified and sequenced using Roche/454, Genome 
Sequencer FLX system.155 This pyrosequencing system is quick and provides long read lengths 
(up to ~700 bps) and thus the mapping and cleavage site determination is clearer.157 On the other 
hand, FLX system is less throughput than Illumina GAII. The high error rate may also be a 
problem especially with homopolymers.157, 158 Besides PolyA-Capture, the group desirably used 
other methods available such as 3’RACE and RNA-Seq to complement their description of the 
3’UTR.155  
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5.B.4.3. 3’Seq84 
Lianoglou et al. recently used a similar technique to profile the tissue specific APA in 
human.84  The total RNA was used to synthesize first strand cDNA synthesis using reverse 
transtriptase and anchored oligo dT primer that contains a uridine (NVT8UT8). Similar to Poly-A 
Capture method, the primer also contained the sequencing adapter and biotin, circumventing 
adapter ligation on one side of the cDNA. The second strand was generated by introducing a nick 
at the position of the uridine using RNase HII, followed by nick translation using DNA 
Polymerase I. As a result, the nick was translated to about 50 to 75 downstream position on the 
second strand of the cDNA. The double stranded cDNA was then blunted at the nick and the 
sequencing adapter was ligated onto the blunt end. The resulting cDNA was PCR amplified and 
sequenced using Illumina HiSeq.  
        
5.B.4.4. Multiplex Analysis of Poly A-linked Sequences (MAPS)159 
Fox-Walsh et al. devised MAPS and used it to monitor the effect of an RNA binding protein 
(FUS/TLS, often implicated in gene expression) on APA usage.159 In this procedure, the pre-
selection of polyadenylated transcripts were bypassed. The biotinylated, anchored oligo dT 
(NVT20) was used as a primer for 1
st strand cDNA synthesis. The second strand synthesis was 
done in presence of Streptavidin magnetic beads, using random octamers linked to the 
sequencing adaptors. Therefore the adaptor ligation to the cDNA was unnecessary. The cDNA 
strands synthesized on the magnetic beads were then released from the beads. The cDNA library 
was then PCR amplified, size selected and sequenced via Illumina GAII. The size selection via 
gel fractionation safeguards that the sequence is long enough to be uniquely mapped to the 
genome.  
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5.B.4.5. Strategy of Sequencing APA Sites (SAPAS)160 
Fu et al. used SAPAS to gage the global PAS usage in human breast cancer cell lines and 
normal cell lines.160 Similar to methods mentioned above, anchored oligo dT (NVT20)   modified 
to include the sequencing adaptor was used as a primer. This method employed template 
switching system to generate the cDNA library. The template switching utilizes MMLV reverse 
transcriptase to add a few C’s at the end of reverse transcribed cDNA. The template switching 
adaptor containing complimentary G’s then act as an extended template for reverse 
transcription.161 It is a noteworthy concern that with small amount of RNA samples, the template 
switching system may induce high background due to concatamerization.162  The 2nd strand 
cDNA generation and amplification was done via PCR. Since homopolymers account for the 
high error rate of Roche/454 sequencing, point mutations were made in the poly A tail during the 
PCR step. Both Roche/454 and Illumina GAIIx were used for sequencing. However, the analysis 
was done only with reads from Illumina GAIIx platform because the data obtained from 
Roche/454 was limited.160  
 
5.B.4.6. Poly A site sequencing (PAS-Seq)144 
PAS-Seq was used by Shepard et al. to map the APAs of various mammalian cells and 
showed the dynamic changes of PAS usage during mouse embryonic stem cell differentiation.144  
The procedure is highly in line with SAPAS method described above except that point mutations 
were not made to the poly A tail. The cDNA library was constructed using template switching 
system followed by PCR. The sequencing platform used was Illumina GAIIx.  
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5.B.4.7. Poly A-Seq151 
Poly A-Seq provides a prominent advantage of time efficiency.151 For first strand cDNA 
generation, anchored oligo dT with10 Ts are used instead of 20 Ts. The shorter oligo dT offers 
more favorable hybridization kinetics, allowing rapid cDNA synthesis. On the contrary, the 
shorter oligo dT increases the internal priming incidents.151 Therefore, an exhaustive algorithm is 
necessary to remove the internally primed reads. The second strand cDNA synthesis is aided by 
random hexamers primer linked to sequencing adaptors. The use random hexamer primer has 
shown bias.149 Thus an extra step to reweigh the read counts is necessary.149 The sequencing was 
done using Illumina GAIIx platform.  
 The use of oligo dT primers are currently the most common approach to describe the 
genome wide PAS usage. The disadvantage of using oligo dT primer is the high percentage of 
internal priming. Various strategies has been used to remove internal priming computationally, 
by eliminating the 3’ reads coming from the internal A rich regions. However, the cleavage and 
polyadenylation that actually occurs in the A rich regions is falsely eliminated in this route. In 
addition, the methods mentioned above commonly utilize reverse transcriptase for cDNA library 
construction. This may introduce ambiguity, as it has been shown that the reverse transcriptase 
may add non-templated nucleotides during first strand cDNA synthesis.163 Other approaches that 
have been proposed to circumvent these issues are described in the following section.  
 
5.B.5. Poly A Position Profiling by Sequencing (3P-Seq)164  
 Jan et al. devised 3P-Seq to annotate the 3’ transcript ends of C. elegans and avoid the 
internal priming problem.164 Briefly, the polyadenylated mRNAs were ligated to the biotinylated 
adaptor using “splint DNA oligo nucleotide” and RNA ligase. The “splint DNA oligo 
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nucleotide” is a single stranded oligo dT followed by double stranded primer sequence. This 
splint ligation favors the ends of the transcripts rather than internal poly A chains. The ligated 
mRNAs are partially fragmented using T1 nuclease. The polyadenylated mRNA ends are then 
captured using Streptavidin magnetic beads. The reverse transcription takes place with only the 
dTTP available, so that only the poly A tail is reverse transcribed. The duplex is then digested 
with RNaseH and this frees the mRNA with a minimal length of A’s. The mRNA fragments are 
then gel purified, followed by adaptor ligation, amplification and sequencing via Illumina 
platform. While internal priming is unlikely, this method lacks the simplicity in that the sample 
mRNAs are manipulated over multiple steps. Also, the ligation of the 5’ and 3’ adapters has 
shown to introduce biases.165 This can be overcome by using 5’ adaptors with randomized 3’ 
nucleotides and 3’ adaptors with randomized 5’ nucleotides.165 Another caveat may be that this 
method ends up including the poly A tail in the sequence, which may introduce an extra step 
during the processing of the reads.  
  
5.B.6. 3’ Region Extraction and Deep Sequencing (3’ READS) 166, 167 
 Hoque et al. devised 3’ READS to profile the mRNA 3’ ends without relying on oligo dT 
mediated cDNA synthesis.166, 167 This method eliminates the internal priming events by 
concentrating the mRNA ends with about 60 A’s. Briefly, the polyadenylated mRNAs are 
isolated and fragmented at first. The 3’ ends of the fragmented RNAs are then captured on 
magnetic beads containing an oligomer of 45 Ts followed by 5 Us. This chimeric oligonucleotide 
is longer than that of the anchored oligo dTs. Stringent washing ensures that only the mRNAs 
with a long poly A tails remain on the beads. The RNAs are released from the beads by digesting 
with RNaseH. During this step, most part of the poly A chain is digested but a few A’s are 
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protected by pairing with the terminal 5Us since RNaseH only digests the RNA/DNA duplex. 
The eluted RNAs are then ligated with 5’ and 3’ adaptors, followed by reverse transcription, 
PCR amplification, and sequencing by Illumina GAIIx. As is the case with 3P-Seq, the cDNA 
synthesis using reverse transcriptase takes place after the adapters are ligated. Therefore, the 
ambiguity coming from possible addition of untemplated nucleotides by reverse transcriptase can 
be ruled out.  
For analysis of the obtained reads, only the reads containing at least two non-genomic As 
at the 3’ end were considered for analysis. Therefore, internal priming is unlikely in this method. 
Because no computational removal of predicted internal priming reads are done, the cleavage 
and polyadenylation sites occurring at in the A rich region of the genome can also be identified. 
On the other hand, as is the case with 3P-Seq, the sample RNA goes through numerous 
manipulation steps. The possible bias coming from ligation step must also be resolved.  
 
5.B.7. Flowcell Reverse Transcription Sequencing (FRT-Seq)168 
All the methods described above incorporate cDNA amplification via PCR. However, the 
amplification efficiency of PCR is known to be unequal between fragments.169 Mamanova et al. 
devised amplification free sequencing method called FRT-Seq.168  The unamplified RNA 
fragments with 5’ and 3’ adapters can be loaded directly to the flowcells of Illumina 
Sequencers.168 FRT-Seq has not yet been used for sequencing 3’ ends of mRNA.168 
 
5.B.8. Direct RNA Sequencing (DRS)170 
Ozsolak et al. developed another 3’ sequencing method using that doesn’t require cDNA 
synthesis, amplification and ligation step. This strategy, DRS was used to map the APA usage in 
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yeast and human cell lines while avoiding the biases and artifacts arising from cDNA library 
synthesis.170 Since the RNA molecules are directly sequenced, the method can be considered 
more quantitative in nature than using the cDNA library. Internal priming events are found to be 
rare.171 The method also circumvents the complicated sample RNA treatment. Therefore, less 
mRNA is required for sequencing.  
DRS is a sequencing by synthesis method and utilizes a modified polymerase and 
fluorescent nucleotide analogues, virtual terminator nucleotides (VT). Each VT has an inhibitor 
and a fluorescent dye tethered by a cleavable bond, allowing sequencing one nucleotide at a 
time.172 From the total RNA, polyadenylated mRNAs are captured on the flow cell coated with 
poly dT, a chain of 50T’s.171 The remaining A’s on the transcripts are “filled” using polymerase 
with only natural dTTP available. This “fill” step ensures that the sequencing starts right from 
the cleavage site rather than the poly A tail. Then the transcripts are “locked” by introducing VT-
A, -C and G. Further synthesis is inhibited due to the inhibitor tethered on the nucleotides. The 
unincorporated VT’s are washed away and images are taken. The fluorescent dye and inhibitor 
are then cleaved off and the remaining nucleotide becomes suitable for next nucleotide addition. 
Each of the VT’s (C,T,A and G) are made available one at a time for synthesis on the Helicos 
Genetic Analysis System. Each round is followed by rinsing, imaging, and cleavage steps.171 
While DRS provides unbiased sequencing method that locates the cleavage site at a nucleotide 
resolution, it does suffer from higher error rate.173       
 
In summary, many deep sequencing techniques have been devised for genome wide 
profiling of APA usage. While methods that rely on oligo dT primers for cDNA library 
construction are quick and convenient, they present the issue of internal priming and other 
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biases. The use of splint primers or a long chimeric oligonucleotide to isolate the 3’ ends offer 
clever solutions to internal priming. The method mentioned above can be adapted with or 
without suitable variations according to experimental objectives and available resources.   
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Part II. Mammalian Pre-mRNA 3’ Processing and Odorant Receptor Genes 
Chapter 6. Polyadenylation Site Usage of Odorant Receptors 
 
Synopsis 
The 3’untranslated regions often contain regulatory elements such as RNA binding 
protein binding sites, AU-rich elements, and miRNA target sites.135 Driven by cis-acting 
polyadenylation signals, the 3’ untranslated regions are formed by cleavage and polyadenylation 
of the nascent transcript. A majority of mammalian genes have multiple polyadenylation signals 
(PAS) per gene. Through alternative polyadenylation (APA), different PAS are used and the 
regulatory elements on the 3’ untranslated regions are either included or excluded from the 
transcripts. This alternative polyadenylation is tissue specific, and can produce different 
transcript isoforms in different tissues.84, 124 Compared to other genes, odorant receptors in 
olfactory epithelium have been shown to have shorter 3’ untranslated regions, likely allowing 
them to bypass negative regulatory elements such as miRNA target sites.127 This possibly 
contributes to the robust expression of the odorant receptor (OR) genes in olfactory sensory 
neurons; the odorant receptor transcripts make up nearly ~1% of the mRNAs in the olfactory 
sensory neurons.11  
Although odorant receptor genes have been long believed to be functional only in the 
olfactory epithelium and olfactory bulb, the expression of odorant receptors in non-olfactory 
tissues has been repeatedly reported.128, 129 The expression level of the odorant receptors in the 
non-olfactory tissues are not as robust as in the olfactory epithelium.174  However, how the 
ectopically expressed odorant receptor genes are regulated remains poorly understood. The 3’ 
untranslated regions of the ectopically expressed odorant receptors are also poorly annotated. 
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Herein, as a side project, we aimed to investigate a possible role of alternative polyadenylation in 
tissue specific expression and regulation of the odorant receptors, by profiling the 3’ untranslated 
regions. To that end, 3’ RNA extraction and deep sequencing was performed using the mRNAs 
extracted from the olfactory epithelium and, for a comparison within the olfactory system, the 
olfactory bulb. Our data would also allow comparison of the 3’ UTR of the OR transcripts that 
are expressed in the MOE and the ectopically expressed ORs in other tissues. Bioinformatic 
analysis of the sequenced reads awaits the need to find a bioinformatics collaborator.  
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Section 6.A. Introduction 
Mammals can detect and discriminate countless number of distinct odors through their 
olfactory system. This ability is mediated by a large number of odorant receptor genes (ORs). 
Mice express ~1100 OR genes in the main olfactory epithelium (MOE). Each mature olfactory 
sensory neuron (OSN) chooses one OR from this repertoire to express, although recent studies 
showed that a small fraction of immature neurons can transiently express multiple ORs.20, 22, 175 
Also, other tissues such as brain, testis, and etc. have shown expression of various OR genes.128, 
129 The mechanism behind the gene selection in OSNs has been mainly attributed to epigenetic 
signatures.101, 176 However, the post transcriptional regulation of the OR genes in the MOE, 
olfactory bulb (OB), and other tissues have been incompletely characterized and could 
conceivably play a role.  
The 3’ UTRs of mature mRNAs typically harbor gene regulatory elements such as micro-
RNA binding sites and AU-rich elements. Through APA, these regulatory elements can be either 
included or excluded for differential regulation.7 While general transcript profiling of the MOE 
has been available, the precise 3’ ends of the OR genes have not been studied or annotated with 
APA sites thoroughly at the single base resolution.174 The APA usage among the ORs that are 
expressed in non-olfactory tissues (ectopic expression) is also still unknown. To that end, 3’ 
RNA extraction and deep sequencing (3’ READS) method was initiated to sequence the 3’ends 
of transcripts in mouse MOE, OB. The PAS usage of OR genes will be compared to that of at 
least one non-olfactory tissue that has previously been shown to express ORs. This particular  
method has been used to successfully map the APA sites in various mouse tissues and cell lines 
including brain and testis, but not MOE and OB.166 Ideally, the OSNs should be separated from 
other cells in the MOE before isolation of the mRNA, and this has been recently done.177 The 
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transcriptome of the separated OSNs were sequenced using the standard RNA-Seq.177 One 
advantage of using 3’ READS over other methods like the standard RNA-seq method is that this 
method avoids internal priming at oligo A sites. Profiling the APA of ORs expressed in MOE, 
OB and in other tissues will provide a basis for investigating how OR gene expression in these 
tissues might be regulated at the RNA processing level. 
 
Section 6.B. Progress 
This project was begun as a back-up project, or one that might be continued by another 
student, and it is still under way since the alignment to genomic sequence of the retrieved 
sequences and annotation of the 3’ ends have not been done. Total RNA samples of MOE and 
OB from 3 mice were prepared separately. The quality of RNA was analyzed using BioAnalyzer. 
The RNA integrity number (RIN) of each sample is summarized in Table 6-1. RIN of >7.0 is 
considered acceptable for further processing of the samples.167 The library was then prepared 
using 3’ READS method and deep sequencing was done using Genome Analyzer GAIIx.166 (The 
library preparation was performed by Dr. Mainul Hoque in Center for Genome Informatics, New 
Jersey Medical School.) The data sets await analysis by a skilled bioinformatician collaborator. 
 
 
Table 6-1. RNA Integrity values obtained for each sample 
Sample RIN 
OB 1 8.70 
OB 2 7.60 
OB 3 8.50 
MOE 1 8.80 
MOE2 8.30 
MOE3 8.50 
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Section 6.C. Materials & Methods 
6.C.1. Isolation of Main Olfactory Epithelium and Olfactory Bulb 
All use and care of the laboratory animals were in compliance with guidelines of The 
City College of New York Institutional Animal Care and Use Committee. (Protocol number 937) 
Six to eight week old male C57BL/6 mice (Charles River) were overdosed with ketamine 
(Ketaset) at 100 mg/kg and xylazine (AnaSed) at 10 mg/kg via intraperitoneal injection, followed 
by decapitation. The depth of anesthesia was assessed before decapitation by observing inability 
to remain upright, loss of purposeful voluntary movement, and loss of response to reflex 
stimulation (toe pinch with firm pressure). The MOE and OB was dissected out from the head, in 
a petri dish filled with RNALater or divalent-cation-free-Ringer solution (145 mM NaCl, 5.6 
mM KCl, 10 mM HEPES, 10 mM glucose, 4 mM EGTA, pH 7.4).  
 
6.C.2. Extraction of Total RNA 
The MOE and the OB were homogenized separately using pre-chilled dounce containing 
500 μL of Trizol (Invitrogen). The total RNA from MOE and OB tissues each mouse was 
extracted separately, using Trizol (Invitrogen). The amount of total RNA from each sample was 
measured using NanoDrop. The amount of total RNA extracted from MOE were 14 μg, 10 μg, 
and 30 μg for mouse 1, mouse 2 and mouse 3, respectively. The amount of total RNA extracted 
from OB were 12 μg, 22 μg, and 33 μg for mouse 1, mouse 2, and mouse 3, respectively. 
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Part II. Mammalian Pre-mRNA 3’ Processing and Odorant Receptor Genes 
Chapter 7. Optimizing In Vitro Pre-mRNA 3' Cleavage Efficiency: Reconstitution from Anion-
Exchange Separated HeLa Cleavage Factors and from Adherent HeLa Cell Nuclear Extract 
 
This chapter has been published as 
“Optimizing In Vitro Pre-mRNA 3' Cleavage Efficiency: Reconstitution from Anion-
Exchange Separated HeLa Cleavage Factors and from Adherent HeLa Cell Nuclear 
Extract” Na, M., Valente, S. T. & Ryan, K. in Eukaryotic Transcriptional and Post-
Transcriptional Gene Expression Regulation Methods in Molecular Biology (eds Narendra 
Wajapeyee & Romi Gupta) 179-198 (Springer New York, 2017).178 
 
Synopsis 
  Eukaryotic RNA processing steps during mRNA maturation present the cell with 
opportunities for gene expression regulation. One such step is the pre-mRNA 3’ cleavage 
reaction, which defines the downstream end of the 3’ untranslated region and, in nearly all 
mRNA, prepares the message for addition of the poly (A) tail. The in vitro reconstitution of 3’ 
cleavage provides an experimental means to investigate the roles of the various multi-subunit 
cleavage factors. Anion exchange chromatography is the simplest procedure for separating the 
core mammalian cleavage factors. Here we describe a method for optimizing the in vitro 
reconstitution of 3’ cleavage activity from the DEAE-sepharose separated HeLa cleavage factors, 
and show how to ensure, or avoid, dependence on creatine phosphate. Important reaction 
components needed for optimal processing are discussed. We also provide an optimized 
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procedure for preparing small scale HeLa nuclear extracts from adherent cells for use in 3’ 
cleavage in vitro. 
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Section 7.A.  Introduction 
The site-specific cleavage of nascent pre-mRNA transcripts downstream from the stop 
codon is a mandatory step in the biogenesis of all eukaryotic mRNA. Cell-free systems that 
reconstitute pre-mRNA 3’ cleavage activity in vitro have enabled RNA biochemists to identify 
and study the large protein complexes responsible for this gene expression step. Early work on 
the pre-mRNA that receive a poly(A) tail following 3’ cleavage, that is, all pre-mRNA except 
those from about sixty replication dependent histone genes 179, used HeLa cell nuclear extract to 
reconstitute 3’ cleavage activity 180-184. HeLa nuclear extract was subsequently fractionated to 
reveal a set of separable multi-subunit complexes essential for in vitro 3’ cleavage activity 185-188. 
These core cleavage factors are: cleavage polyadenylation specificity factor (CPSF, 6 subunits) 
189, 190, cleavage stimulation factor (CstF, 3 subunits) 191, mammalian cleavage factors I (CF Im 2 
subunits) 192, 193 and II (CF IIm 2 or more subunits) 
194 and, for most substrates, poly(A) 
polymerase (PAP) 188, 195. Owing to the large number of essential cleavage factor polypeptides 
and, for several, their large size and poor solubility, the reaction has never been reconstituted 
using recombinant proteins. Moreover, the CF IIm fraction has not yet been fully characterized, 
despite earnest attempts 194, 196, 197. The daunting complexity of the cleavage factors, and other 
proteins associating with them 198, poses a dilemma for biochemists seeking to learn more about 
the 3’ cleavage reaction: given that a recombinant system is not yet practical, and purification to 
homogeneity is expensive and arduous, to what extent should the cleavage factors be purified 
before in vitro experimentation? The answer of course depends on the nature of the experiments 
proposed. On the one hand, the use of unfractionated nuclear extract does not allow for the 
selective treatment of the cleavage factors with modifying enzymes or other reagents before 
reconstitution. On the other hand, over-purification risks the loss of ancillary factors that may 
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have potentially interesting regulatory or coordinating roles via interaction with the core 
cleavage factors.  
A compromise we have employed is to use cleavage factors fractionated from HeLa cell 
nuclear extract on the anion exchange diethylaminoethyl (DEAE)-sepharose resin 199. Several 
early studies began their multi-step fractionation procedures with either anion exchange 186, 188, 
190, 195 or size exclusion chromatography 188, 197. Size exclusion chromatography, using for 
example Superose 6 resin, separates poly(A) polymerase (PAP) from all other core cleavage 
factors, referred to collectively during early studies as the cleavage specificity factor (CSF) 188, 
while anion exchange separates the core factors into CPSF, CstF (co-eluting with PAP) and CFm 
(denotes unseparated CF Im and CF IIm). Thus, DEAE-sepharose anion exchange represents a 
simple fractionation procedure resulting in the separation of HeLa CPSF, CstF and CFm in vitro 
activities. It should be emphasized that the DEAE-separated factors are only separated from one 
another, not purified; they contain many co-eluting HeLa proteins, RNA 197 and, very likely, 
other nuclear extract constituents. Still, in combination with ammonium sulfate precipitation and 
a final dialysis, the DEAE-fractionated factors enable types of experiments not possible with 
nuclear extract (for example, see 199). In this report, we discuss factors that should be considered 
when optimizing 3’ cleavage activity using the DEAE-separated factors.  
To obtain useable amounts of the partially purified cleavage factors from HeLa nuclear 
extract, it has been necessary to begin multi-step fractionation procedures with large amounts of 
HeLa cells grown in suspension, typically using large flasks with spinner agitation. For example, 
the first report on CF Im, where this factor was purified to apparent homogeneity, began with 240 
liters of HeLa cells grown at a density of 4-6 X 105 cells/mL, which resulted in at least 312 mL 
of nuclear extract 192. This volume of extract is considerable, and immediately discourages 
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experiments aiming to begin with extracts from cells transiently transfected with plasmids 
encoding recombinant proteins of interest. Transient transfection experiments normally reduce 
the scale from cells grown in liters to cells grown on 10-15 cm plates in monolayer, where the 
amount of extract produced is too small to begin a chromatographic separation of the factors. 
Nevertheless, interesting 3’ cleavage experiments can be envisioned in unfractionated nuclear 
extract made from transfected cells, and several methods have been reported for preparing 
nuclear extracts from adherent cells for in vitro 3’ cleavage activity 200-205 as well as for other 
nuclear activities 206-210. Commercial kits are also available. In our experience, nuclear extracts 
made from plated HeLa cells tend to have lower pre-mRNA 3’ cleavage activity per extract 
volume than extracts made from cells grown in suspension. We have evaluated a variety of 
published methods for making HeLa nuclear extracts from plated cells and, in addition to our 
DEAE-factors discussion, describe here our current best procedure for making adherent HeLa 
cell nuclear extracts for use in 3’ pre-mRNA cleavage experiments. 
 
Section 7.B. Materials 
It is obviously important to work using RNase-free precautions. Guidance for working 
RNase-free can be found in this reference 211. The solutions of the following cleavage reaction 
components should be made up in diethyl pyrocarbonate (DEPC)-treated water of the highest 
purity available. Insofar as possible, purchase RNase-free reagents, sterilize by syringe or suction 
filtration and use autoclaved plasticware. 
 
7.B.1. Cleavage reaction component stock solutions (water-based) 
1. tRNA: approx. 10 mg/mL, e.g. E. coli MRE600  
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2. 2’-dATP, pH 7-8, (in place of ATP): 100 mM, (see Note 1) 
3. Creatine phosphate, disodium salt (adjust for water content mass): 1 M, sterile-filtered, make 
fresh every 3 months or less, store in single-use aliquots at -80 C. 
4. Dithiothreitol (DTT): 200 mM (made just before use by diluting a 1 M stock (1M stock is 
made in 20 mM NaOAc, pH 5.2; dilution done in water)  
5. Ethylenediaminetetraacetic acid (EDTA): 25 mM (pH 8), diluted from 500 mM stock 
6. RNase-Inhibitor, recombinant or placental: 40 units/L (see Note 2) 
7. Polyvinyl alcohol (PVA, ≈90% hydrolyzed, avg. MW 30-70 kDa): 10% by weight in water. 
(see Note 3)  
8. Buffer D50: 20% glycerol, 20 mM Hepes-Na, pH 7.9, 0.2 mM EDTA, 0.5 mM DTT, 50 mM 
(NH4)2SO4, and 0.2 mM phenylmethylsulfonyl fluoride (PMSF) (see Note 4)  
9. 5’-capped, radiolabeled poly(A) signal-containing RNA substrate 211: e.g. simian virus 40 late 
poly(A) signal substrate, SV40L 188, or e.g. Adenovirus 2 late 3 substrate, Ad2L3 188, or other 
pre-mRNA substrate, aim for about 50 nM in DEPC-treated water 
 
7.B.2. Cleavage reaction component solutions (Buffer D50-based)  
Use DEAE-fractionated CPSF, CstF-PAP, CFm (see Note 5). Alternatively, HeLa cell nuclear 
extract from cells grown in suspension 188, 212 or from adherent cells (see below) may be used, 2--
10 mg/mL total protein. 
1. DEAE-CPSF, typically 2--7 mg/mL (total protein compared to BSA standards) dialyzed in 
Buffer D50 
2. DEAE-CstF, 2--7 mg/mL, dialyzed in Buffer D50 
3. DEAE-CFm, 2--7 mg/mL, dialyzed in Buffer D50 
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4. BSA (Bovine serum albumin): 10 mg/mL (molecular biology grade, in Buffer D50) (see Note 
6) 
5. Proteinase K 2X buffer: 100 mM Tris-HCl (pH 7.5), 20 mM EDTA, 200 mM NaCl, 2% SDS 
6. Glycogen: 10 mg/mL 
7. Proteinase K: 10 mg/mL in water 
8. Saturated phenol-chloroform: equilibrated with 0.1 M Tris-HCl (pH 7.6) 213 
9. Chloroform 
10. Ammonium acetate: 10 M in water, filtered through 0.22 micron syringe filter  
11. Formamide gel loading buffer: Highest purity formamide, 12 mM EDTA (diluted from 500 
mM aqueous stock), 0.3 % bromophenol blue and 0.3 % xylene cyanol, by weight, added dry. 
 
7.B.3. Components Used in Adherent HeLa Cell Nuclear Extract Preparation  
1. Dulbecco’s Modification of Eagle’s Medium (DMEM) with L-glutamine, 4.5 g/L glucose and 
sodium pyruvate  
2. Cosmic calf serum (CCS) 
3. Penicillin/Streptomycin, 10,000 IU/mL and 10,000 µg/mL, respectively 
4. HeLa JW36 cells (or other adherent HeLa cell type) 
5. Cell culture plates: e.g. 10 cm diameter 
6. Dounce homogenizer, 7 mL, type B pestle 
7. Buffer A: 10 mM Tris, pH 8, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.5 mM PMSF 
8. Buffer C: 25% glycerol, 20 mM Tris, pH 8, 0.2 mM EDTA, 1.5 mM MgCl2, 420 mM NaCl,   
9. Buffer D50: 20% glycerol, 20 mM Hepes-Na, pH 7.9, 0.2 mM EDTA, 0.5 mM DTT, 50 mM 
(NH4)2SO4, 0.2 mM PMSF 
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10. Trypan Blue solution 
11. Dialysis membrane (MWCO 1000 Da), cut into 2 cm by 2 cm pieces 
12. Small-scale dialysis chamber: Prepared by severing a capped microfuge tube (e.g. Sarstedt 
cat. No. 72.690.001) near its 1.5 mL mark with a new razor blade. The space inside the lid of the 
tube serves as the dialysis chamber while the ring of remaining microfuge tube plastic serves as a 
clamp to hold the stretched dialysis membrane over the chamber like a drum.  
 
Section 7.C. Methods 
The reconstituted in vitro cleavage reaction carried out using the DEAE-fractionated 
cleavage factors will be described first, followed by details on balancing the relative amounts of 
the cleavage factors and a discussion of three reaction components (creatine phosphate, 
polyvinyl alcohol (PVA) and ATP, or certain structural analogs) important for consistently 
efficient 3’ cleavage activity. The in vitro cleavage protocol described here is adapted from work 
from several laboratories 196, 214-216.  
 
7.C.1. In Vitro 3’ Cleavage Reaction Using DEAE-Fractionated HeLa Cleavage Factors 
The reaction is conveniently carried out in a final volume of 12.5 L, but it may be scaled 
up or down as desired. Half of the volume is based on Buffer D50 and contains either nuclear 
extract or the DEAE factors, all previously dialyzed in this buffer, and should be prepared 
entirely on ice in a 4 C cold room using only pre-chilled, autoclaved plasticware. The other half 
is unbuffered water-based and contains aqueous solutions of tRNA, ATP (or structural analog), 
DTT, EDTA, creatine phosphate, RNase inhibitor, polyvinyl alcohol (PVA) and the in vitro 
transcribed, [-32P]-NTP uniformly labeled RNA substrate under study. Components that are 
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common to all tubes in an experiment are combined in either the Buffer D50 or in the aqueous 
master mix. The aqueous half of the reaction (and its master mix) should also be made on ice but 
can be prepared in a room at ambient temperature, and then moved to the cold room. The two 
6.25 L master mix halves are mixed in a reaction tube and placed at 30 C to start the reaction. 
The final buffer and salt concentrations therefore become equivalent to 0.5 X Buffer D50. (see 
Note 7) The volumes of Buffer D50 and water can be lowered in their respective mixtures to 
make room for other components such as small molecules, enzymes and other variables to be 
tested.  
This procedure describes a cleavage reaction using the DEAE-fractionated cleavage 
factors. If the goal is to locate cleavage factor activities following a chromatographic separation, 
this protocol must be adapted to that use by withholding the factor in question from the Buffer 
D50 master mix tube, and adding the individual column fractions to the reaction tubes in place of 
the withheld factor, as done for example in this reference 197. In addition to being useful in 
locating cleavage factor activities among the fractions of a chromatographic separation, this 
procedure provides a control cleavage reaction starting point for experimenting with the DEAE 
factors. There is much room for flexibility in planning diverse experiments, individually pre-
treating the factors with reagents, for example, but for consistent results it is best to aim for the 
same final concentrations of the water-based components listed here. For the actual cleavage 
factor amounts, see the discussion in Section 3.2 for balancing the cleavage factor volumes for 
optimal processing. Note that the volumes in the tables are the amounts per 12.5 L reaction and 
the volumes pipetted are small. Many reaction tubes with variations in each are typically run in a 
single experiment; scaling up will increase the pipetting volumes to volumes that can be 
accurately pipetted. 
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1. Remove the DEAE factor aliquots to be used from -80 C storage and place tubes on ice in the 
cold room. 
2. Add all necessary Buffer D50, and the BSA, to the pre-iced Buffer D50 based master-mix tube 
scaled up from the following table and leave on ice in the cold room. In scaling up, allow for one 
extra reaction tube (i.e. x 11 per 10 reaction tubes). Autoclaved 1.6 mL microfuge tubes are used 
for master mixes and reaction tubes throughout. 
 
Table 7-1. In vitro 3’ cleavage reaction using DEAE-fractionated HeLa cleavage factors: Buffer D50 based 
master mix 
Buffer D50-based Stocks Typical* Volume 
Buffer D50 Enough to make 6.25 L 
BSA, 10 mg/mL  0.31 (250 ng) 
DEAE-CPSF (4-7 mg/mL total protein) 0.4 L 
DEAE-CstF (4-7 mg/mL total protein) (see 
Note 8) 
0.3 L 
DEAE-CFm (4-7 mg/mL total protein) 1.2 L 
Total volume 6.25 L (per reaction) 
* See discussion below on balancing the volumes of the DEAE factor preparations. 
 
3. While the factors are slowly thawing on ice in the cold room, begin to assemble the water-
based master-mix tube scaled up from the table below. The indicated order of mixing is 
recommended but probably not critical, except that the RNase Inhibitor should be added after the 
DTT. Mixing is done by flicking the tube gently with a finger. If following this order of addition, 
after adding the RNase Inhibitor, but before adding the PVA, mix the tube’s contents by flicking, 
spin briefly and then leave the capped tube on ice. 
 
Table 7-2. In vitro 3’ cleavage reaction using DEAE-fractionated HeLa cleavage factors: water based master 
mix 
Water-based Stocks Typical Volume Final conc. 
DEPC-water as needed  
tRNA, 10 mg/mL 0.125 L 0.1 mg/mL 
2’-dATP, 100 mM 0.25 L 2 mM 
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Creatine phosphate, 1 M 0.625 L 50 mM 
DTT, 0.2M 0.1 L 1.6 mM 
EDTA, pH 8, 25 mM 1.0 L 2 mM 
RNase Inhibitor, 40 u/L 0.1 L  
PVA, 10%  3.125 L 2.5% 
RNA substrate, ≈50 nM 0.5 L < 5 nM 
Total volume 6.25 L  
 
 
4. Thaw the RNA substrate and dilute a portion to 50 nM in DEPC-treated water, heat it to 80 C 
for 2 minutes, snap chill in an ice-water bath, vortex, spin to the bottom of the tube, and leave on 
ice. (see Note 9) 
5. Before adding the RNA to the mix, return to the cold room and mix the now-thawed DEAE 
factor tubes by gentle flicking, then spin them at 13200 rpm in a pre-cooled microfuge located in 
the cold room for about 1 minute 
6. Add the factors one after the other to the Buffer D50 master-mix tube, mixing by gentle 
flicking and then spinning briefly in the microfuge after each addition. Minimize the time outside 
of the ice tray. After the last factor is added, mix well and spin again in the cold microfuge for 2 
minutes to remove any surface bubbles. Return the tube to the ice tray. Immediately re-freeze 
any remaining cleavage factor stock by immersing the tip of the microfuge tube in liquid 
nitrogen (or pulverized dry ice). Mark the tube to indicate that this aliquot has been thawed and 
refrozen one time. 
7. Continue making the aqueous master mix by adding the PVA. Before adding the PVA, 
vigorously mix the 10% stock solution on a benchtop vortexer and spin the tube at 13200 rpm in 
a microfuge at room temperature for 5 minutes to sediment any insoluble debris. (see Note 10) 
8. Complete the aqueous master mix tube by adding the labeled RNA substrate. Despite the 
presence of the RNase Inhibitor protein, the PVA allows the tube to be vortexed at medium 
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speed without the formation of bubbles. Bring the tube to the cold room and spin at 13200 rpm 
for 1-2 minutes in the microfuge there. 
9. On ice in the cold room, distribute 6.25 L of the aqueous master mix into the series of 
reaction tubes in which the in vitro cleavage experiments will be performed  
10. Distribute 6.25 L of the DEAE factors master mix into each tube. Mix by gentle flicking 
and spin for about 1 minute in the cold room microfuge. (When adapting this procedure to 
specific experiments having liquid additions unique to the various tubes, it is possible to pipette 
small volumes onto the inside wall of the reaction tube, and then add to the reaction mix by 
spinning briefly in the microfuge. In this way, the addition of different ingredients to different 
reaction tubes can be synchronized. This works for aqueous solutions only, where the surface 
tension is higher than when PVA or high protein concentrations are present.) 
11. Place the tubes in a 30 C circulating water bath for 2 hours. 
12. During the in vitro cleavage reaction, the denaturing polyacrylamide gel (DPAGE) 213 that 
will be used to separate the RNA cleavage products can be cast. In vitro cleavage does not work 
well on very long RNA substrates, so most are kept in the 125 to 250 nucleotides (nt) range. The 
standard SV40L and Ad2L3 substrates are in this range and a 6% DPAGE is used to resolve 
them. 
13. Also during the in vitro cleavage incubation period, make the Proteinase K 2X buffer mix. 
Scale up the following recipe by the number of reaction tubes, plus one. 
 
Table 7-3. Proteinase K mix 
Proteinase K mix Volume 
Water 85.5 L 
2X Proteinase K buffer  100 L 
Glycogen, 10 mg/mL 1 L 
Proteinase K, 10 mg/mL 1 L 
Total volume 187.5 
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14. At the end of the 2 hour cleavage reaction incubation, add 187.5 L of the Proteinase K mix 
to each tube at room temperature, mix by inverting or flicking, spin briefly in a microfuge, and 
incubate at 37 C for 15 minutes. 
15. Add an equal volume of saturated phenol-chloroform 213, vortex strongly to completely 
emulsify and then spin in a room temperature microfuge for 15 minutes. 
16. Carefully transfer the top (aqueous) phase of each tube to a fresh tube containing 67 L of 10 
M ammonium acetate; mix. 
17. Add 2.5 volumes (668 L) of 95--100 % ethanol, place on dry ice for 10 minute or longer. 
(see Note 12) 
18. Spin 15 minutes in the cold room microfuge at 13200 rpm.  
19. Remove all but about 10 L of the supernatant while carefully monitoring with a handheld 
radioactivity monitor (i.e. Geiger counter) to avoid discarding the pellet. Spin 1 minute and very 
carefully remove every last bit of visible liquid while holding the tube up to a 60 watt 
incandescent lamp if possible, while also monitoring for radioactivity. (see Note 13) The 
glycogen usually makes the pellet visible. It may resemble a tiny piece of wet cotton. Leave the 
microfuge tube open on the bench for 2 minutes. 
20. Resuspend the pellet in 8 L formamide gel loading buffer by flicking and vortexing, then 
spin briefly in the microfuge to concentrate the liquid at bottom of tube. 
21. Clamp the microfuge tubes shut with Sorenson LidlocksTM or other means, and heat to 80 C 
for 2 minutes in an aluminum microfuge tube holder block on a hotplate (or heated sand), then 
snap chill on ice. Vortex strongly, spin contents to the bottom of the tube and leave tubes at room 
temperature until the gel is ready to load. 
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22. Load equal volumes (typically 7 L) of each sample in a pre-flushed well of a (typically) 6% 
denaturing “sequencing” electrophoresis gel, 20 x 20 cm size, 0.4 mm thickness (see Note 14). 
For the SV40L and Ad2L3 substrates cited here, run the faster xylene cyanol dye to the bottom 
edge, but no farther as the 3’ cleavage fragments may run off the gel. Dry the gel on Whatman 
gel drying paper and expose to a phosphorimager plate, or X-ray film, to image the result. 
 
7.C.2. Balancing the DEAE Factor Amounts for Maximum 3’ Cleavage Activity 
In practice, it can be difficult to attain consistently high efficiency when reconstituting in 
vitro 3’ cleavage with partially purified factors. We will focus here on important experimental 
details for maximizing processing in a standard 120 minute in vitro cleavage reaction. We 
mention again the need for working under RNase-free conditions. This minimizes the 
background and consequently makes clearer the gel bands resulting from RNA cleavage. 
Another consideration, not often detailed in the literature, is the need to balance the relative 
amounts of the factors for optimal activity. There is evidence that in cells some of the cleavage 
factors are recruited co-transcriptionally to the RNA via the RNA Pol II largest subunit’s C-
terminal domain (CTD) 217, and this process undoubtedly facilitates the formation of complexes 
with the proper stoichiometry for in vivo cleavage. In vitro, the pathway to pre-cleavage complex 
assembly may be different because it is not coupled to transcription. In our experience, in vitro 
cleavage efficiency depends on the relative amounts of the DEAE cleavage factor preparations 
mixed in a reaction and must be determined experimentally. In theory, quantitative western 
blotting could be used to specify the stoichiometry of the factors, but this would be laborious and 
the functional stoichiometry has not been determined for all factors 218, 219. Interestingly, we have 
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found that the ratio of the volumes is related to the still unexplained need for high concentrations 
of creatine phosphate to yield efficient in vitro 3’ cleavage 196.  
An example of varying the DEAE factor volumes is shown in Fig. 7-1. The total protein 
concentration of these preparations was between 4 and 7 mg/mL (see Note 15). The starting 
point in this case was to use approximately equal volumes of CPSF and CstF, and to use about 
twice this volume of CFm. The relative cleavage efficiency obtained in this experiment is shown 
in lane 3. Holding CPSF and CstF constant and doubling CFm led to an increase in relative 
cleavage (lanes 3 and 5), whereas holding CFm constant and doubling CPSF and CstF did not 
significantly change the amount of cleavage products (lane 3 vs. lane 7). These results show that 
CFm was the limiting factor in the first ratio chosen. At a higher volume of CPSF and CstF (0.8 
and 0.6 L, respectively), the amount of cleavage increases with the amount CFm from 0.6 to 3.5 
L. Thus, when balancing a new batch of DEAE factors, it is CFm that is typically limiting, and 
increasing its volume usually leads to more cleavage. CstF can have the opposite effect; too 
much can inhibit 3’ cleavage in vitro. A sound strategy to begin with is to hold CPSF (0.5 L) 
and CFm (1 L) constant while increasing CstF from about 0.3 to 1.3 L. This should quickly 
lead to the optimal ratio of CPSF to CstF (they are typically similar if their total protein content 
is similar). CFm is then increased until cleavage activity levels off or no more room is available 
in the Buffer D50 half of the reaction volume. However, there is one caveat to this, and it relates 
to creatine phosphate.  
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7.C.3. Dependence of the In Vitro Cleavage Reaction on Creatine Phosphate 
The relationship to the creatine phosphate effect on in vitro cleavage activity is also 
illustrated in Fig. 7-1. In lanes 1 to 7, where the factors were used at comparatively low levels, 
detectable cleavage was clearly dependent on the addition of 50 mM creatine phosphate. But at 
the higher volume of CPSF (0.8 L) and CstF (0.6 L), increasing the CFm from 0.6 to 3.5 L 
led to some creatine phosphate-independent cleavage, as the reactions without it start to produce 
significant amounts of cleavage (compare lanes 6, 8 and 10). The cleavage stimulation property 
 
Figure 7-1. In-vitro 3' cleavage of SV40L pre-mRNA: Balancing the DEAE-fractionated HeLa cleavage 
factors for optimal activity and creatine phosphate dependence. The indicated volume in microliters (L) 
of the DEAE-fractionated factors used is listed. Total protein concentrations were: CPSF, 5.7 mg/mL; CstF, 
6.4 mg/mL; CFm 4.0 mg/mL. The upstream (5’ fragment) and downstream (3’) cleavage products are 
indicated. The relative cleavage (R.C., ratio of 5’ fragment to uncleaved substrate) for each reaction is 
normalized to lane 5 conditions. 6% DPAGE.  
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of creatine phosphate and related compounds may hold clues to the molecular details of 3’ 
cleavage 196, 220, 221. It has at different times been postulated to be a mimic of a phosphoprotein, a 
mimic of the RNA Pol II CTD 220 and a serendipitous inhibitor of a 3’ cleavage-suppressing 
protein phosphatase 199. How it works though, is still unknown. The balancing experiment shown 
in Fig. 7-1 reveals that it can boost the activity of low CFm concentrations just as increasing the 
amount of CFm concentration can. There is evidence that the binding of CF Im (the CFm sub-
complex containing CF Im25 and either the 59, 68 or 72 subunit) to the RNA substrate is 
important for the early steps of pre-cleavage complex assembly 193. At low CFm concentrations, 
creatine phosphate may foster the proper binding of CF Im to the RNA substrate and/or to other 
factors. The DEAE CF Im fraction we used here is less pure than that from the kinetic study 
193, 
so other explanations are certainly possible (see Note 16). Whatever the explanation, when 
balancing the factors for maximum in vitro cleavage activity, the nature of the planned 
experiments should be taken into consideration. For example, when searching for small 
molecules 221 or proteins 220 that can take the place of creatine phosphate, it is obviously 
necessary to use a combination of factors that ensures dependence on the creatine phosphate for 
cleavage activity. 
 
7.C.4. Other Reaction Components That Affect In Vitro 3’ Cleavage Efficiency 
ATP. With the exception of the SV40L pre-mRNA substrate, ATP, or one of its structural 
analogs, is required for efficient in vitro cleavage 182, 196. In fact, ATP was first thought to satisfy 
an energy requirement for the reaction (see Note 17), and creatine phosphate was included to 
allow creatine kinase to replenish the ATP pool 182. Though the role of ATP in 3’ cleavage is still 
unknown, the need for its hydrolysis has been shown to be unnecessary 196. We have found that 
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2’-dATP used in place of ATP leads to more efficient cleavage of the Ad2L3 substrate with the 
DEAE factors, and we therefore recommend its use, but most other analogs, including 3’-dATP, 
are less efficient than ATP. The 3’-dATP analog, cordycepin triphosphate, can nevertheless be 
used to replace ATP when there is a need for Mg2+ but when polyadenylation, which can obscure 
the cleavage reaction outcome, is to be avoided. The first 3’-dATP added by PAP to the cleaved 
5’ fragment in the presence of Mg2+ cannot be extended by the polymerase, even when Mg2+ is 
present, because the 3’-OH is lacking. The 2’-dATP analog may also work in this way, though it 
lacks the 2’-OH, not the 3’-OH. 
PVA. PVA is required for efficient in vitro cleavage and how it works is also unknown. It is 
sometimes assumed to be a molecular crowding agent, but we have observed that other crowding 
agents, like polyethylene glycol (PEG) and polyvinylpyrrolidone, cannot replace PVA. PVA is a 
polyol, and has a dense array of alcohol groups along its chains. Interestingly, the consensus 
sequence of the CTD of RNA Polymerase II is also very rich in alcohol side chains. Its sequence 
is YSPTSPS, so the consensus heptads have 5 hydroxyls per 7 amino acid residues. The isolated 
recombinant CTD can stimulate 3’ cleavage in place of creatine phosphate for the Ad2L3 
substrate 220, 222 (see Note 18). We have wondered if, in addition to a crowding agent role, PVA 
works also as a CTD mimic. However, we have no evidence for this speculation.  
RNA substrate concentration. Lastly, we note that the RNA substrate should be kept below 5 
nM concentration. Increasing the concentration, for example by adding cold substrate to decrease 
the specific activity of the labeled substrate, decreases in vitro cleavage activity. The likely 
explanation is that when the RNA concentration is increased, incomplete sets of cleavage factors 
are distributed among different substrate molecules, statistically lowering the number of RNA 
substrates that can interact with all of the factors simultaneously. 
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7.C.5. In Vitro pre-mRNA 3’ Cleavage Using HeLa Nuclear Extract From Adherent Cells 
HeLa cell nuclear extract can be prepared from adherent HeLa cells for use in pre mRNA 
3’ cleavage reactions, though in our initial experience, extracts made from suspended HeLa cells 
generally showed greater activity. Despite the small scale used for adherent cells, which does not 
allow for cleavage factor separation, the use of adherent cells can be convenient because their 
growth can be combined with transfection, allowing for ectopic protein expression, over-
expression or RNAi knockdown experiments. Using the protocol described here, two 10 cm 
plates of HeLa cells grown to 80–90 % confluency typically yield 60–80 L of HeLa nuclear 
extract with 3’ cleavage activity comparable to that made from a large volume suspension cells 
(see Fig. 7-2a). In vitro 3’ cleavage carried out with HeLa nuclear extract is also to some extent 
dependent on creatine phosphate (see Fig. 7-2b). In our experience though, it is less dependent 
on creatine phosphate addition than is the reaction reconstituted from the DEAE-separated 
factors, and it can be difficult to find an amount of nuclear extract, from suspension cells or 
adherent cells, that will be completely dependent on creatine phosphate addition for detectable 
activity. The method we present here is in itself not new, but combines features from other 
published nuclear extract preparation methods to maximize in vitro 3’ cleavage activity. It should 
be noted that using transfection reagents may lead to decreased 3’ cleavage activity (see Fig. 7-
2c), and vehicle-only control experiments should be used to gauge this effect.  
Most small scale extraction procedures are based on the classic Dignam nuclear extract 
preparation method 212 and involve i) harvesting , ii) swelling, and iii) bursting the cells, 
followed by extraction of the nuclei at moderate salt concentration. Several protocols are 
available for nuclear extraction from adherent cells, mainly differing in the cell bursting 
technique used 203, 207-210. To our knowledge, among these, only one method has been used to 
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prepare in vitro 3’ cleavage activity 200-204. The procedure we describe here is based on that 
method. One important modification we include is the addition of a small-scale dialysis step after 
salt extraction--also a typical step in the preparation of nuclear extract from suspended cells--
which despite being inconvenient we found to be necessary for reliable pre-mRNA 3’ cleavage 
activity.  
Lastly, we note that some extract-to-extract variability is unavoidable in all methods. 
Though we have not systematically studied it, we suspect that the precise confluency and general 
health of the cultured cells may be responsible for this variability. Therefore, caution should be 
 
Figure 7-2. In vitro 3’ cleavage activity using HeLa cell nuclear extract (Nxt) made from suspension cells 
and adherent cells. (a) Extract prepared from adherent cells as described here produces in vitro 3’ cleavage 
activity on par with that from extract made from suspension cells, per microgram (g) total protein. (b) Creatine 
phosphate (CP, 50 mM) enhances cleavage activity but is not required when a typical amount (3 L, 11.6 g) of 
extract is used per 12.5 L in vitro reaction. (c) HeLa cells treated with Lipofectamine 2000 (no plasmid, and 
according to manufacturer’s instructions) yielded an extract with lower cleavage activity. The SV40L pre-
mRNA substrate was used in all cases. 6% DPAGE. 
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exercised when drawing conclusions from experiments where different extracts are used within 
one experiment, and extensive controls and repetitions are recommended. RNAi knockdown and 
transient transfection are two such experiment types. 
1. Grow HeLa JW36 cells (or other HeLa cell type as long as they adhere well to the plate) on 
two or more 10 cm plates with DMEM media supplemented with 10% CCS and 1% 
Penicillin/Streptomycin in an incubator at 37 °C and 5% CO2. Cells should be grown until they 
are 80~90% confluent. 
2. All steps beyond this point should be carried out in the cold room using pre-chilled solutions 
and glassware. Prepare 100 mL of PBS, 10 mL of Buffer A, and 1 mL of Buffer C on ice. PMSF 
and DTT should be added just before use.   
3. Bring the cell culture plates to the cold room. Aspirate the media and wash each plate with 10 
mL of PBS three times. Aspirate all the remaining PBS from the plates after leaving the plates 
slanted for a few seconds. 
4. Add 5 mL of PBS 213 to each plate and scrape the cells off the plates using a rubber policeman.  
5. Transfer the detached cells to the 15 mL falcon tube using a 10 mL pipette. Prepare a 
microscope slide with 2 µL of the suspension, diluting further with PBS if necessary. 
6. Centrifuge at 2000 rpm in a cold room clinical centrifuge for 5 minutes to collect the cells to 
the bottom. 
7. Aspirate all the supernatant PBS and gently re-suspend the cell pellet in 3 mL Buffer A first 
by using the 10 mL pipette. Then pipette the cells up and down using a 1000 L micropipettor to 
thoroughly re-suspend the cells.  
8. Incubate on ice for 10 min, allowing cells to swell. Verify that the cells have swollen by 
preparing a microscope slide with 2 µL of the suspension, and compare it to the pre-swelling 
136 
 
sample, from Step 5, under a light microscope. In swollen cells, the nuclei look like distinct dark 
spots within large translucent spheres. 
9. During the swelling period, rinse the inside of the dounce homogenizer with Buffer A and 
place it on ice.  
10. Transfer the cell suspension to the dounce homogenizer using a 10 mL pipette. Carefully 
insert the B type pestle into the dounce, avoiding bubbles, and slowly move it up and down 20 
times, on ice. (see Note 19)  
11. Check for cell lysis by taking 2 µL of the cells in Buffer A and mixing in a microfuge tube 
with an equal volume of Trypan Blue. Observe cell lysis under the microscope. The lysed cells 
appear blue and ~90% of the cells should be lysed. If they are not, a few more dounce strokes 
can be added until most of the cells are lysed. Transfer the lysate back to the 15 mL falcon tube.  
12. Centrifuge at 4000 rpm for 10 minutes and aspirate the supernatant away from the nuclei. 
13. Estimate the packed nuclear volume (PNV) either by using the graduation on the falcon tube 
or using a separate empty falcon tube and water.  
14. Slowly resuspend the nuclear pellet in 1.5 PNV of Buffer C, using a 200 L micropipettor. 
This results in a ~250 mM NaCl concentration for the nuclear extraction.  
15. Transfer the nuclear mixture to a microfuge tube. Incubate for 30 minutes on a nutator mixer.  
16. During this time, wash the dialysis membrane in DEPC treated water and leave it submerged 
in a 50 mL falcon tube with DEPC treated water. 
17. Centrifuge the nuclei suspension at 13200 rpm for 15 minutes. 
18. Transfer the supernatant (the nuclear extract) to the small-scale dialysis chamber. Lay the 
dialysis membrane over the top and then seal the “drum” by sliding the ring of cut tube over the 
opening. Invert the chamber and make sure the liquid moves into contact with the membrane. 
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Place the small-scale dialysis chamber in a beaker containing 250 mL of Buffer D50, membrane 
facing down and in contact with the buffer (no trapped air).  
19. Dialyze with gentle stirring for 2 hours.   
20. Remove the dialysis chamber from Buffer D50 and place on the bench, membrane facing up. 
Blot away any excess buffer sitting on the membrane. Using a new razor, cut a slit into the 
dialysis membrane. Using a P200 micropipettor, collect as much of the dialyzed nuclear extract 
as possible and deposit into a pre-chilled microfuge tube. (see Note 20) 
21. Use 2 µL to measure the total protein concentration via Bradford assay, compared to standard 
solutions of a protein such as BSA. Starting from two 10 cm plates of HeLa cells, this procedure 
typically yields 60--80 µL of nuclear extract having a protein concentration of 1-2 mg/mL. 
22. Aliquot the rest of the extract in microfuge tubes. Snap freeze the aliquots in liquid nitrogen 
and store at -80 °C. Avoid repeated freeze-thaw cycles. 
24. For in vitro cleavage reactions, use 3-6.25 µL of the nuclear extract in place of the DEAE 
cleavage factors as described in Section 3.1. 
 
Section 7.D. Notes 
1. We have surveyed a variety of ATP structural analogs and find that 2’-dATP is the most 
effective (unpublished data). 
2. RNase-inhibitors work against a type of ribonuclease unrelated to the 3’ cleavage 
endoribonuclease; there is no danger of inhibiting 3’ cleavage.  
3. Dissolve PVA with rocking on nutator at room temperature over 1--2 days, vortex and spin in 
microfuge at 13200 rpm for 5 minutes just before each use. 
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4. Add PMSF, a serine protease inhibitor, just before contact with factors when possible. It has a 
short half-life in water. 
5. DEAE-sepharose and MonoQ are the two anion exchange resins that have been used the most 
to separate the cleavage factor activities. For DEAE-sepharose chromatographic procedures, see 
the following references 186, 188, 190, 195, 216, 222. 
6. BSA prevents the total protein concentration from falling too low. 250--500 ng are typically 
used per 12.5 L reaction. DEAE factors work well with 250 ng. To be safe, more highly 
purified factors, which have less total protein, should be supplemented by higher amounts of 
BSA. 
7. This results in a buffer concentration of only 10 mM, while the creatine phosphate 
concentration is 50 mM. Fortunately, the creatine phosphate pH is close to that of the buffer and 
does not change the pH. If acidic or basic components are used in adaptations of this protocol, 
take care to keep the pH in the 7.5 to 8.0 range. 
8. CstF and PAP elute in the void volume of anion exchange columns such as DEAE and 
MonoQ. It is therefore not necessary to supplement the DEAE factors with recombinant PAP 
when processing PAP-dependent substrates, i.e. all substrates except the SV40L pre-mRNA. If 
PAP is suspected to be low, 2 ng recombinant bovine PAP can be used 223.  
9. Though heat-denaturation is probably not critical for most substrates, it is done to break up 
any unexpectedly strong intramolecular secondary structure that might be present and affect 
processing. Longer substrates have more chance for secondary structure and may work poorly in 
vitro. 
10. 10% PVA is normally stored at -20 C and can be thawed quickly in a warm water bath. 
PVA is viscous and difficult to pipette accurately. Draw it slowly into the pipette tip to avoid air 
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bubbles, and gently pump after dispensing into the mixture to rinse the inside of the pipette tip. 
The benchtop microfuge used throughout this method was an Eppendorf 5415D. Its top speed is 
13200 rpm.  
11. Excessive insoluble material at the phase interface may indicate (i) the PVA solution is too 
old or too concentrated, (ii) tubes are made out of material other than polypropylene and react 
with chloroform, (iii) a need for longer microfuge centrifugation time to separate phases. 
12. It is safe to stop the procedure at this step and leave the precipitation tubes at -20 C or lower 
overnight. 
13. This procedure can be tedious for a large number of samples but it is critical since the pellet 
can be lost or fracture and be partially lost. For best results, remove as much supernatant as 
possible with a P1000 micropipettor, spin again, remove all but 10 L, spin again and remove 
every last trace. If this is done, there is no need to rinse the pellet with 70% aqueous ethanol. If 
the salt in the supernatant is not removed at this step, migration through the gel may be adversely 
affected. 
14. One of the plates can be siliconized 213 to help the gel adhere to only one of the plates when 
the gel is removed from the glass plates. Since sequencing gels are now rarely used, the spacers 
and gel combs to form the square wells can be hard to find. Labrepco is currently selling them 
under SKU: 21035043. 
15. BioRad Bradford reagent method was used, with comparison to BSA standards. 
16. RNA Pol II can replace creatine phosphate in in vitro cleavage 220, and we have detected 
some RNA Pol II in CFm by western blotting. Though it seems not to be in high enough 
concentration to be responsible for this creatine phosphate independent cleavage, we cannot rule 
it out. 
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17. The hydrolysis of esters such as RNA and DNA in water is thermodynamically favorable. 
Thus, no ATP should be required. However, energy could be required to assemble the proper 
cleavage factor complexes needed to carry out cleavage at a specific site. 
18. Along with the partially purified core cleavage factors, the recombinant RNA Pol II CTD, in 
the form of a GST-CTD fusion protein, can stimulate in vitro cleavage in place of creatine 
phosphate for the Ad2L3 substrate but not for the SV40L substrate 220, 222. In our experience, it 
cannot replace creatine phosphate in unfractionated HeLa cell nuclear extract with either 
substrate. 
19. As an alternative to douncing, cells can also be passed through syringe needle. 208 However, 
using a syringe needle tends to generate bubbles. The detergents such as NP-40 and Digitonin 
have also been used 209, 210. The extent to which cells are exposed to the detergent must be 
empirically determined. Repeated freeze-thaw cycles (3 times) can also lyse the cells, but this 
method can be time consuming 206.    
20. The plastic ring may be removed and the chamber, with its loose membrane still over the top, 
may be inserted into a new microfuge tube whose cap has been removed. Brief spinning in a 
microfuge will transfer any remaining extract through the slit and into the tube. There may also 
be commercially available small-scale dialysis alternatives. 
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